Table of Contents Print a PDF References Figures & Tables
< Previous Next >


Antman et al., Management of Patients With STEMI: Executive Summary
J Am Coll Cardiol 2004;44:671-719

ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary

A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction)

Developed in Collaboration With the Canadian Cardiovascular Society


References

1. Gunnar RM, Passamani ER, Bourdillon PD, et al. Guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction) J Am Coll Cardiol 1990;16:249-92.

2. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996;28:1328-428.

3. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999;34:890-911.

4. Braunwald E, Antman E, Beasley J, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002;40:1366.

5. Mehta RH, Montoye CK, Gallogly M, et al, for the GAP Steering Committee of the American College of Cardiology. Improving quality of care for acute myocardial infarction: the Guidelines Applied in Practice (GAP) initiative. JAMA 2002;287:1269-76.

6. Jencks SF, Huff ED, Cuerdon T. Change in the quality of care delivered to medicare beneficiaries, 1998-1999 to 2000-2001. JAMA 2003;289:305-12.

7. Schneider EC, Zaslavsky AM, Epstein AM. Racial disparities in the quality of care for enrollees in medicare managed care. JAMA 2002;287:1288-94.

8. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104:365-72.

9. Hamm CW, Bertrand M, Braunwald E. Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet 2001;358:1533-8.

10. Davies MJ. The pathophysiology of acute coronary syndromes. Heart 2000;83:361-6.

11. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis: characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983;50:127-34.

12. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988;78:1157-66.

13. Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA 1999;282:2035-42.

14. Rothwell PM, Villagra R, Gibson R, Donders RC, Warlow CP. Evidence of a chronic systemic cause of instability of atherosclerotic plaques. Lancet 2000;355:19-24.

15. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.

16. Dahlbäck B. Blood coagulation. Lancet 2000;355:1627-32.

17. Rosenberg RD, Aird WC. Vascular-bed: specific hemostasis and hypercoagulable states. N Engl J Med 1999;340:1555-64.

18. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death: 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 1977;56:786-94.

19. Hasche ET, Fernandes C, Freedman SB, Jeremy RW. Relation between ischemia time, infarct size, and left ventricular function in humans. Circulation 1995;92:710-9.

20. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902.

21. de Feyter PJ, van den Brand M, Serruys PW, Wijns W. Early angiography after myocardial infarction: what have we learned? Am Heart J 1985;109:194-9.

22. DeWood MA, Stifter WF, Simpson CS, et al. Coronary arteriographic findings soon after non–Q-wave myocardial infarction. N Engl J Med 1986;315:417-23.

23. Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest: results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) trial. Circulation 1993;87:38-52.

24. Boersma E, Mercado N, Poldermans D, Gardien M, Vos J, Simoons ML. Acute myocardial infarction. Lancet 2003;361:847-58.

25. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.

26. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118-23.

27. The Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. N Engl J Med 1997;337:1124-30.

28. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Lancet 1999;354:716-22.

29. Intravenous NPA for the Treatment of Infarcting Myocardium Early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000;21:2005-13.

30. Topol EJ, for the GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357:1905-14.

31. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-13.

32. Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998;98:2695-701.

33. White H, for the Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised vascutrial. Lancet 2001;358:1855-63.

34. Brener SJ, Barr LA, Burchenal JE, et al, for the ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998;98:734-41.

35. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000;35:915-21.

36. Montalescot G, Barragan P, Wittenberg O, et al, for the Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up (ADMIRAL) Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-903.

37. Zhu MM, Feit A, Chadow H, Alam M, Kwan T, Clark LT. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials. Am J Cardiol 2001;88:297-301.

38. Stone GW, Grines CL, Cox DA, et al, for the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-66.

39. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients’ data. Lancet 2002;359:294-302.

40. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361:13-20.

41. Braunwald E, Pfeffer MA. Ventricular enlargement and remodeling following acute myocardial infarction: mechanisms and management. Am J Cardiol 1991;68:1D-6D.

42. Pfeffer MA. Left ventricular remodeling after acute myocardial infarction. Annu Rev Med 1995;46:455-66.

43. Weisman HF, Healy B. Myocardial infarct expansion, infarct extension, and reinfarction: pathophysiologic concepts. Prog Cardiovasc Dis 1987;30:73-110.

44. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-97.

45. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol 2000;36: 2056-63.

46. American Heart Association. Heart Disease and Stroke Statistics — 2004 Update. Dallas, TX: American Heart Association; 2003. Available at http://www.americanheart.org/presenter.jhtml?identifier=3000090. Accessed November 15, 2003.

46a.Wiviott SD, Morrow DA, Giugliano RP, et al. Performance of the thrombolysis in myocardial infarction risk index for early acute coronary syndrome in the National Registry of Myocardial Infarction: a simple risk index predicts mortality in both ST and non-ST elevation myocardial infarction. J Am Coll Cardiol 2003;41:365A.

47. Guidry UC, Evans JC, Larson MG, Wilson PW, Murabito JM, Levy D. Temporal trends in event rates after Q-wave myocardial infarction: the Framingham Heart Study. Circulation 1999;100: 2054-9.

48. Goldberg RJ, Yarzebski J, Lessard D, Gore JM. A two-decades (1975 to 1995) long experience in the incidence, in-hospital and long-term case-fatality rates of acute myocardial infarction: a community-wide perspective. J Am Coll Cardiol 1999;33:1533-9.

49. Rouleau JL, Talajic M, Sussex B, et al. Myocardial infarction patients in the 1990s: their risk factors, stratification and survival in Canada: the Canadian Assessment of Myocardial Infarction (CAMI) Study. J Am Coll Cardiol 1996;27:1119-27.

50. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.

51. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137-47.

52. National Heart, Lung, and Blood Institute. Act in Time to Heart Attack. Available at http://www.nhlbi.nih.gov/actintime, 2003. Accessed May 15, 2003.

53. Wenger NK. You’ve come a long way, baby: cardiovascular health and disease in women: problems and prospects. Circulation 2004;109:558-60.

54. American College of Cardiology. Guidelines Applied in Practice. Available at http://www.acc.org/gap/gap.htm, 2003. Accessed May 15, 2003.

55. American Heart Association. Get With the Guidelines. Available at http://www.americanheart.org/presenter.jhtml?identifier=1165, 2003. Accessed May 15, 2003.

56. Topol EJ, Kereiakes DJ. Regionalization of care for acute ischemic heart disease: a call for specialized centers. Circulation 2003;107:1463-6.

57. Califf RM, Faxon DP. Need for centers to care for patients with acute coronary syndromes. Circulation 2003;107:1467-70.

58. Willerson JT. Editor’s commentary: centers of excellence. Circulation 2003;107:1471-2.

59. National Cholesterol Education Program. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Pub. No. 02-5125. Bethesda, MD: National Heart, Lung, and Blood Institute, 2002;284 pages. Guidelines, Related Tools, and Patient Information available at http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm. Accessed May 15, 2003.

60. Wielgosz AT. What do we really know about secondary prevention after myocardial infarction? Can J Cardiol 1995;11(Suppl A):31A-32A.

61. Ebrahim S, Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev 2000CD001561.

62. Ross SD, Allen IE, Connelly JE, et al. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 1999;159: 1793-802.

63. Grundy SM, Pasternak R, Greenland P, Smith S, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999;100:1481-92.

64. Risk Assessment. American Heart Association. Available at: http://www.americanheart.org/presenter.jhtml?identifier=3003499, 2004. Accessed May 15, 2003.

65. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;106:388-91.

66. Wilson K, Gibson N, Willan A, Cook D. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med 2000;160:939-44.

67. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-7.

68. Smith SC, Blair SN, Bonow RO, et al. AHA/ACC scientific statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001;104:1577-9.

69. Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004;109:672-93.

70. Treating tobacco use and dependence: a clinical practice guideline. Office of the Surgeon General. Available at http://www.surgeongeneral.gov/tobacco, 2000. Accessed May 15, 2003.

71. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients with Chronic Stable Angina). Available at www.acc.org/clinical/guidelines/stable/stable.pdf, 2002. Accessed December 2, 2003.

72. Chobanian AV, Bakris GL, Black HR, et al, for the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.

73. Pignone M, Mulrow CD. Evidence based management of hypertension: Using cardiovascular risk profiles to individualise hypertensive treatment. BMJ 2001;322:1164-6.

74. Turnbull F. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectivelydesigned overviews of randomised trials. Lancet 2003;362:1527-35.

75. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-64.

76. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161-72.

77. U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002;136:157-60.

78. Peters RJ, Mehta SR, Fox KA, et al, for the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003; 108:1682-7.

79. Hung J. Medical Issues Committee of the National Heart Foundation of Australia. Aspirin for cardiovascular disease prevention. Med J Aust 2003;179:147-52.

80. Dracup K, Alonzo AA, Atkins JM, et al. The physician’s role in minimizing prehospital delay in patients at high risk for acute myocardial infarction: recommendations from the National Heart Attack Alert Program (Working Group on Educational Strategies to Prevent Prehospital Delay in Patients at High Risk for Acute Myocardial Infarction). Ann Intern Med 1997;126:645-51.

81. Hedges JR, Feldman HA, Bittner V, et al, for the REACT Study Group. Impact of community intervention to reduce patient delay time on use of reperfusion therapy for acute myocardial infarction: Rapid Early Action for Coronary Treatment (REACT) trial. Acad Emerg Med 2000;7:862-72.

82. Canto JG, Zalenski RJ, Ornato JP, et al, for the National Registry of Myocardial Infarction 2 Investigators. Use of emergency medical services in acute myocardial infarction and subsequent quality of care: observations from the National Registry of Myocardial Infarction 2. Circulation 2002;106:3018-23.

83. Goldberg R, Goff D, Cooper L, et al. Age and sex differences in presentation of symptoms among patients with acute coronary disease: the REACT Trial. Rapid Early Action for Coronary Treatment. Coron Artery Dis 2000;11:399-407.

84. Hutchings CB, Mann NC, Daya M, et al. Rapid Early Action for Coronary Treatment Study. Patients with chest pain calling 9-1-1 or self-transporting to reach definitive care: which mode is quicker? Am Heart J 2004;147:35-41.

85. Becker L, Larsen MP, Eisenberg MS. Incidence of cardiac arrest during self-transport for chest pain. Ann Emerg Med 1996;28: 612-6.

86. Brown AL, Mann NC, Daya M, et al. Demographic, belief, and situational factors influencing the decision to utilize emergency medical services among chest pain patients: Rapid Early Action for Coronary Treatment (REACT) study. Circulation 2000;102: 173-8.

87. Goff DC, Feldman HA, McGovern PG, et al, for the Rapid Early Action for Coronary Treatment (REACT) Study Group. Prehospital delay in patients hospitalized with heart attack symptoms in the United States: the REACT trial. Am Heart J 1999;138: 1046-57.

88. Herlitz J, Karlson BW, Liljeqvist JA, Strömbom U, Holmberg S. Early identification of acute myocardial infarction and prognosis in relation to mode of transport to hospital. Am J Emerg Med 1992;10:406-12.

89. Ho MT, Eisenberg MS, Litwin PE, Schaeffer SM, Damon SK. Delay between onset of chest pain and seeking medical care: the effect of public education. Ann Emerg Med 1989;18:727-31.

90. Dracup K, Moser DK, Eisenberg M, Meischke H, Alonzo AA, Braslow A. Causes of delay in seeking treatment for heart attack symptoms. Soc Sci Med 1995;40:379-92.

91. Herlitz J, Blohm M, Hartford M, et al. Follow-up of a 1-year media campaign on delay times and ambulance use in suspected acute myocardial infarction. Eur Heart J 1992;13:171-7.

92. Luepker RV, Raczynski JM, Osganian S, et al. Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease: the Rapid Early Action for Coronary Treatment (REACT) Trial. JAMA 2000;284:60-7.

93. Wright RS, Kopecky SL, Timm M, et al, for the Wabasha Heart Attack Team. Impact of community-based education on health care evaluation in patients with acute chest pain syndromes: the Wabasha Heart Attack Team (WHAT) project. Fam Pract 2001; 18:537-9.

94. Access to Timely and Optimal Care of Patients with Acute Coronary Syndromes - Community Planning Considerations: a report by the National Heart Attack Alert Program. J Thromb Thrombolysis 1998;6:19-46.

95. Leslie WS, Urie A, Hooper J, Morrison CE. Delay in calling for help during myocardial infarction: reasons for the delay and subsequent pattern of accessing care. Heart 2000;84:137-41.

96. Simon AB, Feinleib M, Thompson HK. Components of delay in the pre-hospital phase of acute myocardial infarction. Am J Cardiol 1972;30:476-82.

97. Alonzo AA. The impact of the family and lay others on care-seeking during life-threatening episodes of suspected coronary artery disease. Soc Sci Med 1986;22:1297-311.

98. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care: part 12: from science to survival: strengthening the chain of survival in every community. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation 2000;102:I358-70.

99. McDermott MM, Mandapat AL, Moates A, et al. Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease. Arch Intern Med 2003;163:2157-62.

100. Canto JG, Shlipak MG, Rogers WJ, et al. Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain. JAMA 2000;283:3223-9.

101. Faxon D, Lenfant C. Timing is everything: motivating patients to call 9-1-1 at onset of acute myocardial infarction. Circulation 2001;104:1210-1.

102. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care: part 7: the era of reperfusion: section 1: acute coronary syndromes (acute myocardial infarction). The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation 2000;102:I172-203.

103. U.S. Department of Health and Human Services. Public Health Service. National Institutes of Health. National Heart, Lung, and Blood Institute. NIH Publication No. 01-3525. September 2001. Available at: http://www.nhlbi.nih.gov/health/public/heart/mi/ core_bk.pdf. Accessed December 16, 2002.

104. U.S. Department of Health and Human Services. Public Health Service. National Institutes of Health. National Heart, Lung, and Blood Institute. NIH Publication No. 01-3526. November 2001. Available at: http://www.nhlbi.nih.gov/health/public/heart/mi/ core_sp.pdf. Accessed December 16, 2002.

105. U.S. Department of Health and Human Services. Public Health Service. National Institutes of Health. National Heart, Lung, and Blood Institute. NIH Publication No. 01-3667. September 2001. Available at: http://www.nhlbi.nih.gov/health/public/heart/mi/ wallet.pdf. Accessed December 16, 2002.

106. U.S. Department of Health and Human Services. Public Health Service. National Institutes of Health. National Heart, Lung, and Blood Institute. NIH Publication No. 01-3669. September 2001. Available at: http://www.nhlbi.nih.gov/health/public/heart/mi/ act_ plan.pdf. Accessed December 16, 2002.

107. U.S. Department of Health and Human Services. Public Health Service. National Institutes of Health. National Heart, Lung, and Blood Institute. NIH Publication No. 01-3313. September 2001. Available at: http://www.nhlbi.nih.gov/health/prof/heart/mi/ provider.pdf. Accessed December 16, 2002.

108. Act in Time to Heart Attack Signs: Physician Quick Reference Tool for Palm OS. Department of Health and Human Services. Public Health Service. National Institutes of Health. National Heart, Lung, and Blood Institute. 2001. Available at: http://hin.nhlbi.nih.gov/haac_palm/haac_palm.htm. Accessed Decmeber 16, 2002.

109. U.S. Department of Health and Human Services. Public Health Service. National Institutes of Health. National Heart, Lung, and Blood Institute. NIH Publication No. 01-3646. September 2001. Available at: http://www.nhlbi.nih.gov/health/public/heart/mi/ poster.pdf. Accessed Decmeber 16, 2002.

110. Deleted in press.

111. Goff DC, Sellers DE, McGovern PG, et al. Knowledge of heart attack symptoms in a population survey in the United States: the REACT Trial. Rapid Early Action for Coronary Treatment. Arch Intern Med 1998;158:2329-38.

112. Welsh RC, Ornato J, Armstrong PW. Prehospital management of acute ST-elevation myocardial infarction: a time for reappraisal in North America. Am Heart J 2003;145:1-8.

113. Goldberg RJ, Steg PG, Sadiq I, et al. Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry). Am J Cardiol 2002; 89:791-6.

114. Finnegan JR, Meischke H, Zapka JG, et al. Patient delay in seeking care for heart attack symptoms: findings from focus groups conducted in five U.S. regions. Prev Med 2000;31:205-13.

115. Feldman HA, Proschan MA, Murray DM, et al. Statistical design of REACT (Rapid Early Action for Coronary Treatment), a multisite community trial with continual data collection. Control Clin Trials 1998;19:391-403.

116. McKinley S, Moser DK, Dracup K. Treatment-seeking behavior for acute myocardial infarction symptoms in North America and Australia. Heart Lung 2000;29:237-47.

117. Rucker D, Brennan T, Burstin H. Delay in seeking emergency care. Acad Emerg Med 2001;8:163-9.

118. Sheifer SE, Gersh BJ, Yanez ND, Ades PA, Burke GL, Manolio TA. Prevalence, predisposing factors, and prognosis of clinically unrecognized myocardial infarction in the elderly. J Am Coll Cardiol 2000;35:119-26.

119. Kannel WB. Silent myocardial ischemia and infarction: insights from the Framingham Study. Cardiol Clin 1986;4:583-91.

120. Rathore SS, Weinfurt KP, Gersh BJ, Oetgen WJ, Schulman KA, Solomon AJ. Treatment of patients with myocardial infarction who present with a paced rhythm. Ann Intern Med 2001;134:644- 51.

121. Cummins RO, Ornato JP, Thies WH, Pepe PE. Improving survival from sudden cardiac arrest: the “chain of survival” concept: a statement for health professionals from the Advanced Cardiac Life Support Subcommittee and the Emergency Cardiac Care Committee, American Heart Association. Circulation 1991;83: 1832-47.

122. Cummins RO, Eisenberg MS, Hallstrom AP, Litwin PE. Survival of out-of-hospital cardiac arrest with early initiation of cardiopulmonary resuscitation. Am J Emerg Med 1985;3:114-9.

123. Weisfeldt ML, Becker LB. Resuscitation after cardiac arrest: a 3- phase time-sensitive model. JAMA 2002;288:3035-8.

124. Stapczynski JS, Svenson JE, Stone CK. Population density, automated external defibrillator use, and survival in rural cardiac arrest. Acad Emerg Med 1997;4:552-8.

125. Becker LB, Ostrander MP, Barrett J, Kondos GT. Outcome of CPR in a large metropolitan area: where are the survivors? Ann Emerg Med 1991;20:355-61.

126.Lombardi G, Gallagher J, Gennis P. Outcome of out-of-hospital cardiac arrest in New York City: the Pre-Hospital Arrest Survival Evaluation (PHASE) Study. JAMA 1994;271:678-83.

127. White RD, Asplin BR, Bugliosi TF, Hankins DG. High discharge survival rate after out-of-hospital ventricular fibrillation with rapid defibrillation by police and paramedics. Ann Emerg Med 1996;28:480-5.

128. White RD, Hankins DG, Bugliosi TF. Seven years’ experience with early defibrillation by police and paramedics in an emergency medical services system. Resuscitation 1998;39:145-51.

129. Bunch TJ, White RD, Gersh BJ, et al. Long-term outcomes of outof- hospital cardiac arrest after successful early defibrillation. N Engl J Med 2003;348:2626-33.

130. Stiell IG,Wells GA, Field BJ, et al. Improved out-of-hospital cardiac arrest survival through the inexpensive optimization of an existing defibrillation program: OPALS study phase II. Ontario Prehospital Advanced Life Support. JAMA 1999;281:1175-81.

131. Caffrey SL, Willoughby PJ, Pepe PE, Becker LB. Public use of automated external defibrillators. N Engl J Med 2002;347:1242-7.

132. Dracup K, Moser DK, Guzy PM, Taylor SE, Marsden C. Is cardiopulmonary resuscitation training deleterious for family members of cardiac patients? Am J Public Health 1994;84:116-8.

133. Dracup K, Moser DK, Taylor SE, Guzy PM. The psychological consequences of cardiopulmonary resuscitation training for family members of patients at risk for sudden death. Am J Public Health 1997;87:1434-9.

134. Chen MA, Eisenberg MS, Meischke H. Impact of in-home defibrillators on postmyocardial infarction patients and their significant others: an interview study. Heart Lung 2002;31:173-85.

135. Home Automatic External Defibrillator Trial. National Heart, Lung, and Blood Institute (NHLBI). Available at: http:// www.clinicaltrials.gov/ct/show/NCT00047411?order=46. 2004. NLM Identifier: NCT00047411. Accessed December 22, 2003.

136. Hallstrom AP, Cobb LA, Johnson E, Copass MK. Dispatcher assisted CPR: implementation and potential benefit: a 12-year study. Resuscitation 2003;57:123-9.

137. Cummins RO. From concept to standard-of-care? Review of the clinical experience with automated external defibrillators. Ann Emerg Med 1989;18:1269-75.

138. Cummins RO, Schubach JA, Litwin PE, Hearne TR. Training lay persons to use automatic external defibrillators: success of initial training and one-year retention of skills. Am J Emerg Med 1989;7:143-9.

139. Mosesso VN, Davis EA, Auble TE, Paris PM, Yealy DM. Use of automated external defibrillators by police officers for treatment of out-of-hospital cardiac arrest. Ann Emerg Med 1998;32:200-7.

140. Valenzuela TD, Roe DJ, Nichol G, Clark LL, Spaite DW, Hardman RG. Outcomes of rapid defibrillation by security officers after cardiac arrest in casinos. N Engl J Med 2000;343:1206- 9.

141. Page RL, Joglar JA, Kowal RC, et al. Use of automated external defibrillators by a U.S. airline. N Engl J Med 2000;343:1210-6.

142. Nichol G, Hallstrom AP, Kerber R, et al. American Heart Association report on the second public access defibrillation conference, April 17-19, 1997. Circulation 1998;97:1309-14.

143. Nichol G, Hallstrom AP, Ornato JP, et al. Potential cost-effectiveness of public access defibrillation in the United States. Circulation 1998;97:1315-20.

144. Kerber RE, Becker LB, Bourland JD, et al. Automatic external defibrillators for public access defibrillation: recommendations for specifying and reporting arrhythmia analysis algorithm performance, incorporating new waveforms, and enhancing safety: statement for health professionals from the American Heart Association Task Force on Automatic External Defibrillation, Subcommittee on AED Safety and Efficacy. Circulation 1997;95:1677-82.

145. Weisfeldt ML, Kerber RE, McGoldrick RP, et al, for the Automatic Defibrillation Task Force. Public access to defibrillation. Am J Emerg Med 1996;14:684-92.

146. Weisfeldt ML, Kerber RE, McGoldrick RP, et al, for the Automatic External Defibrillation Task Force. American Heart Association Report on the Public Access Defibrillation Conference December 8-10, 1994. Circulation 1995;92:2740-7.

147. Weisfeldt ML, Kerber RE, McGoldrick RP, et al. Public access defibrillation: a statement for healthcare professionals from the American Heart Association Task Force on Automatic External Defibrillation. Circulation 1995;92:2763.

148. Deleted in press.

149. Ornato JP, Racht EM, Fitch JJ, Berry JF. The need for ALS in urban and suburban EMS systems. Ann Emerg Med 1990; 19:1469-70.

150. Stout J, Pepe PE, Mosesso VN. All-advanced life support vs tiered-response ambulance systems. Prehosp Emerg Care 2000;4:1-6.

151. Eisenberg MJ, Topol EJ. Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction. Arch Intern Med 1996;156:1506-10.

152. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.

153. Hutter AM, Weaver WD. 31st Bethesda Conference: emergency cardiac care: task force 2: acute coronary syndromes: section 2A–prehospital issues. J Am Coll Cardiol 2000;35:846-53.

154. Lau J, Ioannidis J, Balk E, et al. Evaluation of Technologies for Identifying Acute Cardiac Ischemia in Emergency Departments. Evidence Report/Technology Assessment Number 26. (Prepared by the New England Medical Center Evidence-based Practice Center under Contract No. 290-97-0019). AHRQ Publication No. 01-E006, Rockville, MD: Agency for Healthcare Research and Quality, May 2001.

155. Armstrong PW, Collen D, Antman E. Fibrinolysis for acute myocardial infarction: the future is here and now. Circulation 2003;107:2533-7.

156. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.

157. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-402.

158. Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003;108:135-42.

159. Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy: the Myocardial Infarction Triage and Intervention trial. JAMA 1993;270:1211-6.

160. Hermens WT, Willems GM, Nijssen KM, Simoons ML. Effect of thrombolytic treatment delay on myocardial infarct size. Lancet 1992;340:1297.

161. Gersh BJ, Anderson JL. Thrombolysis and myocardial salvage: results of clinical trials and the animal paradigm: paradoxic or predictable? Circulation 1993;88:296-306.

162. Newby LK, Rutsch WR, Califf RM, et al, for the GUSTO-1 Investigators. Time from symptom onset to treatment and outcomes after thrombolytic therapy. J Am Coll Cardiol 1996;27:1646-55.

163. Milavetz JJ, Giebel DW, Christian TF, Schwartz RS, Holmes DR, Gibbons RJ. Time to therapy and salvage in myocardial infarction. J Am Coll Cardiol 1998;31:1246-51.

164. Chareonthaitawee P, Gibbons RJ, Roberts RS, Christian TF, Burns R, Yusuf S, for the CORE investigators (Collaborative Organisation for RheothRx Evaluation). The impact of time to thrombolytic treatment on outcome in patients with acute myocardial infarction. Heart 2000;84:142-8.

165. McNeill AJ, Cunningham SR, Flannery DJ, et al. A double-blind placebo controlled study of early and late administration of recombinant tissue plasminogen activator in acute myocardial infarction. Br Heart J 1989;61:316-21.

166. Castaigne AD, Hervé C, Duval-Moulin AM, et al. Prehospital use of APSAC: results of a placebo-controlled study. Am J Cardiol 1989;64:30A-33A; discussion.

167. Barbash GI, Roth A, Hod H, et al. Improved survival but not left ventricular function with early and prehospital treatment with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990;66:261-6.

168. Schofer J, Büttner J, Geng G, et al Prehospital thrombolysis in acute myocardial infarction. Am J Cardiol 1990;66:1429-33.

169. McAleer B, Ruane B, Burke E, et al. Prehospital thrombolysis in a rural community: short- and long-term survival. Cardiovasc Drugs Ther 1992;6:369-72.

170. Grampian Region Early Anistreplase Trial (GREAT) Group. Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: BMJ 1992;305:548-53.

171. The European Myocardial Infarction Project Group. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 1993;329:383-9.

172. Morrow DA, Antman EM, Sayah A, et al. Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase- Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial. J Am Coll Cardiol 2002;40:71-7.

173. Bonnefoy E, Lapostolle F, Leizorovicz A, et al for the Comparison of Angioplasty and Prehospital Thrombolysis in Acute Myocardial Infarction Study Group. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet 2002;360:825-9.

174. Spinler SA, Mikhail PA. Prehospital-initiated thrombolysis. Ann Pharmacother 1997;31:1339-46.

175. Karagounis L, Ipsen SK, Jessop MR, et al. Impact of field-transmitted electrocardiography on time to in-hospital thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1990;66:786-91.

176. Steg PG, Bonnefoy E, Chabaud S, et al. Impact of Time to Treatment on Mortality After Prehospital Fibrinolysis or Primary Angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003;108:2851-6.

177. Widimský P, Budesinský T,Vorác D, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction: final results of the randomized national multicentre trial-PRAGUE-2. Eur Heart J 2003;24:94-104.

178. Deleted in press.

179. Emergency department: rapid identification and treatment of patients with acute myocardial infarction. National Heart Attack Alert Program Coordinating Committee, 60 Minutes to Treatment Working Group. Ann Emerg Med 1994;23:311-29.

180. Cannon CP, Antman EM, Walls R, Braunwald E. Time as an adjunctive agent to thrombolytic therapy. J Thromb Thrombolysis 1994;1:27-34.

181. Weaver WD, Litwin PE, Martin JS, et al, for the MITI Project Group. Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction. J Am Coll Cardiol 1991;18:657- 62.

182. Gibler WB, Kereiakes DJ, Dean EN, et al. Prehospital diagnosis and treatment of acute myocardial infarction: a north-south perspective. The Cincinnati Heart Project and the Nashville Prehospital TPA Trial. Am Heart J 1991;121:1-11.

183. Pedley DK, Bissett K, Connolly EM, et al. Prospective observational cohort study of time saved by prehospital thrombolysis for ST elevation myocardial infarction delivered by paramedics. BMJ 2003;327:22-6.

184. Hochman JS, Sleeper LA, White HD, et al, for the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) Investigators. One-year survival following early revascularization for cardiogenic shock. JAMA 2001;285:190-2.

185. Cannon CP. Time to treatment: a crucial factor in thrombolysis and primary angioplasty. J Thromb Thrombolysis 1996;3:249-255.

186. Steg PG, Goldberg RJ, Gore JM, et al, for the GRACE Investigators. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 2002;90:358-63.

187. Storrow AB, Gibler WB. Chest pain centers: diagnosis of acute coronary syndromes. Ann Emerg Med 2000;35:449-61.

188. Pope JH, Aufderheide TP, Ruthazer R, et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med 2000;342:1163-70.

189. Jesse RL, Kontos MC. Evaluation of chest pain in the emergency department. Curr Probl Cardiol 1997;22:149-236.

190. Karcz A, Korn R, Burke MC, et al. Malpractice claims against emergency physicians in Massachusetts: 1975-1993. Am J Emerg Med 1996;14:341-5.

191. Graff L. Missed MI diagnosis. Ann Emerg Med 1994;23:141-2.

192. McCarthy BD, Beshansky JR, D’Agostino RB, Selker HP. Missed diagnoses of acute myocardial infarction in the emergency department: results from a multicenter study. Ann Emerg Med 1993;22:579-82.

193. Tatum JL, Jesse RL, Kontos MC, et al. Comprehensive strategy for the evaluation and triage of the chest pain patient. Ann Emerg Med 1997;29:116-25.

194. Tatum JL. Cost effective nuclear scanning in a comprehensive and systematic approach to the evaluation of chest pain in the emergency department. Md Med J 1997;Suppl:25-9.

195. Ornato JP. Chest pain emergency centers: improving acute myocardial infarction care. Clin Cardiol 1999;22:IV3-9.

196. Newby LK, Storrow AB, Gibler WB, et al. Bedside multimarker testing for risk stratification in chest pain units: the chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. Circulation 2001;103:1832-7.

197. Lateef F, Storrow AB, Gibler BW, Liu T. Heart emergency room: effective for both geriatric and younger patients. Singapore Med J 2001;42:259-63.

198. Lateef F, Storrow AB, Malone K, Liu T, Gibler BW. Comparison of a 6-hour and 9-hour protocol for evaluation of moderate-to-low risk chest pain patients in an emergency department diagnostic unit. Singapore Med J 2001;42:052-6.

199. Gibler WB. Chest pain units: do they make sense now? Ann Emerg Med 1997;29:168-71.

200. Gibler WB. Evaluation of chest pain in the emergency department. Ann Intern Med 1995;123:315; discussion 317.

201. Gibler WB. Chest pain evaluation in the ED: beyond triage. Am J Emerg Med 1994;12:121-2.

202. Gibler WB. Evaluating patients with chest pain in the ED: improving speed, efficiency, and cost-effectiveness, or teaching an old dog new tricks. Ann Emerg Med 1994;23:381-2.

203. Hoekstra JW, Gibler WB, Levy RC, et al. Emergency-department diagnosis of acute myocardial infarction and ischemia: a cost analysis of two diagnostic protocols. Acad Emerg Med 1994;1:103-10.

204. Hoekstra JW, Hedges JR, Gibler WB, Rubison RM, Christensen RA, for the National Cooperative CK-MB Project Group. Emergency department CK-MB: a predictor of ischemic complications. Acad Emerg Med 1994;1:17-27.

205. Cannon CP, Hand MH, Bahr R, et al, for the. National Heart Attack Alert Program (NHAAP) Coordinating Committee Critical Pathways Writing Group. Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program. Am Heart J 2002;143:777- 89.

206. Zalenski RJ, Selker HP, Cannon CP, et al. National Heart Attack Alert Program position paper: chest pain centers and programs for the evaluation of acute cardiac ischemia. Ann Emerg Med 2000;35:462-71.

207. Lambrew CT,Weaver WD, Rogers WJ, Bowlby LJ, Rubison RM, French WJ. Hospital protocols and policies that may delay early identification and thrombolytic therapy of acute myocardial infarction patients. J Thromb Thrombolysis 1996;3:301-306.

208. Farkouh ME, Smars PA, Reeder GS, et al, for the Chest Pain Evaluation in the Emergency Room (CHEER) Investigators. A clinical trial of a chest-pain observation unit for patients with unstable angina. N Engl J Med 1998;339:1882-8.

209. Deleted in press.

210. Charney P. Coronary artery disease in young women: the menstrual cycle and other risk factors. Ann Intern Med 2001;135: 1002-4.

211. Hasdai D, Porter A, Rosengren A, Behar S, Boyko V, Battler A. Effect of gender on outcomes of acute coronary syndromes. Am J Cardiol 2003;91:1466-9–A6.

212. Kudenchuk PJ, Maynard C, Martin JS, Wirkus M, Weaver WD. Comparison of presentation, treatment, and outcome of acute myocardial infarction in men versus women (the Myocardial Infarction Triage and Intervention Registry) Am J Cardiol 1996;78:9-14.

213. Goldberg RJ, McCormick D, Gurwitz JH,Yarzebski J, Lessard D, Gore JM. Age-related trends in short- and long-term survival after acute myocardial infarction: a 20-year population-based perspective (1975-1995). Am J Cardiol 1998;82:1311-7.

214. Meischke H, Dulberg EM, Schaeffer SS, Henwood DK, Larsen MP, Eisenberg MS. ‘Call fast, Call 911’: a direct mail campaign to reduce patient delay in acute myocardial infarction. Am J Public Health 1997;87:1705-9.

215. McSweeney JC, Cody M, O’Sullivan P, Elberson K, Moser DK, Garvin BJ. Women’s early warning symptoms of acute myocardial infarction. Circulation 2003;108:2619-23.

216. Bonow RO, Mitch WE, Nesto RW, et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group V: management of cardiovascular-renal complications. Circulation 2002;105:e159-64.

217. Levy DE. How transient are transient ischemic attacks? Neurology 1988;38:674-7.

218. Sloan MA, Gore JM. Ischemic stroke and intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction: a risk-benefit analysis. Am J Cardiol 1992;69:21A-38A.

219. Hochman JH, Gersh BJ. Acute myocardial infarction. In: Topol EJ, ed. Textbook of Cardiovascular Medicine. 2nd ed. Philadelphia, PA: Lippincott, Williams, and Wilkins; 2002:438.

220. Spodick DH. Diagnostic electrocardiographic sequences in acute pericarditis: significance of PR segment and PR vector changes. Circulation 1973;48:575-80.

221. Menown IB, Mackenzie G, Adgey AA. Optimizing the initial 12- lead electrocardiographic diagnosis of acute myocardial infarction. Eur Heart J 2000;21:275-83.

222. Mauri F, Gasparini M, Barbonaglia L, et al. Prognostic significance of the extent of myocardial injury in acute myocardial infarction treated by streptokinase (the GISSI trial). Am J Cardiol 1989;63:1291-5.

223. Antman EM, Rutherford JD. Coronary care medicine: a practical approach. Boston, MA: Martinus Nijhoff Publishing;1986:81.

224. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non–Q-wave myocardial infarction: results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation 1994;89: 1545-56.

225. Matetzky S, Freimark D, Chouraqui P, et al. Significance of ST segment elevations in posterior chest leads (V7 to V9) in patients with acute inferior myocardial infarction: application for thrombolytic therapy. J Am Coll Cardiol 1998;31:506-11.

226. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). American College of Cardiology Web Site. Available at: www.acc.org/clinical/guidelines/echo/index.pdf, 2003. Accessed August 4, 2003.

227. Goldman L, Cook EF, Brand DA, et al. A computer protocol to predict myocardial infarction in emergency department patients with chest pain. N Engl J Med 1988;318:797-803.

228. Wang K, Asinger RW, Marriott HJ. ST-segment elevation in conditions other than acute myocardial infarction. N Engl J Med 2003;349:2128-35.

229. Sgarbossa EB, Pinski SL, Barbagelata A, et al, for the GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. N Engl J Med 1996;334:481-7.

230. Sgarbossa EB. Value of the ECG in suspected acute myocardial infarction with left bundle-branch block. J Electrocardiol 2000;33(Suppl):87-92.

231. Luepker RV, Apple FS, Christenson RH, et al. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation 2003;108:2543-9.

232. Adams JE, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury: is MB creatine kinase the choice for the 1990s? Circulation 1993;88:750-63.

233. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69.

234. Wu AH, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes R. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem 1999;45:1104-21.

235. Ohman EM, Armstrong PW, White HD, et al for the Global Use of Strategies To Open Occluded Coronary Arteries (GUSTO III) Investigators. Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. Am J Cardiol 1999;84:1281-6.

236. Tanasijevic MJ, Cannon CP, Wybenga DR, et al. Myoglobin, creatine kinase MB, and cardiac troponin-I to assess reperfusion after thrombolysis for acute myocardial infarction: results from TIMI 10A. Am Heart J 1997;134:622-30.

237. Puleo PR, Meyer D, Wathen C, et al. Use of a rapid assay of subforms of creatine kinase-MB to diagnose or rule out acute myocardial infarction. N Engl J Med 1994;331:561-6.

238. Antman EM, Sacks DB, Rifai N, McCabe CH, Cannon CP, Braunwald E. Time to positivity of a rapid bedside assay for cardiac- specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy. J Am Coll Cardiol 1998;31:326-30.

239. Klocke FJ, Baird MG, Bateman TM, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Radionuclide Imaging). American College of Cardiology Web Site. Available at http://www.acc.org/clinical/ guidelines/radio/rni_fulltext.pdf, 2003. Accessed August 18, 2003.

240. Lee KL, Woodlief LH, Topol EJ, et al, for the GUSTO-I Investigators. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41,021 patients. Circulation 1995;91:1659-68.

241. Morrow DA, Antman EM, Giugliano RP, et al. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet 2001;358:1571-5.

242. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000;102:2031-7.

243. Selker HP, Griffith JL, Beshansky JR, et al. Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrument. Ann Intern Med 1997;127:538-56.

244. Selker HP, Beshansky JR, Griffith JL, for the TPI Trial Investigators. Use of the electrocardiograph-based thrombolytic predictive instrument to assist thrombolytic and reperfusion therapy for acute myocardial infarction: a multicenter, randomized, controlled, clinical effectiveness trial. Ann Intern Med 2002;137: 87-95.

245. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM, for the National Registry of Myocardial Infarction 2 Participants. Sex-based differences in early mortality after myocardial infarction. N Engl J Med 1999;341:217-25.

246. Brass LM, Lichtman JH, Wang Y, Gurwitz JH, Radford MJ, Krumholz HM. Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. Stroke 2000;31:1802-11.

247. Krumholz HM, Pasternak RC, Weinstein MC, et al L. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med 1992;327:7-13.

248. Maroko PR, Radvany P, Braunwald E, Hale SL. Reduction of infarct size by oxygen inhalation following acute coronary occlusion. Circulation 1975;52:360-8.

249. Madias JE, Hood WB. Reduction of precordial ST-segment elevation in patients with anterior myocardial infarction by oxygen breathing. Circulation 1976;53:I198-200.

250. Fillmore SJ, Shapiro M, Killip T. Arterial oxygen tension in acute myocardial infarction: serial analysis of clinical state and blood gas changes. Am Heart J 1970;79:620-9.

251. Aubier M, Trippenbach T, Roussos C. Respiratory muscle fatigue during cardiogenic shock. J Appl Physiol 1981;51:499-508.

252. Abrams J. Hemodynamic effects of nitroglycerin and long-acting nitrates. Am Heart J 1985;110:216-24.

253. Winbury MM. Redistribution of left ventricular blood flow produced by nitroglycerin: an example of integration of the macroand microcirculation. Circ Res 1971;28(Suppl 1):140-7.

254. Gorman MW, Sparks HV. Nitroglycerin causes vasodilatation within ischaemic myocardium. Cardiovasc Res 1980;14:515-21.

255. Deleted in press.

256. Come PC, Pitt B. Nitroglycerin-induced severe hypotension and bradycardia in patients with acute myocardial infarction. Circulation 1976;54:624-8.

257. Kinch JW, Ryan TJ. Right ventricular infarction. N Engl J Med 1994;330:1211-7.

258. Cheitlin MD, Hutter AM, Brindis RG, et al. ACC/AHA expert consensus document on the use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/ American Heart Association. J Am Coll Cardiol 1999;33:273-82.

259. Antman EM, Braunwald E. Acute myocardial infarction. In: Braunwald E, Zipes DP, Libby P, eds. Heart disease: a textbook of cardiovascular medicine, 6th ed. Philadelphia, PA: WB Saunders Co Ltd; 2001:1114-1251.

260. Hochman JS, Califf RM. Acute myocardial infarction. In: Smith TW. Cardiovascular therapeutics: a companion to Braunwald’s heart disease, 2nd ed. Philadelphia, PA: WB Saunders Co Ltd; 2001:235-291.

261. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349- 60.

262. Roux S, Christeller S, Lüdin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a metaanalysis. J Am Coll Cardiol 1992;19:671-7.

263. Antithrombotic Trialists’ Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002;324:71-86.

264. Sagar KA, Smyth MR. A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography. J Pharm Biomed Anal 1999;21:383-92.

265. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71.

266. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986;2:57- 66.

267. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction: patient population. Am J Cardiol 1985;56:10G- 14G.

268. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med 1989;320:618-27.

269. Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 1991;83: 422-37.

270. Van de Werf F, Janssens L, Brzostek T, et al. Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol 1993;22:407-16.

271. Pfisterer M, Cox JL, Granger CB, et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. J Am Coll Cardiol 1998;32:634-40.

272. Kloner RA, Hale S. Unraveling the complex effects of cocaine on the heart. Circulation 1993;87:1046-7.

273. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90.

274. De Luca G, Suryapranata H, Zijlstra F, et al, for the ZWOLLE Myocardial Infarction Study Group. Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol 2003;42:991-7.

275. De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 2004;109:1223-5.

275a.Williams DO. Treatment delayed is treatment denied. Circulation 2004;109:1806-8.

276. Davies CH, Ormerod OJ. Failed coronary thrombolysis. Lancet 1998;351:1191-6.

277. Ito H, Okamura A, Iwakura K, Masuyama T, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996;93: 1993-9.

278. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998;97: 765-72.

279. Zeymer U, Tebbe U, Essen R, Haarmann W, Neuhaus KL, for the ALKK-Study Group. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. Am Heart J 1999;137:34-8.

280. Gibson CM. Has my patient achieved adequate myocardial reperfusion? Circulation 2003;108:504-7.

281. Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lopez-Sendon J, for the GRACE Investigators. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002;359:373-7.

282. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997; 278:2093-8.

283. Hasdai D, Behar S,Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. The Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002;23:1190-201.

284. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996;348:771-5.

285. Morrison LJ, Verbeek PR, McDonald AC, Sawadsky BV, Cook DJ. Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis. JAMA 2000;283:2686-92.

286. Reimer KA, Jennings RB, Cobb FR, et al. Animal models for protecting ischemic myocardium: results of the NHLBI Cooperative Study: comparison of unconscious and conscious dog models. Circ Res 1985;56:651-65.

287. Christian TF, Schwartz RS, Gibbons RJ. Determinants of infarct size in reperfusion therapy for acute myocardial infarction. Circulation 1992;86:81-90.

288. Huber KC, Bresnahan JF, Bresnahan DR, Pellikka PA, Behrenbeck T, Gibbons RJ. Measurement of myocardium at risk by technetium-99m sestamibi: correlation with coronary angiography. J Am Coll Cardiol 1992;19:67-73.

289. Klarich KW, Christian TF, Higano ST, Gibbons RJ. Variability of myocardium at risk for acute myocardial infarction. Am J Cardiol 1999;83:1191-5.

290. Brodie BR, Stuckey TD, Wall TC, et al. Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 1998;32:1312-9.

291. Brodie BR, Stone GW, Morice MC, et al, for the Stent Primary Angioplasty in Myocardial Infarction Study Group. Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction (results from the Stent Primary Angioplasty in Myocardial Infarction Trial). Am J Cardiol 2001;88:1085-90.

292. Brodie BR, Stuckey TD, Muncy DB, et al. Importance of time-toreperfusion in patients with acute myocardial infarction with and without cardiogenic shock treated with primary percutaneous coronary intervention. Am Heart J 2003;145:708-15.

293. Antoniucci D, Valenti R, Migliorini A, et al. Relation of time to treatment and mortality in patients with acute myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol 2002;89:1248-52.

294. Berger PB, Ellis SG, Holmes DR, et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. Circulation 1999;100: 14-20.

295. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000;283:2941-7.

296. Zijlstra F, Patel A, Jones M, et al. Clinical characteristics and outcome of patients with early (less than 2 h), intermediate (2-4 h) and late (greater than 4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J 2002;23:550-7.

297. Van de Werf F, Ardissino D, Betriu A, et al, for the Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003;24:28-66.

298. Krumholz HM, Chen J, Wang Y, Radford MJ, Chen YT, Marciniak TA. Comparing AMI mortality among hospitals in patients 65 years of age and older: evaluating methods of risk adjustment. Circulation 1999;99:2986-92.

299. Granger CB, Goldberg RJ, Dabbous O, et al, for the Global Registry of Acute Coronary Events Investigators. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003;163:2345-53.

300. Kent DM, Schmid CH, Lau J, Selker HP. Is primary angioplasty for some as good as primary angioplasty for all? J Gen Intern Med 2002;17:887-94.

301. Hochman JS, Sleeper LA, Webb JG, et al, for the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) Investigators. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 1999;341:625-34.

302. Wu AH, Parsons L, Every NR, Bates ER, for the Second National Registry of Myocardial Infarction. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 2002; 40:1389-94.

303. Magid DJ, Calonge BN, Rumsfeld JS, et al, for the National Registry of Myocardial Infarction 2 and 3 Investigators. Relation between hospital primary angioplasty volume and mortality for patients with acute MI treated with primary angioplasty vs thrombolytic therapy. JAMA 2000;284:3131-8.

304. Canto JG, Every NR, Magid DJ, et al, for the National Registry of Myocardial Infarction 2 Investigators. The volume of primary angioplasty procedures and survival after acute myocardial infarction. N Engl J Med 2000;342:1573-80.

305. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? Am J Cardiol 2003;92:824-6.

306. Andersen HR, Nielsen TT, Rasmussen K, et al, for the DANAMI- 2 Investigators. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003;349:733-42.

307. Aversano T, Aversano LT, Passamani E, et al, for the Atlantic Cardiovascular Patient Outcomes Research Team (C-PORT). Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA 2002;287:1943-51.

308. Angeja BG, Gibson CM, Chin R, et al, for the Participants in the National Registry of Myocardial Infarction 2-3. Predictors of door-to-balloon delay in primary angioplasty. Am J Cardiol 2002;89:1156-61.

309. Henriques JP, Haasdijk AP, Zijlstra F, for the Zwolle Myocardial Infarction Study Group. Outcome of primary angioplasty for acute myocardial infarction during routine duty hours versus during off-hours. J Am Coll Cardiol 2003;41:2138-42.

310. Spencer FA, Becker RC. Circadian variations in acute myocardial infarction: patients or health care delivery? J Am Coll Cardiol 2003;41:2143-6.

311. Armstrong PW, Antman EM. Coronary angioplasty versus fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003;349:2167-9; author reply.

312. Herrick JB. Landmark article (JAMA 1912): clinical features of sudden obstruction of the coronary arteries. JAMA 1983;250: 1757-65.

313. Chazov EI, Matveeva LS, Mazaev AV, Sargin KE, Sadovskaia GV, Ruda MI. [Intracoronary administration of fibrinolysin in acute myocardial infarct.] Ter Arkh 1976;48:8-19.

314. Aylward PE, Wilcox RG, Horgan JH, et al, for the GUSTO-I Investigators. Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction: a randomized trial. Ann Intern Med 1996;125:891-900.

315. Antman EM. General hospital management. In: Julian DG, Braunwald E, eds. Management of acute myocardial infarction. London, England: WB Saunders Co Ltd;1994:42-44.

316. Goldberger AL. Hyperacute T waves revisited. Am Heart J 1982;104:888-90.

317. Boden WE, Kleiger RE, Gibson RS, et al. Electrocardiographic evolution of posterior acute myocardial infarction: importance of early precordial ST-segment depression. Am J Cardiol 1987;59: 782-7.

318. Zimetbaum PJ, Josephson ME. Use of the electrocardiogram in acute myocardial infarction. N Engl J Med 2003;348:933-40.

319. Zehender M, Kasper W, Kauder E, et al. Eligibility for and benefit of thrombolytic therapy in inferior myocardial infarction: focus on the prognostic importance of right ventricular infarction. J Am Coll Cardiol 1994;24:362-9.

320. Gore JM, Sloan M, Price TR, et al. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial. Circulation 1991; 83:448-59.

321. Thrombolytic therapy in thrombosis: a National Institutes of Health consensus development conference. Ann Intern Med 1980; 93:141-4.

322. Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis: mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation 1995;92:2811-8.

323. White HD, Aylward PE, Frey MJ, et al, for the Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997;96:2155-61.

324. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics. Lancet 1995;346:329-36.

325. Giugliano RP, McCabe CH, Antman EM, et al. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Am Heart J 2001;141:742-50.

326. Wienbergen H, Schiele R, Gitt AK, et al, for the Myocardial Infarction Registry (MIR) and Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) Study Groups. Incidence, risk factors, and clinical outcome of stroke after acute myocardial infarction in clinical practice. Am J Cardiol 2001;87:782-5, A8.

327. Kandzari DE, Granger CB, Simoons ML, et al, for the Global Utilization of Streptokinase and tPA for Occluded Arteries-I (GUSTO-I) Investigators. Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-I trial). Am J Cardiol 2004;93:458-61.

328. Gurwitz JH, Gore JM, Goldberg RJ, et al, for the Participants in the National Registry of Myocardial Infarction 2. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Ann Intern Med 1998; 129:597-604.

329. Simoons ML, Maggioni AP, Knatterud G, et al. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet 1993;342:1523-8.

330. Sloan MA, Guigliano RP, Thompson SL. Prediction of intracranial hemorrhage in the InTIME-II trial. J Am Coll Cardiol 2001; 37:372A.

331. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988;2:525-30.

332. AIMS Trial Study Group. Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. Lancet 1990;335:427-31.

333. Lamas GA, Flaker GC, Mitchell G, et al, for the Survival and Ventricular Enlargement Investigators. Effect of infarct artery patency on prognosis after acute myocardial infarction. Circulation 1995;92:1101-9.

334. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R, for the ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. ISIS-2: 10-year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. BMJ 1998;316:1337-43.

335. Franzosi MG, Santoro E, De Vita C, et al, for the GISSI Investigators. Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto-1 study. Circulation 1998;98:2659-65.

336. Van de Werf F. Thrombolysis for acute myocardial infarction: why is there no extra benefit after hospital discharge? Circulation 1995;91:2862-4.

337. Deleted in press.

338. Gillium BS, Graves EJ, Wood E. National hospital discharge survey: data from the National Health Survey. Vital and Health Statistics 1998;13:1-51.

339. White HD. Thrombolytic therapy in the elderly. Lancet 2000; 356:2028-30.

340. Thiemann DR, Coresh J, Schulman SP, Gerstenblith G, Oetgen WJ, Powe NR. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation 2000;101:2239-46.

341. Berger AK, Radford MJ, Wang Y, Krumholz HM. Thrombolytic therapy in older patients. J Am Coll Cardiol 2000;36:366-74.

342. Stenestrand U, Wallentin L. Fibrinolytic therapy in patients 75 years and older with ST-segment-elevation myocardial infarction: one-year follow-up of a large prospective cohort. Arch Intern Med 2003;163:965-71.

343. Ross AM, Coyne KS, Moreyra E, et al, for the GUSTO-I Angiographic Investigators. Extended mortality benefit of early postinfarction reperfusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. Circulation 1998;97:1549-56.

344. Ross AM, Lundergan CF, Rohrbeck SC, et al, for the GUSTO-1 Angiographic Investigators. Rescue angioplasty after failed thrombolysis: technical and clinical outcomes in a large thrombolysis trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1998;31:1511-7.

345. Clements IP, Christian TF, Higano ST, Gibbons RJ, Gersh BJ. Residual flow to the infarct zone as a determinant of infarct size after direct angioplasty. Circulation 1993;88:1527-33.

346. Stone GW, Cox D, Garcia E, et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation 2001; 104:636-41.

347. Laster SB, O’Keefe JH, Gibbons RJ. Incidence and importance of thrombolysis in myocardial infarction grade 3 flow after primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996;78:623-6.

348. Stone GW, Peterson MA, Lansky AJ, Dangas G, Mehran R, Leon MB. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol 2002;39:591-7.

349. Angeja BG, Gunda M, Murphy SA, et al. TIMI myocardial perfusion grade and ST segment resolution: association with infarct size as assessed by single photon emission computed tomography imaging. Circulation 2002;105:282-5.

350. Gibbons RJ, Miller DD, Liu P, Guo P, Brooks MM, Schwaiger M. Similarity of ventricular function in patients alive 5 years after randomization to surgery or angioplasty in the BARI trial. Circulation 2001;103:1076-82.

351. Rovelli F, De Vita C, Feruglio GA, Lotto A, Selvini A, Tognoni G, for the Gruppo Italiano per la Sperimentazione della Streptochinasi nell’Infarto Miocardico. GISSI trial: early results and late follow-up. J Am Coll Cardiol 1987;10:33B-39B.

352. Maggioni AP, Franzosi MG, Farina ML, et al, for the Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Cerebrovascular events after myocardial infarction: analysis of the GISSI trial. BMJ 1991;302:1428-31.

353. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65- 71.

354. The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990;336:71-5.

355. Maggioni AP, Franzosi MG, Santoro E, White H, Van de Werf F, Tognoni G, for the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico II (GISSI-2) and the International Study Group. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. N Engl J Med 1992;327:1-6.

356. De Jaegere PP, Arnold AA, Balk AH, Simoons ML. Intracranial hemorrhage in association with thrombolytic therapy: incidence and clinical predictive factors. J Am Coll Cardiol 1992;19:289-94.

357. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-70.

358. Estudio Multicéntrico Estreptoquinasa Repúblicas de América del Sur (EMERAS) Collaborative Group. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 1993;342:767-72.

359. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631-7.

360. Sloan MA, Price TR, Terrin ML, et al. Ischemic cerebral infarction after rt-PA and heparin therapy for acute myocardial infarction: the TIMI-II pilot and randomized clinical trial combined experience. Stroke 1997;28:1107-14.

361. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET study. Anglo-Scandinavian Study of Early Thrombolysis. Lancet 1990;335:1175-8.

362. O’Connor CM, Califf RM, Massey EW, et al. Stroke and acute myocardial infarction in the thrombolytic era: clinical correlates and long-term prognosis. J Am Coll Cardiol 1990;16:533-40.

363. Kase CS, Pessin MS, Zivin JA, et al. Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator. Am J Med 1992;92:384-90.

364. Sloan MA, Price TR, Petito CK, et al. Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience. Neurology 1995;45:649-58.

365. Longstreth WT, Litwin PE, Weaver WD, for the MITI Project Group. Myocardial infarction, thrombolytic therapy, and stroke: a community-based study. Stroke 1993;24:587-90.

366. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993;342:759-66.

367. Vermeer F, Bösl I, Meyer J, et al. Saruplase is a safe and effective thrombolytic agent; observations in 1,698 patients: results of the PASS study. Practical Applications of Saruplase Study. J Thromb Thrombolysis 1999;8:143-50.

368. Neuhaus KL, von Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study: a study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK) Circulation 1994;90:1638-42.

369. Antman EM, Giugliano RP, Gibson CM, et al, for the TIMI 14 Investigators. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 1999;99:2720-32.

370. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. A systems approach to immediate evaluation and management of hyperacute stroke: experience at eight centers and implications for community practice and patient care. Stroke 1997;28:1530-40.

371. Broderick JP, Adams HP, Barsan W, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1999;30:905- 15.

372. Gebel JM, Sila CA, Sloan MA, et al. Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Stroke 1998;29:563-9.

373. Gebel JM, Sila CA, Sloan MA, et al. Comparison of the ABC/2 estimation technique to computer-assisted volumetric analysis of intraparenchymal and subdural hematomas complicating the GUSTO-1 trial. Stroke 1998;29:1799-801.

374. Sane DC, Califf RM, Topol EJ, Stump DC, Mark DB, Greenberg CS. Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management. Ann Intern Med 1989; 111:1010-22.

375. Mahaffey KW, Granger CB, Sloan MA, et al. Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary Arteries. Am Heart J 1999;138:493-9.

376. Sloan MA. Neurologic complications of thrombolytic therapy. In: Biller J, ed. Iatrogenic neurology. Boston, MA: Butterworth Heinemann; 1997:335-78.

377. Sloan MA, Sila CA, Mahaffey KW, et al. Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage. Circulation 1998;98:1376-82.

378. The thrombolytic agent. In: Sherry S, ed. Fibrinolysis, thrombosis, and hemostasis: concepts, perspectives, and clinical applications. Philadelphia, PA: Lea & Febiger; 1992:119-60.

379. Armstrong PW, Collen D. Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1. Circulation 2001;103:2862-6.

380. Cannon CP, Gibson CM, McCabe CH, et al, for the Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Circulation 1998;98:2805-14.

381. Mosby’s Drug Consult 2004 Internet Subscription, 8th ed. Elsevier, 2003. Available at http://www.mosbysdrugconsult.com. Accessed February 27, 2004.

382. Antman EM. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996;94:911-21.

383. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-82.

384. Martin GV, Kennedy JW. Choice of thrombolytic agent. In: Julian DG, Braunwald E, eds. Management of acute myocardial infarction. London, England: WB Saunders Co Ltd; 1994:71-105.

385. Fuster V. Coronary thrombolysis: a perspective for the practicing physician. N Engl J Med 1993;329:723-5.

386. Simoons ML, Arnold AE. Tailored thrombolytic therapy: a perspective. Circulation 1993;88:2556-64.

387. White HD. Selecting a thrombolytic agent. Cardiol Clin 1995; 13:347-54.

388. French JK,Williams BF, Hart HH, et al. Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. BMJ 1996;312:1637-41.

389. Hillis LD, Forman S, Braunwald E, for the Thrombolysis in Myocardial Infarction (TIMI) Phase II Co-Investigators. Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. J Am Coll Cardiol 1990;16:313-5.

390. Normand ST, Glickman ME, Sharma RG, McNeil BJ. Using admission characteristics to predict short-term mortality from myocardial infarction in elderly patients: results from the Cooperative Cardiovascular Project. JAMA 1996;275:1322-8.

391. Becker RC, Burns M, Gore JM, et al, for the National Registry of Myocardial Infarction (NRMI-2) Participants. Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: a nationwide perspective of current clinical practice. Am Heart J 1998;135:786- 96.

392. Tu JV, Austin PC, Walld R, Roos L, Agras J, McDonald KM. Development and validation of the Ontario acute myocardial infarction mortality prediction rules. J Am Coll Cardiol 2001; 37:992-7.

393. Jacobs DR, Kroenke C, Crow R, et al. PREDICT: a simple risk score for clinical severity and long-term prognosis after hospitalization for acute myocardial infarction or unstable angina: the Minnesota heart survey. Circulation 1999;100:599-607.

394. Morrow DA, Antman EM, Parsons L, et al. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA 2001;286:1356-9.

395. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000;101:125-30.

395a. Holper EM, Giugliano RP, Antman EM. Glycoprotein IIb/IIIa inhibitors in acute ST-segment myocardial infarction. Coron Artery Dis 1999;10:567-73.

396. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation 2000;101:2788-94.

397. Brener SJ, Zeymer U, Adgey AA, et al. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. J Am Coll Cardiol 2002;39:377-86.

398. Savonitto S, Armstrong PW, Lincoff AM, et al. Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction: dichotomous response as a function of age in the GUSTO V trial. Eur Heart J 2003;24:1807-14.

399. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA 2002;288:2130-5.

400. Antman EM, Gibson CM, de Lemos JA, et al, for the Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. Eur Heart J 2000;21:1944- 53.

401. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. Am Heart J 2003;145:47-57.

402. Wilson SH, Bell MR, Rihal CS, Bailey KR, Holmes DR, Berger PB. Infarct artery reocclusion after primary angioplasty, stent placement, and thrombolytic therapy for acute myocardial infarction. Am Heart J 2001;141:704-10.

403. Grzybowski M, Clements EA, Parsons L, et al. Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy: a propensity analysis. JAMA 2003;290:1891-8.

404. Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680-4.

405. Ribeiro EE, Silva LA, Carneiro R, et al. Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol 1993;22:376-80.

406. Grinfeld L, Berrocal D, Bellardi J, et al. Fibrinolytics versus pri-mary angioplasty in acute myocardial infarction (FAP): a randomized trial in a community hospital in Argentina. J Am Coll Cardiol 1996;27:A222.

407. Zijlstra F, Beukema WP, van’t Hof AW, et al. Randomized comparison of primary coronary angioplasty with thrombolytic therapy in low risk patients with acute myocardial infarction. J Am Coll Cardiol 1997;29:908-12.

408. Widimský P, Groch L, Zelízko M, Aschermann M, Bednár F, Suryapranata H. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study. Eur Heart J 2000;21:823-31.

409. de Boer MJ, Ottervanger JP, van’t Hof AW, Hoorntje JC, Suryapranata H, Zijlstra F, for the Zwolle Myocardial Infarction Study Group. Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy. J Am Coll Cardiol 2002;39:1723-8.

410. Akhras F, Ousa AA, Swann G, et al . Primary coronary angioplasty or intravenous thrombolysis for patients with acute myocardial infarction? Acute and late follow-up results in a new cardiac unit [abstr]. J Am Coll Cardiol 1997;29:A235-6.

411. Deleted in press.

412. Grines CL, Browne KF, Marco J, et al, for the Primary Angioplasty in Myocardial Infarction Study Group. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993;328:673-9.

413. Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspirger MR, Gersh BJ, for the Mayo Coronary Care Unit and Catheterization Laboratory Groups. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 1993;328:685-91.

414. Ribichini F, Steffenino G, Dellavalle A, et al. Comparison of thrombolytic therapy and primary coronary angioplasty with liberal stenting for inferior myocardial infarction with precordial STsegment depression: immediate and long-term results of a randomized study. J Am Coll Cardiol 1998;32:1687-94.

415. García E, Elízaga J, Pérez-Castellano N, et al. Primary angioplasty versus systemic thrombolysis in anterior myocardial infarction. J Am Coll Cardiol 1999;33:605-11.

416. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997;336:1621-8.

417. Le May MR, Labinaz M, Davies RF, et al. Stenting versus thrombolysis in acute myocardial infarction trial (STAT). J Am Coll Cardiol 2001;37:985-91.

418. Schömig A, Kastrati A, Dirschinger J, et al, for the Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. N Engl J Med 2000;343:385-91.

419. Vermeer F, Oude Ophuis AJ, vd Berg EJ, et al. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. Heart 1999;82:426-31.

420. Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. Lancet 2002;359:920-5.

421. Grines CL, Westerhausen DR Jr, Grines LL,, et al, for the Air PAMI Study Group. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study. J Am Coll Cardiol 2002;39:1713-9.

421a.Melandri G. The obsession with primary angioplasty. Circulation 2003;108:e162.

422. Rogers WJ, Dean LS, Moore PB, Wool KJ, Burgard SL, Bradley EL, for the Alabama Registry of Myocardial Ischemia Investigators. Comparison of primary angioplasty versus thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1994;74:111-8.

423. Every NR, Parsons LS, Hlatky M, Martin JS,Weaver WD, for the Myocardial Infarction Triage and Intervention Investigators. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. N Engl J Med 1996;335: 1253-60.

424. Tiefenbrunn AJ, Chandra NC, French WJ, Gore JM, Rogers WJ. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissuetype plasminogen activator) in patients with acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 1998;31: 1240-5.

425. Danchin N, Vaur L, Genès N, et al. Treatment of acute myocardial infarction by primary coronary angioplasty or intravenous thrombolysis in the “real world”: one-year results from a nationwide French survey. Circulation 1999;99:2639-44.

426. Stone GW, Grines CL, Browne KF, et al. Influence of acute myocardial infarction location on in-hospital and late outcome after primary percutaneous transluminal coronary angioplasty versus tissue plasminogen activator therapy. Am J Cardiol 1996;78:19-25.

427. van’t Hof AW, Henriques J, Ottervanger J-P, et al. No mortality benefit of primary angioplasty over thrombolytic therapy in patients with nonanterior myocardial infarction at long-term follow- up: results of the Zwolle trial [abstr]. J Am Coll Cardiol 2003;41:369A.

428. Brodie BR, Stuckey TD, Hansen C, Muncy D. Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction. Am J Cardiol 2000;85:13- 8.

429. Juliard JM, Feldman LJ, Golmard JL, et al. Relation of mortality of primary angioplasty during acute myocardial infarction to door-to-Thrombolysis In Myocardial Infarction (TIMI) time. Am J Cardiol 2003;91:1401-5.

430. Ellis S. Elective coronary intervention: approach, technique, and complications. In: Topol EJ, ed. Textbook of interventional cardiology, 4th ed., Philadelphia, PA:WB Saunders Co Ltd; 2003:163- 181.

431. Levine GN, Kern MJ, Berger PB, et al, for the American Heart Association Diagnostic and Interventional Catheterization Committee and Council on Clinical Cardiology. Management of patients undergoing percutaneous coronary revascularization. Ann Intern Med 2003;139:123-36.

432. Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty). Available at http://www.acc.org/clinical/guidelines/percutaneous/dirIndex.ht, 2001. Accessed December 16, 2003.

433. Cragg DR, Friedman HZ, Bonema JD, et al. Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy. Ann Intern Med 1991;115:173-7.

434. Brodie BR,Weintraub RA, Stuckey TD, et al. Outcomes of direct coronary angioplasty for acute myocardial infarction in candidates and non-candidates for thrombolytic therapy. Am J Cardiol 1991;67:7-12.

435. Himbert D, Juliard JM, Steg PG, et al. Primary coronary angioplasty for acute myocardial infarction with contraindication to thrombolysis. Am J Cardiol 1993;71:377-81.

436. Zahn R, Schuster S, Schiele R, et al, for the Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) Study Group. Comparison of primary angioplasty with conservative therapy in patients with acute myocardial infarction and contraindications for thrombolytic therapy. Catheter Cardiovasc Interv 1999;46:127-33.

437. Iannone LA, Anderson SM, Phillips SJ. Coronary angioplasty for acute myocardial infarction in a hospital without cardiac surgery. Tex Heart Inst J 1993;20:99-104.

438. Weaver WD, Litwin PE, Martin JS, for the Myocardial Infarction, Triage, and Intervention Project Investigators. Use of direct angioplasty for treatment of patients with acute myocardial infarction in hospitals with and without on-site cardiac surgery. Circulation 1993;88:2067-75.

439. Weaver WD, Parsons L, Every N, for the MITI project investigators. Primary coronary angioplasty in hospitals with and without surgery backup. J Invasive Cardiol 1995;7:34F-39F.

440. Brush JE, Thompson S, Ciuffo AA, et al. Retrospective comparison of a strategy of primary coronary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction in a community hospital without cardiac surgical backup. J Invasive Cardiol 1996;8:91-98.

441. Moquet B, Huguet RG, Cami G, et al. [Primary angioplasty in acute myocardial infarction: a one-year experience in a small urban community.] Arch Mal Coeur Vaiss 1997;90:11-5.

442. Smyth DW, Richards AM, Elliott JM. Direct angioplasty for myocardial infarction: one-year experience in a center with surgical back-up 220 miles away. J Invasive Cardiol 1997;9:324-332.

443. Ribichini F. Experiences with primary angioplasty without on site-cardiac surgery. Semin Interv Cardiol 1999;4:47-53.

444. Primary Angioplasty in Acute Myocardial Infarction at Hospitals With No Surgery On-Site (the PAMI-No SOS study) versus transfer to surgical centers for primary angioplasty. J Am Coll Cardiol 2004;43:1943-50.

445. Wharton TP, McNamara NS, Fedele FA, Jacobs MI, Gladstone AR, Funk EJ. Primary angioplasty for the treatment of acute myocardial infarction: experience at two community hospitals without cardiac surgery. J Am Coll Cardiol 1999;33:1257-65.

446. Singh M, Garratt KN, Lennon RJ, et al. Emergent angioplasty for acute myocardial infarction at a community hospital without onsite cardiac surgery [abstr]. J Am Coll Cardiol 2002;39:40A.

447. Sanborn TA, Jacobs AK, Frederick PD, Every NR, French WJ. Nationwide emergent coronary interventions (primary PCI) in patients with acute myocardial infarction in hospitals with and without on-site cardiac surgery: a report from the National Registry of Myocardial Infarction (NRMI) [abstr]. Circulation 2002;106:II-333.

448. Aversano T. Primary angioplasty at hospitals without cardiac surgery: C-PORT Registry outcomes [abstr]. Circulation 2003;108:IV-613.

449. Singh M, Ting HH, Berger PB, Garratt KN, Holmes DR, Gersh BJ. Rationale for on-site cardiac surgery for primary angioplasty: a time for reappraisal. J Am Coll Cardiol 2002;39:1881-9.

450. Kutcher MA, Klein LW, Wharton TP, et al. Clinical outcomes coronary angioplasty centers with off-site versus on-site cardiac surgery capabilities: a preliminary report from the American College of Cardiology—National Cardiovascular Data Registry [abstr]. J Am Coll Cardiol 2004;43:96a.

451. Deleted in press.

452. Lotfi M, Mackie K, Dzavik V, Seidelin PH. Impact of delays cardiac surgery after failed angioplasty and stenting. J Am Coll Cardiol 2004;43:337-42.

453. Dehmer GJ, Gantt DS. Coronary intervention at hospitals without on-site cardiac surgery: are we pushing the envelope too far? J Am Coll Cardiol 2004;43:343-5.

454. Zijlstra F, van’t Hof AW, Liem AL, Hoorntje JC, Suryapranata de Boer MJ. Transferring patients for primary angioplasty: a retrospective analysis of 104 selected high-risk patients with acute myocardial infarction. Heart 1997;78:333-6.

455. Zahn R, Schiele R, Seidl K, et al. Primary angioplasty in acute myocardial infarction: differences between referred patients and those treated in hospitals with on-site facilities? J Invasive Cardiol 1999;11:213-219.

456. Straumann E, Yoon S, Naegeli B, et al. Hospital transfer for primary coronary angioplasty in high-risk patients with acute myocardial infarction. Heart 1999;82:415-9.

457. Liem AL, van ‘t Hof AW, Hoorntje JC, de Boer MJ, Suryapranata H, Zijlstra F. Influence of treatment delay on infarct size and clinical outcome in patients with acute myocardial infarction treated with primary angioplasty. J Am Coll Cardiol 1998;32:629-33.

458. NRMI-4 Investigators: The National Registry of Myocardial Infarction-4 Quarterly Report. Genentech, South San Francisco, CA, March 2003:2.

459. Deleted in press.

460. Antoniucci D, Santoro GM, Bolognese L, Valenti R, Trapani M, Fazzini PF. A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial. J Am Coll Cardiol 1998;31:1234-9.

461. Rodríguez A, Bernardi V, Fernández M, et al. In-hospital and late results of coronary stents versus conventional balloon angioplasty in acute myocardial infarction (GRAMI trial). Gianturco-Roubin in Acute Myocardial Infarction. Am J Cardiol 1998;81:1286-91.

462. Suryapranata H, Ottervanger JP, Nibbering E, et al. Long term outcome and cost-effectiveness of stenting versus balloon angioplasty for acute myocardial infarction. Heart 2001;85:667-71.

463. Saito S, Hosokawa G, Tanaka S, Nakamura S, for the PASTA Trial Investigators. Primary stent implantation is superior to balloon angioplasty in acute myocardial infarction: final results of the primary angioplasty versus stent implantation in acute myocardial infarction (PASTA) trial. Catheter Cardiovasc Interv 1999; 48:262-8.

464. Grines CL, Cox DA, Stone GW, et al, for the Stent Primary Angioplasty in Myocardial Infarction Study Group. Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med 1999;341:1949-56.

465. Kawashima A, Ueda K, Nishida Y, et al. Quantitative angiographic analysis of restenosis of primary stenting using Wiktor stent for acute myocardial infarction: results from a multicenter randomised PRISAM study [abstr]. Circulation 1999;100:I-856.

466. Maillard L, Hamon M, Khalife K, et al, for the STENTIM-2 Investigators. A comparison of systematic stenting and conventional balloon angioplasty during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2000;35:1729-36.

467. Scheller B, Hennen B, Severin-Kneib S, Ozbek C, Schieffer H, Markwirth T. Long-term follow-up of a randomized study of primary stenting versus angioplasty in acute myocardial infarction. Am J Med 2001;110:1-6.

468. Lemos PA, Saia F, Hofma SH, et al. Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol 2004;43:704-8.

469. Gibson CM. A union in reperfusion: the concept of facilitated percutaneous coronary intervention. J Am Coll Cardiol 2000;36: 1497-9.

470. Herrmann HC, Moliterno DJ, Ohman EM, et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. J Am Coll Cardiol 2000;36:1489- 96.

471. Ross AM, Coyne KS, Reiner JS, et al, for the Plasminogen-activator Angioplasty Compatibility Trial (PACT) investigators. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. J Am Coll Cardiol 1999;34:1954-62.

472. Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, et al. Prospective randomized trial comparing a routine invasive strategy within 24 hours to thrombolysis versus an ischemia-guided conservative approach to acute myocardial infarction with ST-segment elevation: the Gracia-1 trial. Lancet. In press. 473. Kastrati A, Mehilli J, Schlotterbeck K, et al, for the Bavarian Reperfusion Alternatives Evaluation (BRAVE) Study Investigators. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. JAMA. 2004;291:947-54.

473a. Ellis SG, Armstrong P, Betriu A, et al. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. Am Heart J 2004;147:E16.

474. Granger CB, White HD, Bates ER, Ohman EM, Califf RM. A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. Am J Cardiol 1994;74:1220-8.

475. Lange RA, Cigarroa RG, Wells PJ, Kremers MS, Hills LD. Influence of anterograde flow in the infarct artery on the incidence of late potentials after acute myocardial infarction. Am J Cardiol 1990;65:554-8.

476. Cigarroa RG, Lange RA, Hillis LD. Prognosis after acute myocardial infarction in patients with and without residual anterograde coronary blood flow. Am J Cardiol 1989;64:155-60.

477. Ellis SG, da Silva ER, Heyndrickx G, et al. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction. Circulation 1994;90:2280-4.

478. Goldman LE, Eisenberg MJ. Identification and management of patients with failed thrombolysis after acute myocardial infarction. Ann Intern Med 2000;132:556-65.

479. The TIMI Research Group. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction: TIMI II A results. JAMA 1988;260:2849-58.

480. Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987;317:581-8.

481. Califf RM, Topol EJ, Stack RS, et al, for the TAMI Study Group. Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction: results of thrombolysis and angioplasty in myocardial infarction: phase 5 randomized trial. Circulation 1991;83:1543-56.

482. Califf RM, Topol EJ, George BS, et al. Characteristics and outcome of patients in whom reperfusion with intravenous tissuetype plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I trial. Circulation 1988;77:1090-9.

483. Lee L, Bates ER, Pitt B, Walton JA, Laufer N, O’Neill WW. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. Circulation 1988;78:1345-51.

484. Jeremy RW, Hackworthy RA, Bautovich G, Hutton BF, Harris PJ. Infarct artery perfusion and changes in left ventricular volume in the month after acute myocardial infarction. J Am Coll Cardiol 1987;9:989-95.

485. Kersschot IE, Brugada P, Ramentol M, et al. Effects of early reperfusion in acute myocardial infarction on arrhythmias induced by programmed stimulation: a prospective, randomized study. J Am Coll Cardiol 1986;7:1234-42.

486. Stadius ML, Davis K, Maynard C, Ritchie JL, Kennedy JW. Risk stratification for 1-year survival based on characteristics identified in the early hours of acute myocardial infarction. The Western Washington Intracoronary Streptokinase Trial. Circulation 1986;74:703-11.

487. Topol EJ, Califf RM, Vandormael M, et al, for the Thrombolysis and Angioplasty in Myocardial Infarction-6 Study Group. A randomized trial of late reperfusion therapy for acute myocardial infarction. Circulation 1992;85:2090-9.

488. Dzavik V, Beanlands DS, Davies RF, et al. Effects of late percutaneous transluminal coronary angioplasty of an occluded infarctrelated coronary artery on left ventricular function in patients with a recent (less than 6 weeks) Q-wave acute myocardial infarction (Total Occlusion Post-Myocardial Infarction Intervention Study [TOMIIS]: a pilot study). Am J Cardiol 1994;73:856-61.

489. Zeymer U, Uebis R, Vogt A, et al, for the ALKK-Study Group. Randomized comparison of percutaneous transluminal coronary angioplasty and medical therapy in stable survivors of acute myocardial infarction with single vessel disease: a study of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte. Circulation 2003;108:1324-8.

490. Horie H, Takahashi M, Minai K, et al. Long-term beneficial effect of late reperfusion for acute anterior myocardial infarction with percutaneous transluminal coronary angioplasty. Circulation 1998;98:2377-82.

491. Yousef ZR, Redwood SR, Bucknall CA, Sulke AN, Marber MS. Late intervention after anterior myocardial infarction: effects on left ventricular size, function, quality of life, and exercise tolerance: results of the Open Artery Trial (TOAT Study). J Am Coll Cardiol 2002;40:869-76.

492. Deleted in press.

493. Sadanandan S, Buller C, Menon V, et al. The late open artery hypothesis: a decade later. Am Heart J 2001;142:411-21.

494. Hochman JS, Boland J, Sleeper LA, et al, for the SHOCK Registry Investigators. Current spectrum of cardiogenic shock and effect of early revascularization on mortality: results of an international registry. Circulation 1995;91:873-81.

495. Urban P, Stauffer JC, Bleed D, et al. A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock-(S)MASH. Eur Heart J 1999;20:1030-8.

496. Dzavik V, Sleeper LA, Cocke TP, et al, for the SHOCK Investigators. Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK trial registry. Eur Heart J 2003;24:828-37.

497. Dauerman HL, Goldberg RJ, Malinski M,Yarzebski J, Lessard D, Gore JM. Outcomes and early revascularization for patients greater than or equal to 65 years of age with cardiogenic shock. Am J Cardiol 2001;87:844-8.

498. Dauerman HL, Ryan TJ, Piper WD, et al. Outcomes of percutaneous coronary intervention among elderly patients in cardiogenic shock: a multicenter, decade-long experience. J Invasive Cardiol 2003;15:380-4.

499. Chan AW, Chew DP, Bhatt DL, Moliterno DJ, Topol EJ, Ellis SG. Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 2002;89:132-6.

500. Giri S, Mitchel J, Azar RR, et al. Results of primary percutaneous transluminal coronary angioplasty plus abciximab with or without stenting for acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 2002;89:126-31.

501. Antoniucci D, Valenti R, Migliorini A, et al. Abciximab therapy improves survival in patients with acute myocardial infarction complicated by early cardiogenic shock undergoing coronary artery stent implantation. Am J Cardiol 2002;90:353-7.

502. Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003;107:2998- 3002.

503. Simoons ML, Arnold AE, Betriu A, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988;1:197-203.

504. Scheller B, Hennen B, Hammer B, et al, for the SIAM III Study Group. Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol 2003; 42:634-41.

505. Should We Intervene Following Thrombolysis? (SWIFT) Trial Study Group. SWIFT trial of delayed elective intervention vs conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. BMJ 1991;302:555-60.

506. Williams DO, Braunwald E, Knatterud G, et al. One-year results of the Thrombolysis in Myocardial Infarction investigation (TIMI) Phase II Trial. Circulation 1992;85:533-42.

507. Terrin ML,Williams DO, Kleiman NS, et al. Two- and three-year results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical trial. J Am Coll Cardiol 1993;22:1763-72.

508. Stenestrand U, Wallentin L. Early revascularisation and 1-year survival in 14-day survivors of acute myocardial infarction: a prospective cohort study. Lancet 2002;359:1805-11.

509. Alter DA, Tu JV, Austin PC, Naylor CD. Waiting times, revascularization modality, and outcomes after acute myocardial infarction at hospitals with and without on-site revascularization facilities in Canada. J Am Coll Cardiol 2003;42:410-9.

510. Zeymer U, Uebis R, Vogt A, et al, for the ALKK-Study Group. Randomized comparison of percutaneous transluminal coronary angioplasty and medical therapy in stable survivors of acute myocardial infarction with single-vessel disease: a study of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte. Circulation 2003;108:1324-8.

511. Gupta M, Chang WC, Van de Werf F, et al, for the ASSENT II Investigators. International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2. Eur Heart J 2003; 24:1640-50.

512. Gibson CM, Karha J, Murphy SA, et al, for the TIMI Study Group. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the thrombolysis in myocardial infarction trials. J Am Coll Cardiol 2003;42:7- 16.

513. Deleted in press.

514. Deleted in press.

515. Madsen JK, Grande P, Saunamäki K, et al. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction. Circulation 1997;96:748-55.

516. Barbash GI, Roth A, Hod H, et al. Randomized controlled trial of late in-hospital angiography and angioplasty versus conservative management after treatment with recombinant tissue-type plasminogen activator in acute myocardial infarction. Am J Cardiol 1990;66:538-45.

517. Ellis SG, Mooney MR, George BS, et al, for the Treatment of Post-Thrombolytic Stenoses (TOPS) Study Group. Randomized trial of late elective angioplasty versus conservative management for patients with residual stenoses after thrombolytic treatment of myocardial infarction. Circulation 1992;86:1400-6.

518. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol In press.

519. Deleted in press.

520. Caracciolo EA, Davis KB, Sopko G, et al. Comparison of surgical and medical group survival in patients with left main coronary artery disease: long-term CASS experience. Circulation 1995;91:2325-34.

521. Davis KB, Chaitman B, Ryan T, Bittner V, Kennedy JW. Comparison of 15-year survival for men and women after initial medical or surgical treatment for coronary artery disease: a CASS registry study. Coronary Artery Surgery Study. J Am Coll Cardiol 1995;25:1000-9.

522. Stone GW, Brodie BR, Griffin JJ, et al. Role of cardiac surgery in the hospital phase management of patients treated with primary angioplasty for acute myocardial infarction. Am J Cardiol 2000;85:1292-6.

523. Hochman JS, Buller CE, Sleeper LA, et al. Cardiogenic shock complicating acute myocardial infarction: etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 2000;36:1063-70.

524. Hochman JS, Gersh B. Acute myocardial infarction. In: Topol EJ, ed. Textbook of cardiovascular medicine. Philadelphia, PA: Lippincott-Raven Publishers; 1998:421-62.

525. DeBusk RF. Specialized testing after recent acute myocardial infarction. Ann Intern Med 1989;110:470-81.

526. Holmes DR, Bates ER, Kleiman NS, et al, for the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) Investigators. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. J Am Coll Cardiol 1995;26:668-74.

527. de Lemos JA, Braunwald E. ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. J Am Coll Cardiol 2001;38:1283-94.

528. Matetzky S, Novikov M, Gruberg L, et al. The significance of persistent ST elevation versus early resolution of ST segment elevation after primary PTCA. J Am Coll Cardiol 1999;34:1932-8.

529. Schröder R, Dissmann R, Brüggemann T, et al. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol 1994;24:384-91.

530. Fu Y, Goodman S, Chang WC, Van De Werf F, Granger CB, Armstrong PW. Time to treatment influences the impact of STsegment resolution on one-year prognosis: insights from the assessment of the safety and efficacy of a new thrombolytic (ASSENT-2) trial. Circulation 2001;104:2653-9.

531. de Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both epicardial flow and myocardial reperfusion in STelevation myocardial infarction: observations from the TIMI 14 trial. Circulation 2000;101:239-43.

532. Santoro GM, Antoniucci D, Valenti R, et al. Rapid reduction of ST-segment elevation after successful direct angioplasty in acute myocardial infarction. Am J Cardiol 1997;80:685-9.

533. Antman EM. The search for replacements for unfractionated heparin. Circulation 2001;103:2310-4.

534. Eisenberg PR. Role of heparin in coronary thrombolysis. Chest 1992;101:131S-139S.

535. Rao AK, Pratt C, Berke A, Jaffe A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial: phase I–hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.

536. Popma JJ, Califf RM, Ellis SG, et al. Mechanism of benefit of combination thrombolytic therapy for acute myocardial infarction: a quantitative angiographic and hematologic study. J Am Coll Cardiol 1992;20:1305-12.

537. Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997;336:847-60.

538. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-22.

539. Col J, Decoster O, Hanique G, Deligne B, Boland J, Pirenne B. Infusion of heparin conjunct to streptokinase accelerates reperfusion of acute myocardial infarction: results of a double-blind randomized study (OSIRIS). Circulation 1992;86:259.

540. Melandri G, Branzi A, Semprini F, Cervi V, Galiè N, Magnani B. Enhanced thrombolytic efficacy and reduction of infarct size by simultaneous infusion of streptokinase and heparin. Br Heart J 1990;64:118-20.

541. White HD,Yusuf S. Issues regarding the use of heparin following streptokinase therapy. J Thromb Thrombolysis 1995;2:5-10.

542. Simoons M, Krzeminska-Pakula M, Alonso A, et al, for the AMISK Investigators. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction: the AMI-SK study. Eur Heart J 2002;23:1282-90.

543. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990;66:1412-7.

544. de Bono DP, Simoons ML, Tijssen J, et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double-blind European Cooperative Study Group trial. Br Heart J 1992;67:122-8.

545. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM, for the Heparin-Aspirin Reperfusion Trial (HART) Investigators. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990;323:1433-7.

546. Mahaffey KW, Granger CB, Collins R, et al. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol 1996;77:551-6.

547. Ogilby JD, Kopelman HA, Klein LW, Agarwal JB. Adequate heparinization during PTCA: assessment using activated clotting times. Cathet Cardiovasc Diagn 1989;18:206-9.

548. Narins CR, Hillegass WB, Nelson CL, et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996;93:667-71.

549. Granger CB, Hirsch J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation 1996;93:870-8.

550. Menon V, Berkowitz SD, Antman EM, Fuchs RM, Hochman JS. New heparin dosing recommendations for patients with acute coronary syndromes. Am J Med 2001;110:641-50.

551. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism: a statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation 1996;93:2212-45.

552. Granger CB, Becker R, Tracy RP, et al, for the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) Hemostasis Substudy Group. Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. J Am Coll Cardiol 1998;31:497-505.

553. Antman EM. Hirudin in acute myocardial infarction: a safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994;90:1624- 30.

554. Thompson PL, Aylward PE, Federman J, et al, for the National Heart Foundation of Australia Coronary Thrombolysis Group. A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. Circulation 1991;83:1534-42.

555. Granger CB, Miller JM, Bovill EG, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995;91:1929-35.

556. Théroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992;327:141-5.

557. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330- 5.

558. Harrington RA, Sane DC, Califf RM, et al, for the Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 1994;23:891-8.

559. Ross AM, Molhoek P, Lundergan C, et al, for the HART Investigators. Randomized comparison of enoxaparin, a low molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001;104:648-52.

560. Baird SH, Menown IB, Mcbride SJ, Trouton TG, Wilson C. Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction. Eur Heart J 2002;23:627-32.

561. Tatu-Chitoiu G, Teodorescu C, Capraru M, et al. Accelerated streptokinase and enoxaparin in ST-segment elevation acute myocardial infarction (the ASENOX study) Polish J Cardiology 2004;60:441-6.

562. Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002;105:1642-9.

563. Wallentin L, Bergstrand L, Dellborg M, et al. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. Eur Heart J 2003;24:897-908.

564. Kontny F, Dale J, Abildgaard U, Pedersen TR. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) study. J Am Coll Cardiol 1997;30:962-9.

565. Frostfeldt G, Ahlberg G, Gustafsson G, et al. Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction: a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). J Am Coll Cardiol 1999;33:627-33.

566. Cohen M, Gensini GF, Maritz F, et al, for the TETAMI Investigators. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): randomized trial. J Am Coll Cardiol 2003;42:1348-56.

567. Kakkar VV, Iyengar SS, De Lorenzo F, Hargreaves JR, Kadziola ZA, for the FAMI Investigator Group. Low molecular weight heparin for treatment of acute myocardial infarction (FAMI): Fragmin (dalteparin sodium) in acute myocardial infarction. Indian Heart J 52:533-9.

568. Wong GC, Giugliano RP, Antman EM. Use of low-molecularweight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA 2003;289:331-42.

569. Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994;23:993-1003.

570. Lidón RM, Théroux P, Lespérance J, et al. A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 1994;89:1567-72.

571. Théroux P, Pérez-Villa F, Waters D, Lespérance J, Shabani F, Bonan R. Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995;91:2132-9.

572. Neuhaus KL, Molhoek GP, Zeymer U, et al. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial. J Am Coll Cardiol 1999;34:966-73.

573. Fung AY, Lorch G, Cambier PA, et al, for the ESCALAT Investigators. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. Am Heart J 1999; 138:696-704.

574. Angiomax (bivalirudin) for injection. Package Insert. The Medicine Company, Parsippany, NJ. Available at http://www. angiomax.com/%7Eproducts_content/PN1002.REV.5.mcR4.pdf, 2003. Accessed December 5, 2003.

575. Coussement PK, Bassand JP, Convens C, et al, for the PENTALYSE investigators. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart 2001;22:1716-24.

576. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, for the Investigators FT. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-9.

577. Mehta SR, Yusuf S, Peters RJ, et al, for the Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.

578. Steinhubl SR, Berger PB, Mann JT 3rd, et al, for the Clopidogrel for the Reduction of Events During Observation (CREDO) Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20.

579. CYPHER™ sirolimus-eluting coronary stent on RAPTORTM over-the-wire delivery system and CYPHER™ sirolimus-eluting coronary stent on RAPTORRAIL® rapid exchange delivery system: instructions for Use. Miami, FL: Cordis: A Johnson & Johnson Company, April 2003.

580. TAXUS: Paclitaxel-eluting coronary stent system Monorail® and over the wire coronary stent delivery system: directions for use. Natick, MA: Boston Scientific; March 2004.

581. Patrono C, Bachmann F, Baigent C, et al. ESC expert consensus document on the use of antiplatelet agents: a report by the Task Force on the Use of Antiplatelet Agents in Patients With Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. Eur Heart J 2004;25:166-81.

582. Antoniucci D, Rodriguez A, Hempel A, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003; 42:1879-85.

583. Topol EJ, Neumann FJ, Montalescot G. A preferred reperfusion strategy for acute myocardial infarction. J Am Coll Cardiol 2003;42:1886-9.

584. Lee DP, Herity NA, Hiatt BL, et al. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation 2003;107:1497- 501.

585. Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G. ACE inhibitor use in patients with myocardial infarction: summary evidence from clinical trials. Circulation 1995;92:3132-7.

586. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico (GISSI). GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.

587. Ambrosioni E, Borghi C, Magnani B, for the Survival Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5.

588. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995;345:686-7.

589. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998; 97:2202-12.

590. Teo K, Yusuf S, Pfeffer M, et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence absence of aspirin: a systematic review. Lancet 2002;360:1037.

591. Meune C, Mahe I, Mourad JJ, et al. Interaction between angiotensin-converting enzyme inhibitors and aspirin: a review. Eur J Clin Pharmacol 2000;56:609-20.

592. Sigurdsson A, Swedberg K. Left ventricular remodelling, neurohormonal activation and early treatment with enalapril (CONSENSUS II) following myocardial infarction. Eur Heart 1994;15(Suppl B):14-9; discussion 26.

593. Sodi-Pallares D, Testelli MR, Fishleder BL, et al. Effects of intravenous infusion of a potassium-glucose-insulin solution the electrocardiographic signs of myocardial infarction: a preliminary clinical report. Am J Cardiol 1962;9:166-81.

594. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 1997;96:1152-6.

595. Díaz R, Paolasso EA, Piegas LS, et al, for the ECLA (Estudios Cardiológicos Latinoamérica) Collaborative Group. Metabolic modulation of acute myocardial infarction. Circulation 1998;98:2227-34.

596. Ceremuzynski L, Budaj A, Czepiel A, et al. Low-dose glucoseinsulin- potassium is ineffective in acute myocardial infarction: results of a randomized multicenter Pol-GIK trial. Cardiovasc Drugs Ther 1999;13:191-200.

597. van der Horst IC, Zijlstra F, van’t Hof AW, et al. Glucose-insulinpotassium infusion in patients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol 2003;42:784-91.

598. Coleman GM, Gradinac S, Taegtmeyer H, Sweeney M, Frazier OH. Efficacy of metabolic support with glucose-insulin-potassium for left ventricular pump failure after aortocoronary bypass surgery. Circulation 1989;80:I91-6.

599. Melidonis A, Stefanidis A, Tournis S, et al. The role of strict metabolic control by insulin infusion on fibrinolytic profile during acute coronary event in diabetic patients. Clin Cardiol 2000;23:160-4.

600. Iwakura K, Ito H, Ikushima M, et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 2003;41:1-7.

601. Oliver MF, Opie LH. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet 1994;343:155-8.

602. Malmberg K, Rydén L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol
1995;26:57-65.

603. Finney SJ, Zekveld C, Elia A, Evans TW. Glucose control and mortality in critically ill patients. JAMA 2003;290:2041-7.

603a. Clement S, Braithwaite SS, Magee MF, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004; 27:553-97

604. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-67.

605. Goldberg PA, Siegel MD, Sherwin RS, et al. Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit. Diabetes Care 2004;27:461-7.

606. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360-72.

607. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003;289:2254-64.

608. Davis SM, Granner DK. Insulin oral hypoglycemic agents and the pharmacology of the endocrine pancreas. In: Hardman J, Limbird L, eds. Goodman and Gilman’s pharmacologic basis of therapeutics. 10th ed. USA: McGraw-Hill, 2001:1705.

609. Teo KK, Yusuf S, Collins R, Held PH, Peto R. Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. BMJ 1991;303:1499-503.

610. Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts: treatments for myocardial infarction. JAMA 1992;268:240-8.

611. Woods KL, Fletcher S. Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1994;343:816-9.

612. Antman EM. Magnesium in acute myocardial infarction: overview of available evidence. Am Heart J 1996;132:487-95; discussion 4.

613. Baxter GF, Sumeray MS,Walker JM. Infarct size and magnesium: insights into LIMIT-2 and ISIS-4 from experimental studies. Lancet 1996;348:1424-6.

614. Magnesium in Coronaries (MAGIC) Trial Investigators. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the agnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. Lancet 2002; 360:1189-96.

615. Morton BC, Nair RC, Smith FM, McKibbon TG, Poznanski WJ. Magnesium therapy in acute myocardial infarction: a doubleblind study. Magnesium 1984;3:346-52.

616. Rasmussen HS, McNair P, Norregard P, Backer V, Lindeneg O, Balslev S. Intravenous magnesium in acute myocardial infarction. Lancet 1986;1:234-6.

617. Smith LF, Heagerty AM, Bing RF, Barnett DB. Intravenous infusion of magnesium sulphate after acute myocardial infarction: effects on arrhythmias and mortality. Int J Cardiol 1986;12:175-83.

618. Woods KL, Fletcher S, Smith LF. Intravenous magnesium in suspected acute myocardial infarction. BMJ 1992;304:119.

619. Abraham AS, Rosenmann D, Kramer M, et al. Magnesium in the prevention of lethal arrhythmias in acute myocardial infarction. Arch Intern Med 1987;147:753-5.

1620. Ceremuzynski L, Jurgiel R, Kulakowski P, Gebalska J. Threatening arrhythmias in acute myocardial infarction are prevented by intravenous magnesium sulfate. Am Heart J 1989;118:1333-4.

621. Shechter M, Hod H, Marks N, et al. Beneficial effect of magnesium sulfate in acute myocardial infarction. Am J Cardiol 1990;66:271-4.

622. Feldstedt M, Boesgaard S, Bouchelouche P, et al. Magnesium substitution in acute ischaemic heart syndromes. Eur Heart J 1991;12:1215-8.

623. Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992;339:1553-8.

624. Thögersen AM, Johnson O, Wester PO. Effects of magnesium infusion on thrombolytic and non-thrombolytic treated patients with acute myocardial infarction. Int J Cardiol 1993;39:13-22.

625. Shechter M, Hod H, Chouraqui P, Kaplinsky E, Rabinowitz B. Magnesium therapy in acute myocardial infarction when patients are not candidates for thrombolytic therapy. Am J Cardiol 1995; 75:321-3.

626. Raghu C, Peddeswara Rao P, Seshagiri Rao D. Protective effect of intravenous magnesium in acute myocardial infarction following thrombolytic therapy. Int J Cardiol 1999;71:209-15.

627. Gyamlani G, Parikh C, Kulkarni AG. Benefits of magnesium in acute myocardial infarction: timing is crucial. Am Heart J 2000;139:703.

628. Woods KL, Abrams K. The importance of effect mechanism in the design and interpretation of clinical trials: the role of magnesium in acute myocardial infarction. Prog Cardiovasc Dis 2002; 44:267-74.

629. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care: part 6: advanced cardiovascular life support: section 5: pharmacology I: agents for arrhythmias. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation 2000;102:I112-28.

630. Muller JE, Morrison J, Stone PH, et al. Nifedipine therapy for patients with threatened and acute myocardial infarction: a randomized, double-blind, placebo-controlled comparison. Circulation 1984;69:740-7.

631. Sirnes PA, Overskeid K, Pedersen TR, et al. Evolution of infarct size during the early use of nifedipine in patients with acute myocardial infarction: the Norwegian Nifedipine Multicenter Trial. Circulation 1984;70:638-44.

632. Wilcox RG, Hampton JR, Banks DC, et al. Trial of early nifedipine in acute myocardial infarction: the Trent study. Br Med J (Clin Res Ed) 1986;293:1204-8.

633. The Israeli Sprint Study Group. Secondary prevention reinfarction Israeli nifedipine trial (SPRINT): a randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J 1988;9:354-64.

634. Goldbourt U, Behar S, Reicher-Reiss H, Zion M, Mandelzweig L, Kaplinsky E. Early administration of nifedipine in suspected acute myocardial infarction: the Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. Arch Intern Med 1993;153:345-53.

635. Buring JE, Glynn RJ, Hennekens CH. Calcium channel blockers and myocardial infarction: a hypothesis formulated but not yet tested. JAMA 1995;274:654-5.

636. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-31.

637. Opie LH, Messerli FH. Nifedipine and mortality: grave defects in the dossier. Circulation 1995;92:1068-73.

638. The Danish Study Group on Verapamil in Myocardial Infarction. Verapamil in acute myocardial infarction. Eur Heart J 1984; 5:516-28.

639. Gheorghiade M. Calcium channel blockers in the management of myocardial infarction patients. Henry Ford Hosp Med J 1991;39:210-6.

640. Held PH, Yusuf S. Effects of beta-blockers and calcium channel blockers in acute myocardial infarction. Eur Heart J 1993;14:18- 25.

641. Hilton TC, Miller DD, Kern MJ. Rational therapy to reduce mortality and reinfarction following myocardial infarction. Am Heart J 1991;122:1740-50.

642. Effect of verapamil on mortality and major events after acute myocardial infarction: the Danish Verapamil Infarction Trial II (DAVIT II). Am J Cardiol 1990;66:779-85.

643. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-92.

644. Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction in patients with non–Q-wave myocardial infarction: results of a double-blind, randomized, multicenter trial. N Engl J Med 1986;315:423-9.

645. Boden WE. Non–Q-wave myocardial infarction: a prognostic paradox. Hosp Pract (Off Ed) 1992;27:129-33,137-8,140.

646. Boden WE, van Gilst WH, Scheldewaert RG, et al. Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post- Thrombolysis (INTERCEPT). Lancet 2000;355:1751-6.

647. American Association of Critical Care Nurses White Paper. Safeguarding the Patient and the Profession: the Value of Critical Care Nurse Certification, Aliso Viejo, CA, December 2002.

648. Dimick JB, Swoboda SM, Pronovost PJ, Lipsett PA. Effect of nurse-to-patient ratio in the intensive care unit on pulmonary complications and resource use after hepatectomy. Am J Crit Care 2001;10:376-82.

649. Needleman J, Buerhaus P, Mattke S, Stewart M, Zelevinsky K. Nurse-staffing levels and the quality of care in hospitals. N Engl J Med 2002;346:1715-22.

650. Pronovost PJ, Dang D, Dorman T, et al. Intensive care unit nurse staffing and the risk for complications after abdominal aortic surgery. Eff Clin Pract 2001;4:199-206.

651. Pilcher T, Odell M. Position statement on nurse-patient ratios in critical care. Nurs Stand 2000;15:38-41.

652. “California Safe Hospital Staffing Law” AB 394.

653. Bolton LB, Jones D, Aydin CE, et al. A response to California’s mandated nursing ratios. J Nurs Scholarship 2001;33:179-84.

654. Maintaining patient-focused care in an environment of nursing staff shortages and financial constraints: a statement from the American Association of Critical-Care Nurses (AACN). Available at http://www.aacn.org/pdfLibra.NSF/Files/burson/$file/burson.pdf, November 2000. Accessed January 7, 2004.

655. Newby LK, Califf RM, Guerci A, et al. Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial. J Am Coll Cardiol 1996;27:625-32.

656. Fein A. Organization and Management of Critical Care Units. In: Irwin RS, Rippe JM, eds. Manual of Intensive Care Medicine. 4th ed. Baltimore, MD: Lippincott-Williams & Wilkins; 1999:2501-9.

657. Drew BJ,Wung SF, Adams MG, Pelter MM. Bedside diagnosis of myocardial ischemia with ST-segment monitoring technology: measurement issues for real-time clinical decision making and trial designs. J Electrocardiol 1998;30:157-65.

658. Bell NN. Clinical significance of ST-segment monitoring. Crit Care Nurs Clin North Am 1992;4:313-23.

659. Johanson P, Rössberg J, Dellborg M. Continuous ST monitoring: a bedside instrument? A report from the Assessment of the Safety of a New Thrombolytic (ASSENT 2) ST monitoring substudy. Am Heart J 2001;142:58-62.

660. Drew BJ, Ide B, Sparacino PS. Accuracy of bedside electrocardiographic monitoring: a report on current practices of critical care nurses. Heart Lung 1991;20:597-607.

661. Romhilt DW, Bloomfield SS, Chou TC, Fowler NO. Unreliability of conventional electrocardiographic monitoring for arrhythmia detection in coronary care units. Am J Cardiol 1973;31:457-61.

662. Drew BJ, Krucoff MW, for the ST- Segment Monitoring Practice Guideline International Working Group. Multilead ST-segment monitoring in patients with acute coronary syndromes: a consensus statement for healthcare professionals. Am J Crit Care 1999;8:372-86; quiz 387-8.

663. Pelter MM, Adams MG, Wung SF, Paul SM, Drew BJ. Peak time of occurrence of myocardial ischemia in the coronary care unit. Am J Crit Care 1998;7:411-7.

664. Dellborg M, Topol EJ, Swedberg K. Dynamic QRS complex and ST segment vectorcardiographic monitoring can identify vessel patency in patients with acute myocardial infarction treated with reperfusion therapy. Am Heart J 1991;122:943-8.

665. Krucoff MW, Croll MA, Pope JE, et al. Continuously updated 12- lead ST-segment recovery analysis for myocardial infarct artery patency assessment and its correlation with multiple simultaneous early angiographic observations. Am J Cardiol 1993;71:145-51.

666. Veldkamp RF, Green CL,Wilkins ML, et al, for the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 7 Study Group. Comparison of continuous ST-segment recovery analysis with methods using static electrocardiograms for noninvasive patency assessment during acute myocardial infarction. Am J Cardiol 1994;73:1069-74.

667. Langer A, Krucoff MW, Klootwijk P, et al. Noninvasive assessment of speed and stability of infarct-related artery reperfusion: results of the GUSTO ST segment monitoring study. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1995;25:1552-7.

668. Santoro GM, Valenti R, Buonamici P, et al. Relation between STsegment changes and myocardial perfusion evaluated by myocardial contrast echocardiography in patients with acute myocardial infarction treated with direct angioplasty. Am J Cardiol 1998; 82:932-7.

669. Krucoff MW, Parente AR, Bottner RK, et al. Stability of multilead ST-segment “fingerprints” over time after percutaneous transluminal coronary angioplasty and its usefulness in detecting reocclusion. Am J Cardiol 1988;61:1232-7.

670. Vatner SF, McRitchie RJ, Maroko PR, Patrick TA, Braunwald E. Effects of catecholamines, exercise, and nitroglycerin on the normal and ischemic myocardium in conscious dogs. J Clin Invest 1974;54:563-75.

671. Chobanian AV, Lille RD, Tercyak A, Blevins P. The metabolic and hemodynamic effects of prolonged bed rest in normal subjects. Circulation 1974;49:551-9.

672. Convertino VA. Value of orthostatic stress in maintaining functional status soon after myocardial infarction or cardiac artery bypass grafting. J Cardiovasc Nurs 2003;18:124-30.

673. Metzger BL, Therrien B. Effect of position on cardiovascular response during the Valsalva maneuver. Nurs Res 1990;39:198- 202.

674. Taggart P, Sutton P, John R, Lab M, Swanton H. Monophasic action potential recordings during acute changes in ventricular loading induced by the Valsalva manoeuvre. Br Heart J 1992;67:221-9.

675. Porth CJ, Bamrah VS, Tristani FE, Smith JJ. The Valsalva maneuver: mechanisms and clinical implications. Heart Lung 1984;13:507-18.

676. Storm DS, Metzger BL, Therrien B. Effects of age on autonomic cardiovascular responsiveness in healthy men and women. Nurs Res 1989;38:326-30.

677. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.

678. Goldstein IB, Shapiro D, Hui KK,Yu JL. Blood pressure response to the “second cup of coffee”. Psychosom Med 1990;52:337-45.

679. Aro A, Teirilä J, Gref CG. Dose-dependent effect on serum cholesterol and apoprotein B concentrations by consumption of boiled, non-filtered coffee. Atherosclerosis 1990;83:257-61.

680. Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley M. Effects of caffeine on human health. Food Addit Contam 2003;20:1-30.

681. Myers MG, Harris L. High-dose caffeine and ventricular arrhythmias. Can J Cardiol 1990;6:95-8.

682. Myers MG, Harris L, Leenen FH, Grant DM. Caffeine as a possible cause of ventricular arrhythmias during the healing phase of acute myocardial infarction. Am J Cardiol 1987;59:1024-8.

683. Pincomb GA, Lovallo WR, Passey RB, Whitsett TL, Silverstein SM, Wilson MF. Effects of caffeine on vascular resistance, cardiac output and myocardial contractility in young men. Am J Cardiol 1985;56:119-22.

684. Hughes JR, Oliveto AH, Bickel WK, Higgins ST, Badger GJ. Caffeine self-administration and withdrawal: incidence, individual differences and interrelationships. Drug Alcohol Depend 1993;32:239-46.

685. van Dusseldorp M, Katan MB. Headache caused by caffeine withdrawal among moderate coffee drinkers switched from ordinary to decaffeinated coffee: a 12-week double-blind trial. BMJ 1990;300:1558-9.

686. Höfer I, Bättig K. Cardiovascular, behavioral, and subjective effects of caffeine under field conditions. Pharmacol Biochem Behav 1994;48:899-908.

687. Lynn LA, Kissinger JF. Coronary precautions: should caffeine be restricted in patients after myocardial infarction? Heart Lung 1992;21:365-71.

688. Boyd MD. Strategies for effective health teaching. In: Boyd MD, Graham BA, Gleit CJ, Whitman NI, eds. Health teaching in nursing practice: a professional model. 3rd ed. Stanford, CT: Appleton and Lange;1998:201-29.

689. Fleury J, Moore SM. Family-centered care after acute myocardial infarction. J Cardiovasc Nurs 1999;13:73-82.

690. Duryée R. The efficacy of inpatient education after myocardial infarction. Heart Lung 1992;21:217-25.ise, and nitroglycerin on the normal and ischemic myocardium in conscious dogs. J Clin Invest 1974;54:563-75.

691. Saarmann L, Daugherty J, Riegel B. Patient teaching to promote behavioral change. Nurs Outlook 2000;48:281-7.

692. Cooper H, Booth K, Fear S, Gill G. Chronic disease patient education: lessons from meta-analyses. Patient Educ Couns 2001;44:107-17.

693. Prochaska JO, DiClemente CC, Norcross JC. In search of how people change: applications to addictive behaviors. Am Psychol 1992;47:1102-14.

694. Nigg CR, Burbank PM, Padula C, et al. Stages of change across ten health risk behaviors for older adults. Gerontologist 1999;39:473-82.

695. Glazer HR, Kirk LM, Bosler FE. Patient education pamphlets about prevention, detection, and treatment of breast cancer for low literacy women. Patient Educ Couns 1996;27:185-9.

696. Antman EM, Kuntz KM. The length of the hospital stay after myocardial infarction. N Engl J Med 2000;342:808-10.

697. Visser A,Wissow L. From patient education to communication in health care. Patient Educ Couns 2003;50:227-8.

698. Frazier SK, Moser DK, O’Brien JL, Garvin BJ, An K, Macko M. Management of anxiety after acute myocardial infarction. Heart Lung 2002;31:411-20.

699. Frazier SK, Moser DK, Daley LK, et al. Critical care nurses’ beliefs about and reported management of anxiety. Am J Crit Care 2003;12:19-27.

700. Devine EC. Effects of psychoeducational care for adult surgical patients: a meta-analysis of 191 studies. Patient Educ Couns 1992;19:129-42.

701. Bartlett EE. Cost-benefit analysis of patient education. Patient Educ Couns 1995;26:87-91.

702. LaBresh KA, Gliklich R, Liljestrand J, Peto R, Ellrodt AG. Using “get with the guidelines” to improve cardiovascular secondary prevention. Jt Comm J Qual Saf 2003;29:539-50.

703. The Mended Hearts, Inc., Dallas, TX. Available at http://www.mendedhearts.org/, November 2003. Accessed December 16, 2002.

704. Hughes JR, Higgins ST, Bickel WK. Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities. Addiction 1994;89:1461-70.

705. Malan SS. Psychosocial adjustment following MI: current views and nursing implications. J Cardiovasc Nurs 1992;6:57-70.

706. Havik OE, Maeland JG. Patterns of emotional reactions after a myocardial infarction. J Psychosom Res 1990;34:271-85.

707. Moser DK, Dracup K. Is anxiety early after myocardial infarction associated with subsequent ischemic and arrhythmic events? Psychosom Med 1996;58:395-401.

708. Frasure-Smith N, Lespérance F, Talajic M. The impact of negative emotions on prognosis following myocardial infarction: is it more than depression? Health Psychol 1995;14:388-98.

709. O’Brien JL, Moser DK, Riegel B, Frazier SK, Garvin BJ, Kim KA. Comparison of anxiety assessments between clinicians and patients with acute myocardial infarction in cardiac critical care units. Am J Crit Care 2001;10:97-103.

710. Frazier SK, Moser DK, Riegel B, et al. Critical care nurses’ assessment of patients’ anxiety: reliance on physiological and behavioral parameters. Am J Crit Care 2002;11:57-64.

711. Simpson T, Shaver J. Cardiovascular responses to family visits in coronary care unit patients. Heart Lung 1990;19:344-51.

712. Schulte DA, Burrell LO, Gueldner SH, et al. Pilot study of the relationship between heart rate and ectopy and unrestricted vs restricted visiting hours in the coronary care unit. Am J Crit Care 1993;2:134-6.

713. Thompson DR, Meddis R. A prospective evaluation of inhospitalcounselling for first-time myocardial infarction men. J Psychosom Res 1990;34:237-48.

714. Thompson DR. A randomized controlled trial of in-hospital nursing support for first-time myocardial infarction patients and their partners: effects on anxiety and depression. J Adv Nurs 1989; 14:291-7.

715. Newby LK, Eisenstein EL, Califf RM, Thompson TD, Nelson CL, Peterson ED,Armstrong PW,Van de Werf F, White HD, Topol EJ, Mark DB. Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med 2000;342:749- 55.

716. Brooten D, Naylor MD, York R, et al. Lessons learned from testing the quality cost model of Advanced Practice Nursing (APN) transitional care. J Nurs Scholarship 2002;34:369-75.

717. Chae CU, Hennekens CH . Beta blockers. In: Hennekens CH, ed. Clinical trials in cardiovascular disease: a companion to Braunwald’s Heart Disease. Philadelphia, PA: WB Saunders Co Ltd; 1999:79-94.

718. Antman E, Braunwald E. Acute myocardial infarction. In: Braunwald E, Zipes DP, Libby P, eds. Heart disease: a textbook of cardiovascular medicine. 6th ed. Philadelphia, PA: WB Saunders Co Ltd; 2001:1114-1231.

719. Beta-Blocker Heart Attack Study Group. The beta-blocker heart attack trial. JAMA 1981;246:2073-4.

720. Flather MD, Yusuf S, Køber L, et al, for the ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACEinhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000;355:1575-81.

721. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.

722. Pitt B, Zannad F, Remme WJ, et al, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.

723. Pitt B, Remme W, Zannad F, et al, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.

724. Dickstein K, Kjekshus J, for the OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-60.

725. Pfeffer MA, McMurray JJ, Velazquez EJ, et al, for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.

726. Mann DL, Deswal A. Angiotensin-receptor blockade in acute myocardial infarction: a matter of dose. N Engl J Med 2003; 349:1963-5.

727. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therap: I–Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.

728. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502.

729. Plavix (clopidogrel) package insert. Sanofi-Synthelabo. New York, NY. March 2002.

730. Hirsh J, Dalen JE, Fuster V, Harker LB, Salzman EW. Aspirin and other platelet-active drugs: the relationship between dose, effectiveness, and side effects. Chest 1992;102:327S-336S.

731. Leonards JR, Levy G. Effect of pharmaceutical formulation on gastrointestinal bleeding from aspirin tablets. Arch Intern Med 1972;129:457-60.

732. MacKercher PA, Ivey KJ, Baskin WN, Krause WJ. Protective effect of cimetidine on aspirin-induced gastric mucosal damage. Ann Intern Med 1977;87:676-9.

733. Bowen BK, Krause WJ, Ivey KJ. Effect of sodium bicarbonate on aspirin-induced damage and potential difference changes in human gastric mucosa. Br Med J 1977;2:1052-5.

734. Graham DY, Smith JL. Aspirin and the stomach. Ann Intern Med 1986;104:390-8.

735. Mielants H, Verbruggen G, Schelstraete K, Veys EM. Salicylateinduced gastrointestinal bleeding: comparison between soluble buffered, enteric-coated, and intravenous administration. J Rheumatol 1979;6:210-8.

736. Goldman S, Copeland J, Moritz T, et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 1988;77:1324-32.

737. Chesebro JH, Clements IP, Fuster V, et al. A platelet-inhibitordrug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. N Engl J Med 1982;307:73-8.

738. Sanz G, Pajarón A, Alegría E, et al, for the Grupo Español para el Seguimiento del Injerto Coronario (GESIC). Prevention of early aortocoronary bypass occlusion by low-dose aspirin and dipyridamole. Circulation 1990;82:765-73.

739. Goldman S, Copeland J, Moritz T, et al, for the Department of Veterans Affairs Cooperative Study Group. Starting aspirin therapy after operation: effects on early graft patency. Circulation 1991;84:520-6.

740. Hass WK, Easton JD, Adams HP, et al, for the Ticlopidine Aspirin Stroke Study Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in highrisk patients. N Engl J Med 1989;321:501-7.

741. Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-9.

742. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.

743. Leon MB, Baim DS, Popma JJ, et al, for the Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998;339:1665-71.

744. The SCATI (Studio sulla Calciparina nell’Angina e nella Trombosi Ventricolare nell’Infarto) Group. Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. Lancet 1989;2:182-6.

745. Deleted in press.

746. 4th American College of Chest Physicians Consensus Conference on Antithrombotic Therapy. Tucson, Arizona, April 1995. Proceedings. Chest 1995;108:225S-522S.

747. Chesebro JH, Fuster V. Antithrombotic therapy for acute myocardial infarction: mechanisms and prevention of deep venous, left ventricular, and coronary artery thromboembolism. Circulation 1986;74:III1-10.

748. Sevilla DC, Wagner NB, Anderson WD, et al. Sensitivity of a set of myocardial infarction screening criteria in patients with anatomically documented single and multiple infarcts. Am J Cardiol 1990;66:792-5.

749. Ideker RE,Wagner GS, Ruth WK, et al. Evaluation of a QRS scoring system for estimating myocardial infarct size–II: correlation with quantitative anatomic findings for anterior infarcts. Am J Cardiol 1982;49:1604-14.

750. Goodman SG, Langer A, Ross AM, et al, for the GUSTO-I Angiographic Investigators. Non–Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. Circulation 1998;97:444-50.

751. Buja LM, Willerson JT. Infarct size: can it be measured or modified in humans? Prog Cardiovasc Dis 1987;29:271-89.

752. Hackel DB, Reimer KA, Ideker RE, et al. Comparison of enzymatic and anatomic estimates of myocardial infarct size in man. Circulation 1984;70:824-35.

753. Panteghini M, Cuccia C, Bonetti G, Giubbini R, Pagani F, Bonini E. Single-point cardiac troponin T at coronary care unit discharge after myocardial infarction correlates with infarct size and ejection fraction. Clin Chem 2002;48:1432-6.

754. Licka M, Zimmermann R, Zehelein J, Dengler TJ, Katus HA, Kübler W. Troponin T concentrations 72 hours after myocardial infarction as a serological estimate of infarct size. Heart 2002; 87:520-4.

755. Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000;21:1502-13.

756. Gibbons RJ, Miller TD, Christian TF. Infarct size measured by single photon emission computed tomographic imaging with (99m)Tc-sestamibi: a measure of the efficacy of therapy in acute myocardial infarction. Circulation 2000;101:101-8.

757. Mahrholdt H, Wagner A, Holly TA, et al. Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging. Circulation 2002;106:2322-7.

758. Mueller HS, Chatterjee K, Davis KB, et al. ACC expert consensus document on the present use of bedside right heart catheterization in patients with cardiac disease. American College of Cardiology. J Am Coll Cardiol 1998;32:840-64.

759. Menon V, Slater JN, White HD, Sleeper LA, Cocke T, Hochman JS. Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: report of the SHOCK trial registry. Am J Med 2000;108:374-80.

760. Hollenberg SM, Hoyt J. Pulmonary artery catheters in cardiovascular disease. New Horiz 1997;5:207-13.

761. Weil MH. The assault on the Swan-Ganz catheter: a case history of constrained technology, constrained bedside clinicians, and constrained monetary expenditures. Chest 1998;113:1379-86.

762. Dalen JE. The pulmonary artery catheter-friend, foe, or accomplice? JAMA 2001;286:348-50.

763. O’Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2002;51:1-29.

764. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit: a two-year experience with 250 patients. Am J Cardiol 1967;20:457-64.

765. Hochman JS, Jaber W, Bates ER, et al. Angioplasty versus thrombolytics for patients presenting with congestive heart failure: GUSTO IIb substudy findings. J Am Coll Cardiol 1998;31:856-4.

766. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care: part 7–the era of reperfusion: section 1–acute coronary syndromes (acute myocardial infarction). Circulation 2000;102:I172-203.

767. Prewitt RM, Gu S, Garber PJ, Ducas J. Marked systemic hypotension depresses coronary thrombolysis induced by intracoronary administration of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1992;20:1626-33.

768. Prewitt RM, Gu S, Schick U, Ducas J. Intraaortic balloon counterpulsation enhances coronary thrombolysis induced by intravenous administration of a thrombolytic agent. J Am Coll Cardiol 1994;23:794-8.

769. Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) N Engl J Med 1992;327:678-84.

770. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531-40.

771. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). American College of Cardiology Web site. Available at: http://www.acc.org/clinical/guidelines/failure/ hf_index.htm, 2001. Accessed August 5, 2003.

772. Goldberg RJ, Gore JM, Alpert JS, et al. Cardiogenic shock after acute myocardial infarction: incidence and mortality from a community- wide perspective, 1975 to 1988. N Engl J Med 1991;325:1117-22.

773. Bengtson JR, Kaplan AJ, Pieper KS, et al. Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. J Am Coll Cardiol 1992;20:1482-9.

774. Berger AK, Radford MJ, Krumholz HM. Cardiogenic shock complicating acute myocardial infarction in elderly patients: does admission to a tertiary center improve survival? Am Heart J 2002;143:768-76.

775. Allen BS, Rosenkranz E, Buckberg GD, et al. Studies on prolonged acute regional ischemia: VI–myocardial infarction with left ventricular power failure: a medical/surgical emergency requiring urgent revascularization with maximal protection of remote muscle. J Thorac Cardiovasc Surg 1989;98:691-702; discussion.

776. Allen BS, Buckberg GD, Fontan FM, et al. Superiority of controlled surgical reperfusion versus percutaneous transluminal coronary angioplasty in acute coronary occlusion. J Thorac Cardiovasc Surg 1993;105:864-79; discussion 8.

777. Dixon SR, Alkafri H, Chami A. Clinical predictors of in-hospital death in patients with cardiogenic shock selected to undergo early revascularization [abstr]. J Am Coll Cardiol 2002;39:808–1.

778. Barron HV, Every NR, Parsons LS, et al, for the Investigators in the National Registry of Myocardial Infarction 2. The use of intraaortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2. Am Heart J 2001;141:933-9.

779. Deleted in press.

780. Zehender M, Kasper W, Kauder E, et al H. Right ventricular infarction as an independent predictor of prognosis after acute inferior myocardial infarction. N Engl J Med 1993;328:981-8.

781. Berger PB, Ryan TJ. Inferior myocardial infarction: high-risk subgroups. Circulation 1990;81:401-11.

782. Jacobs AK, Leopold JA, Bates E, et al. Cardiogenic shock caused by right ventricular infarction: a report from the SHOCK registry. J Am Coll Cardiol 2003;41:1273-9.

783. Weinshel AJ, Isner JM, Salem DN. The coronary anatomy of right ventricular infarction: relationship between the site of right coronary artery occlusion and origin of the right ventricular free wall branches. Circulation 1983;68:III-351.

784. Andersen HR, Falk E, Nielsen D. Right ventricular infarction: frequency, size and topography in coronary heart disease: a prospective study comprising 107 consecutive autopsies from a coronary care unit. J Am Coll Cardiol 1987;10:1223-32.

785. Lee FA. Hemodynamics of the right ventricle in normal and disease states. Cardiol Clin 1992;10:59-67.

786. Cross CE. Right ventricular pressure and coronary flow. Am J Physiol 1962;202:12-16.

787. Haupt HM, Hutchins GM, Moore GW. Right ventricular infarction: role of the moderator band artery in determining infarct size. Circulation 1983;67:1268-72.

788. Setaro JF, Cabin HS. Right ventricular infarction. Cardiol Clin 1992;10:69-90.

789. Goldstein JA, Vlahakes GJ, Verrier ED, et al. The role of right ventricular systolic dysfunction and elevated intrapericardial pressure in the genesis of low output in experimental right ventricular infarction. Circulation 1982;65:513-22.

790. Ferguson JJ, Diver DJ, Boldt M, Pasternak RC. Significance of nitroglycerin-induced hypotension with inferior wall acute myocardial infarction. Am J Cardiol 1989;64:311-4.

791. Goldstein JA, Barzilai B, Rosamond TL, Eisenberg PR, Jaffe AS. Determinants of hemodynamic compromise with severe right ventricular infarction. Circulation 1990;82:359-68.

792. Goldstein JA, Tweddell JS, Barzilai B, Yagi Y, Jaffe AS, Cox JL. Importance of left ventricular function and systolic ventricular interaction to right ventricular performance during acute right heart ischemia. J Am Coll Cardiol 1992;19:704-11.

793. Bowers TR, O’Neill WW, Grines C, Pica MC, Safian RD, Goldstein JA. Effect of reperfusion on biventricular function and survival after right ventricular infarction. N Engl J Med 1998;338:933-40.

794. Bowers TR, O’Neill WW, Pica M, Goldstein JA. Patterns of coronary compromise resulting in acute right ventricular ischemic dysfunction. Circulation 2002;106:1104-9.

795. Dell’Italia LJ, Starling MR, O’Rourke RA. Physical examination for exclusion of hemodynamically important right ventricular infarction. Ann Intern Med 1983;99:608-11.

796. Dell’Italia LJ, Starling MR, Crawford MH, Boros BL, Chaudhuri TK, O’Rourke RA. Right ventricular infarction: identification by hemodynamic measurements before and after volume loading and correlation with noninvasive techniques. J Am Coll Cardiol 1984;4:931-9.

797. Cohn JN, Guiha NH, Broder MI, Limas CJ. Right ventricular infarction: clinical and hemodynamic features. Am J Cardiol 1974;33:209-14.

798. Robalino BD, Whitlow PL, Underwood DA, Salcedo EE. Electrocardiographic manifestations of right ventricular infarction. Am Heart J 1989;118:138-44. 799. Braat SH, Brugada P, de Zwaan C, Coenegracht JM, Wellens HJ.

799. Braat SH, Brugada P, de Zwaan C, Coenegracht JM, Wellens HJ.Value of electrocardiogram in diagnosing right ventricular involvement in patients with an acute inferior wall myocardial infarction. Br Heart J 1983;49:368-72.

800. Sharkey SW, Shelley W, Carlyle PF, Rysavy J, Cohn JN. M-mode and two-dimensional echocardiographic analysis of the septum in experimental right ventricular infarction: correlation with hemodynamic alterations. Am Heart J 1985;110:1210-8.

801. López-Sendón J, López de Sá E, Roldán I, Fernández de Soria R, Ramos F, Martín Jadraque L. Inversion of the normal interatrial septum convexity in acute myocardial infarction: incidence, clinical relevance and prognostic significance. J Am Coll Cardiol
1990;15:801-5.

802. Manno BV, Bemis CE, Carver J, Mintz GS. Right ventricular infarction complicated by right to left shunt. J Am Coll Cardiol 1983;1:554-7.

803. Wellens HJ. The value of the right precordial leads of the electrocardiogram. N Engl J Med 1999;340:381-3.

804. Goldstein JA, Vlahakes GJ, Verrier ED, et al. Volume loading improves low cardiac output in experimental right ventricular infarction. J Am Coll Cardiol 1983;2:270-8.

805. Dell’Italia LJ, Starling MR, Blumhardt R, Lasher JC, O’Rourke RA. Comparative effects of volume loading, dobutamine, and nitroprusside in patients with predominant right ventricular infarction. Circulation 1985;72:1327-35.

806. Love JC, Haffajee CI, Gore JM, Alpert JS. Reversibility of hypotension and shock by atrial or atrioventricular sequential pacing in patients with right ventricular infarction. Am Heart J 1984;108:5-13.

807. Sugiura T, Iwasaka T, Takahashi N, et al. Atrial fibrillation in inferior wall Q-wave acute myocardial infarction. Am J Cardiol 1991;67:1135-6.

808. Braat SH, de Zwaan C, Brugada P, Coenegracht JM, Wellens HJ. Right ventricular involvement with acute inferior wall myocardial infarction identifies high risk of developing atrioventricular nodal conduction disturbances. Am Heart J 1984;107:1183-7.

809. Fantidis P, Castejon R, Fernández Ruiz A, Madero-Jarabo R, Cordovilla G, Sanz Galeote E. Does a critical hemodynamic situation develop from right ventriculotomy and free wall infarct or from small changes in dysfunctional right ventricle afterload? J Cardiovasc Surg (Torino) 1992;33:229-34.

810. Braat SH, Ramentol M, Halders S, Wellens HJ. Reperfusion with streptokinase of an occluded right coronary artery: effects on early and late right and left ventricular ejection fraction. Am Heart J 1987;113:257-60.

811. Schuler G, Hofmann M, Schwarz F, et al. Effect of successful thrombolytic therapy on right ventricular function in acute inferior wall myocardial infarction. Am J Cardiol 1984;54:951-7.

812. Moreyra AE, Suh C, Porway MN, Kostis JB. Rapid hemodynamic improvement in right ventricular infarction after coronary angioplasty. Chest 1988;94:197-9.

813. Gott JP, Han DC. Surgical treatment of acute myocardial infarct: clinical considerations. Semin Thorac Cardiovasc Surg 1995;7: 198-207.

814. Roberts N, Harrison DG, Reimer KA, Crain BS, Wagner GS. Right ventricular infarction with shock but without significant left ventricular infarction: a new clinical syndrome. Am Heart J 1985;110:1047-53.

815. Dell’Italia LJ, Starling MR, O’Rourke RA. Physical examination for exclusion of hemodynamically important right ventricular infarction. Ann Intern Med 1983;99:608-11.

816. Serrano Júnior CV, Ramires JA, César LA, et al. Prognostic significance of right ventricular dysfunction in patients with acute inferior myocardial infarction and right ventricular involvement. Clin Cardiol 1995;18:199-205.

817. Berger PB, Ruocco NA, Ryan TJ, et al, for the The TIMI Research Group. Frequency and significance of right ventricular dysfunction during inferior wall left ventricular myocardial infarction treated with thrombolytic therapy (results from the thrombolysis in myocardial infarction [TIMI] II trial). Am J Cardiol 1993;71:1148-52.

818. Andersen HR, Falk E, Nielsen D. Right ventricular infarction: frequency, size and topography in coronary heart disease: a prospective study comprising 107 consecutive autopsies from a coronary care unit. J Am Coll Cardiol 1987;10:1223-32.

819. Roberts N, Harrison DG, Reimer KA, Crain BS, Wagner GS. Right ventricular infarction with shock but without significant ventricular infarction: a new clinical syndrome. Am Heart 1985;110:1047-53.

820. Serrano Júnior CV, Ramires JA, César LA, et al. Prognostic significance of right ventricular dysfunction in patients with acute inferior myocardial infarction and right ventricular involvement. Clin Cardiol 1995;18:199-205.

821. Berger PB, Ruocco NA, Ryan TJ, et al, for the TIMI Research Group. Frequency and significance of right ventricular dysfunction during inferior wall left ventricular myocardial infarction treated with thrombolytic therapy (results from the thrombolysis in myocardial infarction [TIMI] II trial). Am J Cardiol 1993;71:1148-52.

822. Calvin JE. Optimal right ventricular filling pressures and the role of pericardial constraint in right ventricular infarction in dogs. Circulation 1991;84:852-61.

823. Tobinick E, Schelbert HR, Henning H, et al. Right ventricular ejection fraction in patients with acute anterior and inferior myocardial infarction assessed by radionuclide angiography. Circulation 1978;57:1078-84.

824. Boldt J, Kling D, Thiel A, Scheld HH, Hempelmann Revascularization of the right coronary artery: influence on thermodilution right ventricular ejection fraction. J Cardiothoracic Anesth 1998;2:140-146.

825. Polak JF, Holman BL, Wynne J, Colucci WS. Right ventricular ejection fraction: an indicator of increased mortality in patients with congestive heart failure associated with coronary artery disease. J Am Coll Cardiol 1983;2:217-24.

826. Lloyd EA, Gersh BJ, Kennelly BM. Hemodynamic spectrum “‘dominant” right ventricular infarction in 19 patients. Am Cardiol 1981;48:1016-22.

827. Klein HO, Tordjman T, Ninio R, et al. The early recognition right ventricular infarction: diagnostic accuracy of the electrocardiographic V4R lead. Circulation 1983;67:558-65.

828. Bellamy GR, Rasmussen HH, Nasser FN, Wiseman JC, Cooper RA. Value of two-dimensional echocardiography, electrocardiography, and clinical signs in detecting right ventricular infarction. Am Heart J 1986;112:304-9.

829. Birnbaum Y, Fishbein MC, Blanche C, Siegel RJ. Ventricular septal rupture after acute myocardial infarction. N Engl J Med 2002;347:1426-32.

830. Snyder RW, Glamann DB, Lange RA, et al. Predictive value prominent pulmonary arterial wedge V waves in assessing presence and severity of mitral regurgitation. Am J Cardiol 1994;73:568-70.

831. Dalrymple-Hay MJ, Langley SM, Sami SA, et al. Should coronary artery bypass grafting be performed at the same time repair of a post-infarct ventricular septal defect? Eur Cardiothorac Surg 1998;13:286-92.

832. Thompson CR, Buller CE, Sleeper LA, et al. Cardiogenic shock due to acute severe mitral regurgitation complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we use emergently revascularize Occluded Coronaries cardiogenic shocK? J Am Coll Cardiol 2000;36:1104-9.

833. Lamas GA, Mitchell GF, Flaker GC, et al, for the Survival and Ventricular Enlargement Investigators. Clinical significance of mitral regurgitation after acute myocardial infarction. Circulation 1997;96:827-33.

834. Tepe NA, Edmunds LH. Operation for acute postinfarction mitral insufficiency and cardiogenic shock. J Thorac Cardiovasc Surg 1985;89:525-30.

835. Tavakoli R, Weber A, Vogt P, Brunner HP, Pretre R, Turina M. Surgical management of acute mitral valve regurgitation due post-infarction papillary muscle rupture. J Heart Valve Dis 2002;11:20-5; discussion 26.

836. Chen Q, Darlymple-Hay MJ, Alexiou C, et al. Mitral valve surgery for acute papillary muscle rupture following myocardial infarction. J Heart Valve Dis 2002;11:27-31.

837. Kishon Y, Oh JK, Schaff HV, Mullany CJ, Tajik AJ, Gersh BJ. Mitral valve operation in postinfarction rupture of a papillary muscle: immediate results and long-term follow-up of 22 patients. Mayo Clin Proc 1992;67:1023-30.

838. Fasol R, Lakew F, Wetter S. Mitral repair in patients with a ruptured papillary muscle. Am Heart J 2000;139:549-54.

839. Nishimura RA, Gersh BJ, Schaff HV. The case for an aggressive surgical approach to papillary muscle rupture following myocardial infarction: “from paradise lost to paradise regained”. Heart 2000;83:611-3.

840. Byrne JG, Aranki SF, Cohn LH. Repair versus replacement of mitral valve for treating severe ischemic mitral regurgitation. Coron Artery Dis 2000;11:31-3.

841. Adams DH, Filsoufi F, Aklog L. Surgical treatment of the ischemic mitral valve. J Heart Valve Dis 2002;11:S21-5.

842. Crenshaw BS, Granger CB, Birnbaum Y, et al, for the GUSTO- (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators. Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. Circulation 2000; 101:27-32.

843. Prêtre R, Ye Q, Grünenfelder J, Lachat M, Vogt PR, Turina MI. Operative results of “repair” of ventricular septal rupture after acute myocardial infraction. Am J Cardiol 1999;84:785-8.

844. Lemery R, Smith HC, Giuliani ER, Gersh BJ. Prognosis in rupture of the ventricular septum after acute myocardial infarction and role of early surgical intervention. Am J Cardiol 1992;70:147- 51.

845. Skillington PD, Davies RH, Luff AJ, et al. Surgical treatment for infarct-related ventricular septal defects: improved early results combined with analysis of late functional status. J Thorac Cardiovasc Surg 1990;99:798-808.

846. Topaz O, Taylor AL. Interventricular septal rupture complicating acute myocardial infarction: from pathophysiologic features to the role of invasive and noninvasive diagnostic modalities in current management. Am J Med 1992;93:683-8.

847. Westaby S, Parry A, Ormerod O, Gooneratne P, Pillai R. Thrombolysis and postinfarction ventricular septal rupture. Thorac Cardiovasc Surg 1992;104:1506-9.

848. Muehrcke DD, Daggett WM, Buckley MJ, Akins CW, Hilgenberg AD, Austen WG. Postinfarct ventricular septal defect repair: effect of coronary artery bypass grafting. Ann Thorac Surg 1992;54:876-82; discussion 8.

849. Menon V,Webb JG, Hillis LD, et al. Outcome and profile of ventricular septal rupture with cardiogenic shock after myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK? J Am Coll Cardiol 2000;36:1110-6.

850. Szkutnik M, Bialkowski J, Kusa J, et al. Postinfarction ventricular septal defect closure with Amplatzer occluders. Eur J Cardiothorac Surg 2003;23:323-7.

851. Yusuf S,Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease: I–treatments following myocardial infarction. JAMA 1988;260:2088-93. 852. Nakamura F, Minamino T, Higashino Y, et al. Cardiac free wall rupture in acute myocardial infarction: ameliorative effect of coronary reperfusion. Clin Cardiol 1992;15:244-50.

853. Pollak H, Nobis H, Mlczoch J. Frequency of left ventricular free wall rupture complicating acute myocardial infarction since the advent of thrombolysis. Am J Cardiol 1994;74:184-6.

854. Becker RC, Gore JM, Lambrew C, et al. A composite view of cardiac rupture in the United States National Registry of Myocardial Infarction. J Am Coll Cardiol 1996;27:1321-6.

855. Honan MB, Harrell FE, Reimer KA, et al. Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis. J Am Coll Cardiol 1990;16:359-67.

856. Becker RC, Charlesworth A, Wilcox RG, et al. Cardiac rupture associated with thrombolytic therapy: impact of time to treatment in the Late Assessment of Thrombolytic Efficacy (LATE) study. J Am Coll Cardiol 1995;25:1063-8.

857. Núñez L, de la Llana R, López Sendón J, et al. Diagnosis and treatment of subacute free wall ventricular rupture after infarction. Ann Thorac Surg 1983;35:525-9.

858. Balakumaran K,Verbaan CJ, Essed CE, et al. Ventricular free wall rupture: sudden, subacute, slow, sealed and stabilized varieties. Eur Heart J 1984;5:282-8.

859. McMullan MH, Maples MD, Kilgore TL, Hindman SH. Surgical experience with left ventricular free wall rupture. Ann Thorac Surg 2001;71:1894-8; discussion 1.

860. Padró JM, Mesa JM, Silvestre J, et al. Subacute cardiac rupture: repair with a sutureless technique. Ann Thorac Surg 1993;55:20- 3; discussion 23.

861. Slater J, Brown RJ, Antonelli TA, et al. Cardiogenic shock due to cardiac free-wall rupture or tamponade after acute myocardial infarction: a report from the SHOCK Trial Registry. Should we emergently revascularize occluded coronaries for cardiogenic shock? J Am Coll Cardiol 2000;36:1117-22.

862. Tikiz H, Balbay Y, Atak R, Terzi T, Genç Y, Kütük E. The effect of thrombolytic therapy on left ventricular aneurysm formation in acute myocardial infarction: relationship to successful reperfusion and vessel patency. Clin Cardiol 2001;24:656-62.

863. Premaratne S, Razzuk AM, Koduru SB, Behling A, McNamara JJ. Incidence of postinfarction aneurysm within one month of infarct: experiences with sixteen patients in Hawaii. J Cardiovasc Surg (Torino) 1999;40:473-6.

864. Pasini S, Gagliardotto P, Punta G, et al. Early and late results after surgical therapy of postinfarction left ventricular aneurysm. J Cardiovasc Surg (Torino) 1998;39:209-15.

865. Ohara K. Current surgical strategy for post-infarction left ventricular aneurysm: from linear aneurysmectomy to Dor’s operation. Ann Thorac Cardiovasc Surg 2000;6:289-94.

866. Di Donato M, Sabatier M, Montiglio F, et al. Outcome of left ventricular aneurysmectomy with patch repair in patients with severely depressed pump function. Am J Cardiol 1995;76:557-61.

867. Di Donato M, Toso A, Maioli M, et al, for the RESTORE Group. Intermediate survival and predictors of death after surgical ventricular restoration. Semin Thorac Cardiovasc Surg 2001;13:468-75.

868. Stevenson LW, Kormos RL, Bourge RC, et al. Mechanical cardiac support 2000: current applications and future trial design. June 15-16, 2000 Bethesda, Maryland. J Am Coll Cardiol 2001;37:340-70.

869. Pennington DG, Smedira NG, Samuels LE, Acker MA, Curtis JJ, Pagani FD. Mechanical circulatory support for acute heart failure. Ann Thorac Surg 2001;71:S56-9; discussion S8.

870. Chen JM, DeRose JJ, Slater JP, et al. Improved survival rates support left ventricular assist device implantation early after myocardial infarction. J Am Coll Cardiol 1999;33:1903-8.

871. Champagnac D, Claudel JP, Chevalier P, et al. Primary cardiogenic shock during acute myocardial infarction: results of emergency cardiac transplantation. Eur Heart J 1993;14:925-9.

872. Park SJ, Nguyen DQ, Bank AJ, Ormaza S, Bolman RM. Left ventricular assist device bridge therapy for acute myocardial infarction. Ann Thorac Surg 2000;69:1146-51.

873. Hendry PJ, Masters RG, Mussivand TV, et al. Circulatory support for cardiogenic shock due to acute myocardial infarction: a Canadian experience. Can J Cardiol 1999;15:1090-4.

874. Karagueuzian HS, Mandel WJ. Electrophysiologic mechanisms of ischemic ventricular arrhythmias: experimental and clinical correlations. In Mandel WJ, ed. Cardiac arrhythmias: their mechanisms, diagnosis, and management. Philadelphia, PA: JB Lippincott;1995:563-603.

875. Carmeliet E. Cardiac ionic currents and acute ischemia: from channels to arrhythmias. Physiol Rev 1999;79:917-1017.

876. Campbell RWF. Arrhythmias. In: Julian DG. Braunwald E, eds. Management of acute myocardial infarction. London, England: WB Saunders Co. Ltd;1994:223-240.

877. Nordrehaug JE, von der Lippe G. Hypokalaemia and ventricular fibrillation in acute myocardial infarction. Br Heart J 1983;50:525-9.

878. Higham PD, Adams PC, Murray A, Campbell RW. Plasma potassium, serum magnesium and ventricular fibrillation: a prospective study. Q J Med 1993;86:609-17.

879. Volpi A, Cavalli A, Santoro E, Tognoni G, for the GISSI Investigators. Incidence and prognosis of secondary ventricular fibrillation in acute myocardial infarction: evidence for a protective effect of thrombolytic therapy. Circulation 1990;82:1279-88.

880. Ornato JP, Peberdy MA, Tadler SC, Strobos NC. Factors associated with the occurrence of cardiac arrest during hospitalization for acute myocardial infarction in the second national registry of myocardial infarction in the US. Resuscitation 2001;48:117-23.

881. Campbell RW, Murray A, Julian DG. Ventricular arrhythmias in first 12 hours of acute myocardial infarction: natural history study. Br Heart J 1981;46:351-7.

882. Antman EM, Berlin JA. Declining incidence of ventricular fibrillation in myocardial infarction: implications for the prophylactic use of lidocaine. Circulation 1992;86:764-73.

883. Thompson CA, Yarzebski J, Goldberg RJ, Lessard D, Gore JM, Dalen JE. Changes over time in the incidence and case-fatality rates of primary ventricular fibrillation complicating acute myocardial infarction: perspectives from the Worcester Heart Attack Study. Am Heart J 2000;139:1014-21.

884. Behar S, Goldbourt U, Reicher-Reiss H, Kaplinsky E, for the Principal Investigators of the SPRINT Study. Prognosis of acute myocardial infarction complicated by primary ventricular fibrillation. Am J Cardiol 1990;66:1208-11.

885. Lown B, Fakhro AM, Hood WB, Thorn GW. The coronary care unit: new perspectives and directions. JAMA 1967;199:188-98.

886. Dhurandhar RW, MacMillan RL, Brown KW. Primary ventricular fibrillation complicating acute myocardial infarction. Am J Cardiol 1971;27:347-51.

887. El-Sherif N, Myerburg RJ, Scherlag BJ, et al. Electrocardiographic antecedents of primary ventricular fibrillation: value of the R-on-T phenomenon in myocardial infarction. Br Heart J 1976;38:415-22.

888. Lie KI, Wellens HJ, Durrer D. Characteristics and predictability of primary ventricular fibrillation. Eur J Cardiol 1974;1:379-84.

889. Solomon SD, Ridker PM, Antman EM. Ventricular arrhythmias in trials of thrombolytic therapy for acute myocardial infarction: a meta-analysis. Circulation 1993;88:2575-81.

890. MacMahon S, Collins R, Peto R, Koster RW, Yusuf S. Effects of prophylactic lidocaine in suspected acute myocardial infarction: an overview of results from the randomized, controlled trials. JAMA 1988;260:1910-6.

891. Alexander JH, Granger CB, Sadowski Z, et al, for the GUSTO-I and GUSTO-IIb Investigators. Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. Am Heart J 1999;137:799-805.

892. Hjalmarson A, Herlitz J, Holmberg S, et al. The Göteborg metoprolol trial: effects on mortality and morbidity in acute myocardial infarction. Circulation 1983;67:I26-32.

893. Guidelines for cardiopulmonary resuscitation and emergency cardiac care: part III–adult advanced cardiac life support. Emergency Cardiac Care Committee and Subcommittees, American Heart Association. JAMA 1992;268:2199-241.

894. de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, et al. Circumstances and causes of out-of-hospital cardiac arrest in sudden death survivors. Heart 1998;79:356-61.

895. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 1999;341:871-8.

896. Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 2002;346:884-90.

897. Haynes RE, Chinn TL, Copass MK, Cobb LA. Comparison of bretylium tosylate and lidocaine in management of out of hospital ventricular fibrillation: a randomized clinical trial. Am J Cardiol 1981;48:353-6.

898. Olson DW, Thompson BM, Darin JC, Milbrath MH. A randomized comparison study of bretylium tosylate and lidocaine in resuscitation of patients from out-of-hospital ventricular fibrillation in a paramedic system. Ann Emerg Med 1984;13:807-10.

899. Stiell IG, Wells GA, Hebert PC, Laupacis A, Weitzman BN. Association of drug therapy with survival in cardiac arrest: limited role of advanced cardiac life support drugs. Acad Emerg Med 1995;2:264-73.

900. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care: part 6–advanced cardiovascular life support: section 6–pharmacology II: agents to optimize cardiac output and blood pressure. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation 2000;102:I129-35.

901. Eldar M, Sievner Z, Goldbourt U, Reicher-Reiss H, Kaplinsky E, Behar S, for the SPRINT Study Group. Primary ventricular tachycardia in acute myocardial infarction: clinical characteristics and mortality. Ann Intern Med 1992;117:31-6.

902. Wolfe CL, Nibley C, Bhandari A, Chatterjee K, Scheinman M. Polymorphous ventricular tachycardia associated with acute myocardial infarction. Circulation 1991;84:1543-51.

903. Berger PB, Ruocco NA, Ryan TJ, Frederick MM, Podrid PJ. Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: results from the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial. J Am Coll Cardiol 1993;22:1773-9.

904. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997;350:1417- 24.

905. Nademanee K, Taylor R, Bailey WE, et al. Management and longterm outcome of patients with electrical storm [abstr]. J Am Coll Cardiol 1995;l25:187A.

906. Scheinman MM, Levine JH, Cannom DS, et al, for the Intravenous Amiodarone Multicenter Investigators Group. Doseranging study of intravenous amiodarone in patients with lifethreatening ventricular tachyarrhythmias. Circulation 1995; 92:3264-72.

907. Nademanee K, Taylor R, Bailey WE, Rieders DE, Kosar EM. Treating electrical storm: sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation 2000;102:742-7.

908. Correction: a randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 2000;342:1300.

909. Shea S, Bigger JT, Campion J, et al. Enrollment in clinical trials: institutional factors affecting enrollment in the cardiac arrhythmia suppression trial (CAST). Control Clin Trials 1992;13:466-86.

910. Newby KH, Thompson T, Stebbins A, Topol EJ, Califf RM, Natale A, for the GUSTO Investigators. Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. Circulation 1998;98:2567-73.

911. Al-Khatib SM, Stebbins AL, Califf RM, et al. Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial. Am Heart J 2003;145:515-21.

912. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-83.

913. Siebels J, Kuck KH. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). Am Heart J 1994;127:1139-44.

914. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101:1297-302.

915. Moss AJ, Hall WJ, Cannom DS, et al, for the Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933-40.

916. Buxton AE, Lee KL, Fisher JD, et al, for the Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999;341:1882-90.

917. Moss AJ, Zareba W, Hall WJ, et al, for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877- 83.

918. Lee KL, Hafley G, Fisher JD, et al, for the Multicenter Unsustained Tachycardia Trial Investigators. Effect of implantable defibrillators on arrhythmic events and mortality in the multicenter unsustained tachycardia trial. Circulation 2002;106:233-8.

919. Bigger JT, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984;69:250-8.

920. Buxton AE, Marchlinski FE, Waxman HL, Flores BT, Cassidy DM, Josephson ME. Prognostic factors in nonsustained ventricular tachycardia. Am J Cardiol 1984;53:1275-9.

921. Buxton AE, Lee KL, DiCarlo L, et al, for the Multicenter Unsustained Tachycardia Trial Investigators. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. N Engl J Med 2000;342:1937-45.

922. Buxton AE, Lee KL, Hafley GE, et al, for the MUSTT Investigators. Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease: an analysis of patients enrolled in the multicenter unsustained tachycardia trial. Circulation 2002;106:2466-72.

923. Solomon SD, Glynn RJ, Greaves S, et al. Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study. Ann Intern Med 2001;134:451-8.

924. Ureña PE, Lamas GA, Mitchell G, et al, for the Survival and Ventricular Enlargement (SAVE) Investigators. Ejection fraction by radionuclide ventriculography and contrast left ventriculogram: a tale of two techniques. J Am Coll Cardiol 1999;33:180-5.

925. Deleted in press.

926. Auricchio A, Klein H, Geller CJ, Reek S, Heilman MS, Szymkiewicz SJ. Clinical efficacy of the wearable cardioverterdefibrillator in acutely terminating episodes of ventricular fibrillation. Am J Cardiol 1998;81:1253-6.

927. Kontoyannis DA, Anastasiou-Nana MI, Kontoyannis SA, Zaga AK, Nanas JN. Intravenous amiodarone decreases the duration of atrial fibrillation associated with acute myocardial infarction. Cardiovasc Drugs Ther 2001;15:155-60.

928. Nielsen FE, Andersen HH, Gram-Hansen P, Sørensen HT, Klausen IC. The relationship between ECG signs of atrial infarction and the development of supraventricular arrhythmias in patients with acute myocardial infarction. Am Heart J 1992;123:69-72.

929. Kyriakidis M, Barbetseas J, Antonopoulos A, Skouros C, Tentolouris C, Toutouzas P. Early atrial arrhythmias in acute myocardial infarction: role of the sinus node artery. Chest 1992;101:944-7.

930. Hildebrandt P, Jensen G, Køber L, et al. Myocardial infarction 1979-1988 in Denmark: secular trends in age-related incidence, in-hospital mortality and complications. Eur Heart J 1994;15:877-81.

931. Waldo AL. An approach to therapy of supraventricular tachyarrhythmias: an algorithm versus individualized therapy. Clin Cardiol 1994;17:II21-6.

932. Liberthson RR, Salisbury KW, Hutter AM, DeSanctis RW. Atrial tachyarrhythmias in acute myocardial infarction. Am J Med 1976;60:956-60.

933. Kobayashi Y, Katoh T, Takano T, Hayakawa H. Paroxysmal atrial fibrillation and flutter associated with acute myocardial infarction: hemodynamic evaluation in relation to the development of arrhythmias and prognosis. Jpn Circ J 1992;56:1-11.

934. Rathore SS, Berger AK, Weinfurt KP, et al. Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. Circulation 2000;101:969-74.

935. Pedersen OD, Bagger H, Køber L, Torp-Pedersen C, for the TRAndolapril Cardiac Evaluation (TRACE) Study Group. The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. Eur Heart J 1999; 20:748-54.

936. Goldberg RJ, Seeley D, Becker RC, et al. Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective. Am Heart J 1990;119:996-1001.

937. Hod H, Lew AS, Keltai M, et al. Early atrial fibrillation during evolving myocardial infarction: a consequence of impaired left atrial perfusion. Circulation 1987;75:146-50.

938. Rechavia E, Strasberg B, Mager A, et al. The incidence of atrial arrhythmias during inferior wall myocardial infarction with and without right ventricular involvement. Am Heart J 1992;124:387- 91.

939. Behar S, Tanne D, Zion M, et al, for the Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) Study Group. Incidence and prognostic significance of chronic atrial fibrillation among 5,839 consecutive patients with acute myocardial infarction. Am J Cardiol 1992;70:816-8.

940. James TN. Myocardial infarction and atrial arrhythmias. Circulation 1961;24:761-76.

941. Nielsen FE, Sørensen HT, Christensen JH, Ravn L, Rasmussen SE. Reduced occurrence of atrial fibrillation in acute myocardial infarction treated with streptokinase. Eur Heart J 1991;12:1081-3.

942. Eldar M, Canetti M, Rotstein Z, et al, for the SPRINT and Thrombolytic survey groups. Significance of paroxysmal atrial fibrillation complicating acute myocardial infarction in the thrombolytic era. Circulation 1998;97:965-70.

943. Behar S, Zahavi Z, Goldbourt U, Reicher-Reiss H, for the SPRINT Study Group. Long-term prognosis of patients with paroxysmal atrial fibrillation complicating acute myocardial infarction. Eur Heart J 1992;13:45-50.

944. Crenshaw BS, Ward SR, Granger CB, Stebbins AL, Topol EJ, Califf RM. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 1997;30:406-13.

945. Wong CK, White HD, Wilcox RG, et al. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J 2000;140:878-85.

946. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 2001;86:527-32.

947. Lesser MF. Safety and efficacy of in-office cardioversion for treatment of supraventricular arrhythmias. Am J Cardiol 1990; 66:1267-8.

948. Joglar JA, Hamdan MH, Ramaswamy K, et al. Initial energy for elective external cardioversion of persistent atrial fibrillation. Am J Cardiol 2000;86:348-50.

949. Dahl CF, Ewy GA,Warner ED, Thomas ED. Myocardial necrosis from direct current countershock. Effect of paddle electrode size and time interval between discharges. Circulation 1974;50:956- 61.

950. Moss AJ, Oakes D, Benhorin J, Carleen E, for the Multicenter Diltiazem Post-Infarction Research Group. The interaction between diltiazem and left ventricular function after myocardial infarction. Circulation 1989;80:IV102-6.

951. Clemo HF,Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol 1998;81:594-8.

952. Rawles JM, Metcalfe MJ, Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J 1990;63:225-7.

953. Murgatroyd FD, Gibson SM, Baiyan X, et al. Double-blind placebo- controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation. Circulation 1999;99:2765-70.

954. Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol 1999;33:304-10.

955. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2001;38:1231-66.

956. Lavie CJ, Gersh BJ. Mechanical and electrical complications of acute myocardial infarction. Mayo Clin Proc 1990;65:709-30.

957. Wong CK, White HD, Wilcox RG, et al, for the GUSTO-III Investigators. Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries. Heart 2002;88:357-62.

958. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.

959. Antman EM. General hospital management. In: Julian DG, Braunwald E, eds. Management of acute myocardial infarction. London, England: WB Saunders Co Ltd; 1994:42-4.

960. Brady WJ, Harrigan RA. Diagnosis and management of bradycardia and atrioventricular block associated with acute coronary ischemia. Emerg Med Clin North Am 2001;19:371-84, xi-xii.

961. Pasternak RC, Braunwald E, Sobel BE. Acute myocardial infarction: In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine. Philadelphia, Pa: WB Saunders Co Ltd; 1992:1240-9.

962. Berger PB, Ruocco NA, Ryan TJ, Frederick MM, Jacobs AK, Faxon DP. Incidence and prognostic implications of heart block complicating inferior myocardial infarction treated with thrombolytic therapy: results from TIMI II. J Am Coll Cardiol 1992;20:533-40.

963. McDonald K, O’Sullivan JJ, Conroy RM, Robinson K, Mulcahy R. Heart block as a predictor of in-hospital death in both acute inferior and acute anterior myocardial infarction. Q J Med 1990;74:277-82.

964. Nicod P, Gilpin E, Dittrich H, Polikar R, Henning H, Ross J. Long-term outcome in patients with inferior myocardial infarction and complete atrioventricular block. J Am Coll Cardiol 1988;12:589-94.

965. Antman EM. Cardiovascular therapeutics: a companion guide to Braunwald’s heart disease. 2nd ed. Philadelphia, Pa: WB Saunders Co Ltd; 2001:273.

966. Mahr NC, Valdes A, Lamas G. Use of glucagon for acute intravenous diltiazem toxicity. Am J Cardiol 1997;79:1570-1.

967. Topol EJ, Goldschlager N, Ports TA, et al. Hemodynamic benefit of atrial pacing in right ventricular myocardial infarction. Ann Intern Med 1982;96:594-7.

968. Mavric Z, Zaputovic L, Matana A, et al. Prognostic significance of complete atrioventricular block in patients with acute inferior myocardial infarction with and without right ventricular involvement. Am Heart J 1990;119:823-8.

969. Wenzel V, Krismer AC, Arntz HR, Sitter H, Stadlbauer KH, Lindner KH, for the European Resuscitation Council Vasopressor during Cardiopulmonary Resuscitation Study Group. A comparison
of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N Engl J Med 2004;350:105-13.

970. Hindman MC, Wagner GS, JaRo M, et al. The clinical significance of bundle branch block complicating acute myocardial infarction: 2.–Indications for temporary and permanent pacemaker
insertion. Circulation 1978;58:689-99.

971. Col JJ,Weinberg SL. The incidence and mortality of intraventricular conduction defects in acute myocardial infarction. Am J Cardiol 1972;29:344-50.

972. Ritter WS, Atkins JM, Blomqvist CG, Mullins CB. Permanent pacing in patients with transient trifascicular block during acute myocardial infarction. Am J Cardiol 1976;38:205-8.

973. Ginks WR, Sutton R, Oh W, Leatham A. Long-term prognosis after acute anterior infarction with atrioventricular block. Br Heart J 1977;39:186-9.

974. Domenighetti G, Perret C. Intraventricular conduction disturbances in acute myocardial infarction: short- and long-term prognosis. Eur J Cardiol 1980;11:51-9.

975. Ranganathan N, Dhurandhar R, Phillips JH, Wigle ED. His Bundle electrogram in bundle-branch block. Circulation 1972;45:282-94.

976. Lamas GA, Muller JE, Turi ZG, et al. A simplified method to predict occurrence of complete heart block during acute myocardial infarction. Am J Cardiol 1986;57:1213-9.

977. Harthorne JW, Barold SS. Atherosclerosis, the conduction system and cardiac pacing. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and coronary artery disease. Philadelphia, PA: Lippincott-Raven Publishers;1996:1013-30.

978. Juma Z, Castellanos A, Myerburg RJ. Prognostic significance of the electrocardiogram in patients with coronary heart disease. In: Wellens HJJ, Kulbertus HE, eds. What’s new in electrocardiography. The Hague: Martinus Nijhoff Publishers; 1981:5-22 .

979. Clemmensen P, Bates ER, Califf RM, et al, for the TAMI Study Group. Complete atrioventricular block complicating inferior wall acute myocardial infarction treated with reperfusion therapy. Am J Cardiol 1991;67:225-30.

980. Goldberg RJ, Zevallos JC, Yarzebski J, et al. Prognosis of acute myocardial infarction complicated by complete heart block (the Worcester Heart Attack Study). Am J Cardiol 1992;69: 1135-41.

981. Behar S, Zissman E, Zion M, et al, for the SPRINT Study Group. Prognostic significance of second-degree atrioventricular block in inferior wall acute myocardial infarction. Am J Cardiol
1993;72:831-4.

982. Lie KL,Wellens HJJ, Schuilenburg RM. Bundle branch block and acute myocardial infarction. In: Wellens HJJ, Lie KI, Janse MD, Eds. The conduction system of the heart: structure, function and
clinical implications. Philadelphia, Pa: Lea & Febiger;1976:662-72.

983. Dubois C, Piérard LA, Smeets JP, Carlier J, Kulbertus HE. Longterm prognostic significance of atrioventricular block in inferior acute myocardial infarction. Eur Heart J 1989;10:816-20.

984. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). J Am Coll Cardiol 2002;
40:1703-19.

985. Wilkoff BL, Cook JR, Epstein AE, et al, for the Dual Chamber and VVI Implantable Defibrillator Trial Investigators. Dualchamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 2002;288: 3115- 23.

986. Lamas GA, Ellenbogen KA. Evidence base for pacemaker mode selection: from physiology to randomized trials. Circulation 2004;109:443-51.

987. Rude RE, Poole WK, Muller JE, et al. Electrocardiographic and clinical criteria for recognition of acute myocardial infarction based on analysis of 3,697 patients. Am J Cardiol 1983;52:936- 42.

988. Tofler GH, Muller JE, Stone PH, et al. Pericarditis in acute myocardial infarction: characterization and clinical significance. Am Heart J 1989;117:86-92.

989. Wall TC, Califf RM, Harrelson-Woodlief L, et al, for the TAMI Study Group. Usefulness of a pericardial friction rub after thrombolytic therapy during acute myocardial infarction in predicting amount of myocardial damage. Am J Cardiol 1990;66:1418-21.

990. Oliva PB, Hammill SC. The clinical distinction between regional postinfarction pericarditis and other causes of postinfarction chest pain: ancillary observations regarding the effect of lytic therapy upon the frequency of postinfarction pericarditis, postinfarction angina, and reinfarction. Clin Cardiol 1994;17:471-8.

991. Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA guidelines for the clinical application of echocardiography: executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). J Am Coll Cardiol 1997;29:862-79.

992. Oliva PB, Hammill SC, Talano JV. T wave changes consistent with epicardial involvement in acute myocardial infarction: observations in patients with a postinfarction pericardial effusion without clinically recognized postinfarction pericarditis. J Am Coll Cardiol 1994;24:1073-7.

993. Widimský P, Gregor P. Recent atrial fibrillation in acute myocardial infarction: a sign of pericarditis. Cor Vasa 1993;35:230-2.

994. Erhardt LR. Clinical and pathological observations in different types of acute myocardial infarction. Acta Med Scand 1974; 560:1-78.

995. Spodick D. Pericardial complications of myocardial infarction. In: Francis GS, Alpert JS, eds. Modern coronary care. Boston, MA: Little Brown and Co; 1990:331-9.

996. Shahar A, Hod H, Barabash GM, Kaplinsky E, Motro M. Disappearance of a syndrome: Dressler’s syndrome in the era of thrombolysis. Cardiology 1994;85:255-8.

997. Jain A. “Tombstone” anterior ST-segment elevations secondary to acute pericarditis: the role of two-dimensional echocardiogram. Clin Cardiol 1997;20:404-6.

998. Bonnefoy E, Godon P, Kirkorian G, Fatemi M, Chevalier P, Touboul P. Serum cardiac troponin I and ST-segment elevation in patients with acute pericarditis. Eur Heart J 2000;21:832-6.

999. Berman J, Haffajee CI, Alpert JS. Therapy of symptomatic pericarditis after myocardial infarction: retrospective and prospective studies of aspirin, indomethacin, prednisone, and spontaneous resolution. Am Heart J 1981;101:750-3.

1000. Bulkley BH, Roberts WC. Steroid therapy during acute myocardial infarction: a cause of delayed healing and of ventricular aneurysm. Am J Med 1974;56:244-50.

1001. Kloner RA, Fishbein MC, Lew H, Maroko PR, Braunwald E. Mummification of the infarcted myocardium by high-dose corticosteroids. Circulation 1978;57:56-63.

1002. Taylor SD, Chey WY, Scheiman JM. Acid secretion during indomethacin therapy: effect of misoprostol. J Clin Gastroenterol 1995;20:131-5.

1003. Weir MR, Klassen DK, Hall PS, et al. Minimization indomethacin-induced reduction in renal function by misoprostol. J Clin Pharmacol 1991;31:729-35.

1004. Spodick DH. Pericardial diseases. Eds. Braunwald E, Zipes DP, Libby P. Heart disease: a textbook of cardiovascular medicine. 6th ed. Philadelphia, PA: WB Saunders Co Ltd; 2001:1823.

1005. O’Rourke RA, Fuster V, Alexander RW, Roberts R, King, SB III, Welens HJJ. Hurst’s the heart. 10th ed. Manual of cardiology. United States: McGraw-Hill Companies, Inc; 2001:2066.

1006. Adler Y, Finkelstein Y, Guindo J, et al. Colchicine treatment for recurrent pericarditis: a decade of experience. Circulation 1998;97:2183-5.

1007. Brucato A, Cimaz R, Balla E. Prevention of recurrences of corticosteroid- dependent idiopathic pericarditis by colchicine in an adolescent patient. Pediatr Cardiol 2000;21:395-6.

1008. Troughton RW, Asher CR, Klein AL. Pericarditis. Lancet 2004;363:717-27.

1009. Antman EM. General hospital management. In: Julian DG, Braunwald E, eds. Management of acute myocardial infarction. London, England: WB Saunders Co Ltd; 1994:42-44.

1010. Hutchins GM, Bulkley BH. Infarct expansion versus extension: two different complications of acute myocardial infarction. Am J Cardiol 1978;41:1127-32.

1011. Ohman EM, Califf RM, Topol EJ, et al, for the TAMI Study Group. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990;82:781-91.

1012. Antman E, Braunwald E. Acute myocardial infarction. In: Braunwald E, Zipes DP, Libby P, eds. Heart disease: a textbook of cardiovascular medicine, 6th ed. Philadelphia, PA: WB Saunders Co Ltd; 2001:1114-1251.

1013. Tanne D, Gottlieb S, Hod H, Reicher-Reiss H, Boyko V, Behar for the Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) and Israeli Thrombolytic Survey Groups. Incidence and mortality from early stroke associated with acute myocardial infarction in the prethrombolytic and thrombolytic eras. J Am Coll Cardiol 1997;30:1484-90.

1014. Mooe T, Eriksson P, Stegmayr B. Ischemic stroke after acute myocardial infarction: a population-based study. Stroke 1997; 28:762-7.

1015. Mahaffey KW, Granger CB, Sloan MA, et al. Risk factors for inhospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTOI. Circulation 1998;97:757-64.

1016. Prieto A, Eisenberg J, Thakur RK. Nonarrhythmic complications of acute myocardial infarction. Emerg Med Clin North Am 2001; 19:397-415, xii-xiii.

1017. Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997;336:251-7.

1018. Bodenheimer MM, Sauer D, Shareef B, Brown MW, Fleiss JL, Moss AJ. Relation between myocardial infarct location and stroke. J Am Coll Cardiol 1994;24:61-6.

1019. Tanne D, Goldbourt U, Zion M, Reicher-Reiss H, Kaplinsky Behar S, for the SPRINT Study Group. Frequency and prognosis of stroke/TIA among 4808 survivors of acute myocardial infarction. Stroke 1993;24:1490-5.

1020. Spirito P, Bellotti P, Chiarella F, Domenicucci S, Sementa A, Vecchio C. Prognostic significance and natural history of left ventricular thrombi in patients with acute anterior myocardial infarction: a two-dimensional echocardiographic study. Circulation 1985;72:774-80.

1021. Celik S, Ovali E, Baykan M, et al. Factor V Leiden and its relation to left ventricular thrombus in acute myocardial infarction. Acta Cardiol 2001;56:1-6.

1022. Stratton JR, Resnick AD. Increased embolic risk in patients with left ventricular thrombi. Circulation 1987;75:1004-11.

1023. Nordrehaug JE, Johannessen KA, von der Lippe G. Usefulness of high-dose anticoagulants in preventing left ventricular thrombus in acute myocardial infarction. Am J Cardiol 1985;55:1491- 3.

1024. Vaitkus PT, Berlin JA, Schwartz JS, Barnathan ES. Stroke complicating acute myocardial infarction: a meta-analysis of risk modification by anticoagulation and thrombolytic therapy. Arch Intern Med 1992;152:2020-4.

1025. Arvan S, Boscha K. Prophylactic anticoagulation for left ventricular thrombi after acute myocardial infarction: a prospective randomized trial. Am Heart J 1987;113:688-93.

1026. Eigler N, Maurer G, Shah PK. Effect of early systemic thrombolytic therapy on left ventricular mural thrombus formation in acute anterior myocardial infarction. Am J Cardiol 1984;54:261-3.

1027. Motro M, Barbash GI, Hod H, et al. Incidence of left ventricular thrombi formation after thrombolytic therapy with recombinant tissue plasminogen activator, heparin, and aspirin in patients with acute myocardial infarction. Am Heart J 1991;122:23-6.

1028. Heik SC, Kupper W, Hamm C, et al. Efficacy of high-dose intravenous heparin for treatment of left ventricular thrombi with high embolic risk. J Am Coll Cardiol 1994;24:1305-9.

1029. Barnett HJ, Taylor DW, Eliasziw M, et al, for the North American Symptomatic Carotid Endarterectomy Trial Collaborators. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med 1998;339:1415-25.

1030. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994;90:61-8.

1031. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988;1:545-9.

1032. Ringleb PA, Bhatt DL, Hirsch AT, Topol EJ, Hacke W, for the Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events Investigators. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 2004;35:528-32.

1033. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study: 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.

1034. Rothwell PM, Gutnikov SA, Warlow CP, for the European Carotid Surgery Trialists Collaboration. Reanalysis of the final results of the European Carotid Surgery Trial. Stroke 2003;34:514-23.

1035. Rothwell PM, Eliasziw M, Gutnikov SA, et al, for the Carotid Endarterectomy Trialists’ Collaboration. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 2003;361:107-16.

1036. Wholey MH, Wholey M, Mathias K, et al. Global experience in cervical carotid artery stent placement. Catheter Cardiovasc Interv 2000;50:160-7.

1037. Malek AM, Higashida RT, Phatouros CC, et al. Stent angioplasty for cervical carotid artery stenosis in high-risk symptomatic NASCET-ineligible patients. Stroke 2000;31:3029-33.

1038. Deleted in press.

1039. Turpie AG, Chin BS, Lip GY. Venous thromboembolism: pathophysiology, clinical features, and prevention. BMJ 2002; 325:887-90. 1040. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119:132S-175S.

1041. Green L, Fay W, Frey KA, et al. Diagnosis and Treatment of Venous Thromboembolic Disease Guideline. University of Michigan Health System. National Guidelines Clearinghouse 2004. In press.

1042. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160:181-188.

1043. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119:176S-193S.

1044. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003; 107:1692-711.

1045. Boden WE. Is it time to reassess the optimal timing of coronary artery bypass graft surgery following acute myocardial infarction? Am J Cardiol 2002;90:35-8.

1046. Crossman AW, D’Agostino HJ, Geraci SA. Timing of coronary artery bypass graft surgery following acute myocardial infarction: a critical literature review. Clin Cardiol 2002;25:406-10.

1047. Braxton JH, Hammond GL, Letsou GV, et al. Optimal timing of coronary artery bypass graft surgery after acute myocardial infarction. Circulation 1995;92:II66-8.

1048. Lee DC, Oz MC,Weinberg AD, Lin SX, Ting W. Optimal timing of revascularization: transmural versus nontransmural acute myocardial infarction. Ann Thorac Surg 2001;71:1197-202; discussion.

1049. Creswell LL, Moulton MJ, Cox JL, Rosenbloom M. Revascularization after acute myocardial infarction. Ann Thorac Surg 1995;60:19-26.

1050. Acinapura AJ, Rose DM, Jacobowitz IJ, et al. Internal mammary artery bypass grafting: influence on recurrent angina and survival in 2,100 patients. Ann Thorac Surg 1989;48:186-91.

1051. Hirose H, Amano A, Yoshida S, et al. Surgical management of unstable patients in the evolving phase of acute myocardial infarction. Ann Thorac Surg 2000;69:425-8.

1052. Hirotani T, Kameda T, Shirota S, Nakao Y. Coronary artery bypass grafting within 30 days of an acute myocardial infarction. Ann Thorac Cardiovasc Surg 2001;7:28-34.

1053. Gersh BJ, Chesebro JH, Braunwald E, et al. Coronary artery bypass graft surgery after thrombolytic therapy in the Thrombolysis in Myocardial Infarction Trial, Phase II (TIMI II). J Am Coll Cardiol 1995;25:395-402.

1054. Holmes DR, Califf RM, Topol EJ. Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries. J Am Coll Cardiol 1995;25:10S-17S.

1055. Kereiakes DJ, Topol EJ, George BS, et al, for the TAMI Study Group. Favorable early and long-term prognosis following coronary bypass surgery therapy for myocardial infarction: results of a multicenter trial. Am Heart J 1989;118:199-207.

1056. Skinner JR, Phillips SJ, Zeff RH, Kongtahworn C. Immediate coronary bypass following failed streptokinase infusion in evolving myocardial infarction. J Thorac Cardiovasc Surg 1984;87:567-70.

1057. Barner HB, Lea JW, Naunheim KS, Stoney WS. Emergency coronary bypass not associated with preoperative cardiogenic shock in failed angioplasty, after thrombolysis, and for acute myocardial infarction. Circulation 1989;79:I152-9.

1058. Efstratiadis T, Munsch C, Crossman D, Taylor K. Aprotinin used in emergency coronary operation after streptokinase treatment. Ann Thorac Surg 1991;52:1320-1.

1059. Breyer RH, Engelman RM, Rousou JA, Lemeshow S. Postinfarction angina: an expanding subset of patients undergoing coronary artery bypass. J Thorac Cardiovasc Surg 1985; 90:532-40.

1060. Hochberg MS, Parsonnet V, Gielchinsky I, Hussain SM, Fisch DA, Norman JC. Timing of coronary revascularization after acute myocardial infarction: early and late results in patients
revascularized within seven weeks. J Thorac Cardiovasc Surg 1984;88:914-21.

1061. Fremes SE, Goldman BS, Weisel RD, et al. Recent preoperative myocardial infarction increases the risk of surgery for unstable angina. J Card Surg 1991;6:2-12.

1062. Omoigui NA, Miller DP, Brown KJ, et al. Outmigration for coronary bypass surgery in an era of public dissemination of clinical outcomes. Circulation 1996;93:27-33.

1063. Burack JH, Impellizzeri P, Homel P, Cunningham JN. Public reporting of surgical mortality: a survey of New York State cardiothoracic surgeons. Ann Thorac Surg 1999;68:1195-200; discussion.

1064. Nallamothu BK, Saint S, Ramsey SD, Hofer TP, Vijan S, Eagle KA. The role of hospital volume in coronary artery bypass grafting: is more always better? J Am Coll Cardiol 2001;38:1923-30.

1065. Applebaum R, House R, Rademaker A, et al. Coronary artery bypass grafting within thirty days of acute myocardial infarction: early and late results in 406 patients. J Thorac Cardiovasc Surg 1991;102:745-52.

1066. Mangano DT, for the Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002;347:1309-17.

1067. Topol EJ. Aspirin with bypass surgery: from taboo to new standard of care. N Engl J Med 2002;347:1359-60.

1068. Hongo RH, Ley J, Dick SE,Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002;40:231-7.

1069. Boehrer JD, Kereiakes DJ, Navetta FI, Califf RM, Topol EJ, for the Evaluation Prevention of Ischemic Complications (EPIC) Investigators. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. Am J Cardiol 1994;74:1166-70.

1070. Singh M, Nuttall GA, Ballman KV, et al. Effect of abciximab on the outcome of emergency coronary artery bypass grafting after failed percutaneous coronary intervention. Mayo Clin Proc
2001;76:784-8.

1071. Lincoff AM, LeNarz LA, Despotis GJ, et al. Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing. Ann Thorac Surg 2000;70:516-26.

1072. Dyke C, Bhatia D. Inhibitors of the platelet receptor glycoprotein
IIb-IIIa and complications during percutaneous coronary revascularization:
management strategies for the cardiac surge
on. J Cardiovasc Surg (Torino) 1999;40:505-16.

1073. Clopidigrel. Package insert. Physican’s Desk Reference. Medical Economics Co. Montvale, NJ:2756.

1074. Crawford MH, Bernstein SJ, Deedwania PC, et al. ACC/AHA guidelines for ambulatory electrocardiography: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography). J Am Coll Cardiol 1999;34:912-48.

1075. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). 2002. Available at: http://www.acc.org/clinical/guidelines/exercise/ exercise_clean.pdf. Accessed January 4, 2004.

1076. Théroux P, Waters DD, Halphen C, Debaisieux JC, Mizgala HF. Prognostic value of exercise testing soon after myocardial infarction. N Engl J Med 1979;301:341-5.

1077. DeBusk RF, Kraemer HC, Nash E, Berger WE, Lew H. Stepwise risk stratification soon after acute myocardial infarction. Am J Cardiol 1983;52:1161-6.

1078. Krone RJ, Gillespie JA,Weld FM, Miller JP, Moss AJ. Low-level exercise testing after myocardial infarction: usefulness in enhancing clinical risk stratification. Circulation 1985;71:80-9.

1079. Valentine PA, Frew JL, Mashford ML, Sloman JG. Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction: a double-blind study. N Engl J Med 1974;291:1327- 31.

1080. Ross J, Gilpin EA, Madsen EB, et al. A decision scheme for coronary angiography after acute myocardial infarction. Circulation 1989;79:292-303.

1081. Ritchie JL, Cerqueira M, Maynard C, Davis K, Kennedy JW. Ventricular function and infarct size: the Western Washington Intravenous Streptokinase in Myocardial Infarction Trial. J Am Coll Cardiol 1988;11:689-97.

1082. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: phase I findings. N Engl J Med 1985;312:932-6.

1083. Hamm LF, Crow RS, Stull GA, Hannan P. Safety and characteristics of exercise testing early after acute myocardial infarction. Am J Cardiol 1989;63:1193-7.

1084. Juneau M, Colles P, Théroux P, et al. Symptom-limited versus low level exercise testing before hospital discharge after myocardial infarction. J Am Coll Cardiol 1992;20:927-33.

1085. Jain A, Myers GH, Sapin PM, O’Rourke RA. Comparison of symptom-limited and low level exercise tolerance tests early after myocardial infarction. J Am Coll Cardiol 1993;22:1816- 20.

1086. Mark DB, Shaw L, Harrell FE, et al. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med 1991;325:849-53.

1087. Piccalò G, Pirelli S, Massa D, Cipriani M, Sarullo FM, De Vita C. Value of negative predischarge exercise testing in identifying patients at low risk after acute myocardial infarction treated by systemic thrombolysis. Am J Cardiol 1992;70:31-3.

1088. Heger JJ, Weyman AE, Wann LS, Rogers EW, Dillon JC, Feigenbaum H. Cross-sectional echocardiographic analysis of the extent of left ventricular asynergy in acute myocardial infarction. Circulation 1980;61:1113-8.

1089. Gibson RS, Bishop HL, Stamm RB, Crampton RS, Beller GA, Martin RP. Value of early two dimensional echocardiography in patients with acute myocardial infarction. Am J Cardiol 1982;49:1110-9.

1090. Nishimura RA, Tajik AJ, Shub C, Miller FA, Ilstrup DM, Harrison CE. Role of two-dimensional echocardiography in the prediction of in-hospital complications after acute myocardial infarction. J Am Coll Cardiol 1984;4:1080-7.

1091. Horowitz RS, Morganroth J. Immediate detection of early highrisk patients with acute myocardial infarction using two-dimensional echocardiographic evaluation of left ventricular regional wall motion abnormalities. Am Heart J 1982;103:814-22.

1092. Minardi G, Di Segni M, Manzara CC, et al. Diagnostic and prognostic value of dipyridamole and dobutamine stress echocardiography in patients with Q-wave acute myocardial infarction. Am J Cardiol 1997;80:847-51.

1093. Smart S, Wynsen J, Sagar K. Dobutamine-atropine stress echocardiography for reversible dysfunction during the first week after acute myocardial infarction: limitations and determinants of accuracy. J Am Coll Cardiol 1997;30:1669-78.

1094. Bolognese L, Antoniucci D, Rovai D, et al. Myocardial contrast echocardiography versus dobutamine echocardiography for predicting functional recovery after acute myocardial infarction treated with primary coronary angioplasty. J Am Coll Cardiol 1996;28:1677-83.

1095. Poli A, Previtali M, Lanzarini L, et al. Comparison of dobutamine stress echocardiography with dipyridamole stress echocardiography for detection of viable myocardium after myocardial infarction treated with thrombolysis. Heart 1996;75:240-6.

1096. Salustri A, Elhendy A, Garyfallydis P, et al. Prediction of improvement of ventricular function after first acute myocardial infarction using low-dose dobutamine stress echocardiography. Am J Cardiol 1994;74:853-6.

1097. Watada H, Ito H, Oh H, et al. Dobutamine stress echocardiography predicts reversible dysfunction and quantitates the extent of irreversibly damaged myocardium after reperfusion of anterior myocardial infarction. J Am Coll Cardiol 1994;24:624-30.

1098. Previtali M, Poli A, Lanzarini L, Fetiveau R, Mussini A, Ferrario M. Dobutamine stress echocardiography for assessment of myocardial viability and ischemia in acute myocardial infarction treated with thrombolysis. Am J Cardiol 1993;72:124G- 130G.

1099. Smart SC, Sawada S, Ryan T, et al. Low-dose dobutamine echocardiography detects reversible dysfunction after thrombolytic therapy of acute myocardial infarction. Circulation 1993;88:405-15.

1100. Piérard LA, De Landsheere CM, Berthe C, Rigo P, Kulbertus HE. Identification of viable myocardium by echocardiography during dobutamine infusion in patients with myocardial infarction after thrombolytic therapy: comparison with positron emission tomography. J Am Coll Cardiol 1990;15:1021-31.

1101. Barilla F, Gheorghiade M, Alam M, Khaja F, Goldstein S. Lowdose dobutamine in patients with acute myocardial infarction identifies viable but not contractile myocardium and predicts the magnitude of improvement in wall motion abnormalities in response to coronary revascularization. Am Heart J 1991; 122:1522-31.

1102. Lundgren C, Bourdillon PD, Dillon JC, Feigenbaum H. Comparison of contrast angiography and two-dimensional echocardiography for the evaluation of left ventricular regional wall motion abnormalities after acute myocardial infarction. Am J Cardiol 1990;65:1071-7.

1103. Applegate RJ, Dell’Italia LJ, Crawford MH. Usefulness of twodimensional echocardiography during low-level exercise testing early after uncomplicated acute myocardial infarction. Am J Cardiol 1987;60:10-4.

1104. Picano E, Pingitore A, Sicari R, et al, for the Echo Persantine International Cooperative (EPIC) Study Group. Stress echocardiographic results predict risk of reinfarction early after uncomplicated acute myocardial infarction: large-scale multicenter study. J Am Coll Cardiol 1995;26:908-13.

1105. Bolognese L, Rossi L, Sarasso G, et al. Silent versus symptomatic dipyridamole-induced ischemia after myocardial infarction: clinical and prognostic significance. J Am Coll Cardiol 1992;19:953-9.

1106. Quintana M, Lindvall K, Rydén L, Brolund F. Prognostic value of predischarge exercise stress echocardiography after acute myocardial infarction. Am J Cardiol 1995;76:1115-21.

1107. Orlandini AD, Tuero EI, Diaz R, Vilamajó OA, Paolasso EA. Acute cardiac rupture during dobutamine-atropine echocardiography stress test. J Am Soc Echocardiogr 2000;13:152-3.

1108. Carlos ME, Smart SC,Wynsen JC, Sagar KB. Dobutamine stress echocardiography for risk stratification after myocardial infarction. Circulation 1997;95:1402-10.

1109. Greco CA, Salustri A, Seccareccia F, et al. Prognostic value of dobutamine echocardiography early after uncomplicated acute myocardial infarction: a comparison with exercise electrocardiography. J Am Coll Cardiol 1997;29:261-7.

1110. Sclavo MG, Noussan P, Pallisco O, Presbitero P. Usefulness of dipyridamole-echocardiographic test to identify jeopardized myocardium after thrombolysis: limited clinical predictivity of dipyridamole-echocardiographic test in convalescing acute myocardial infarction: correlation with coronary angiography. Eur Heart J 1992;13:1348-55.

1111. Picano E, Landi P, Bolognese L, et al, for the EPIC Study Group. Prognostic value of dipyridamole echocardiography early after uncomplicated myocardial infarction: a large-scale, multicenter trial. Am J Med 1993;95:608-18.

1112. Sicari R, Picano E, Landi P, et al. Prognostic value of dobutamine- atropine stress echocardiography early after acute myocardial infarction. Echo Dobutamine International Cooperative (EDIC) Study. J Am Coll Cardiol 1997;29:254-60.

1113. Gibson RS, Watson DD, Craddock GB, et al. Prediction of cardiac events after uncomplicated myocardial infarction: a prospective study comparing predischarge exercise thallium- 201 scintigraphy and coronary angiography. Circulation 1983;68:321-36.

1114. Hung J, Goris ML, Nash E, et al. Comparative value of maximal treadmill testing, exercise thallium myocardial perfusion scintigraphy and exercise radionuclide ventriculography for distinguishing high- and low-risk patients soon after acute myocardial infarction. Am J Cardiol 1984;53:1221-7.

1115. Abraham RD, Freedman SB, Dunn RF, et al. Prediction of multivessel coronary artery disease and prognosis early after acute myocardial infarction by exercise electrocardiography and thallium- 201 myocardial perfusion scanning. Am J Cardiol 1986;58:423-7.

1116. Wilson WW, Gibson RS, Nygaard TW, et al. Acute myocardial infarction associated with single vessel coronary artery disease: an analysis of clinical outcome and the prognostic importance of vessel patency and residual ischemic myocardium. J Am Coll Cardiol 1988;11:223-34.

1117. Leppo JA, O’Brien J, Rothendler JA, Getchell JD, Lee VW. Dipyridamole-thallium-201 scintigraphy in the prediction of future cardiac events after acute myocardial infarction. N Engl J Med 1984;310:1014-8.

1118. Pirelli S, Inglese E, Suppa M, Corrada E, Campolo L. Dipyridamole-thallium 201 scintigraphy in the early post-infarction period: safety and accuracy in predicting the extent of coronary disease and future recurrence of angina in patients suffering from their first myocardial infarction. Eur Heart J 1988;9:1324-31.

1119. Younis LT, Byers S, Shaw L, Barth G, Goodgold H, Chaitman BR. Prognostic value of intravenous dipyridamole thallium scintigraphy after an acute myocardial ischemic event. Am J Cardiol 1989;64:161-6.

1120. Figueredo V, Cheitlin MD. Risk stratification. In: Julian DG, Braunwald E, eds. Management of acute myocardial infarction. London, England: WB Saunders Co Ltd; 1994:361-91.

1121. Tilkemeier PL, Guiney TE, LaRaia PJ, Boucher CA. Prognostic value of predischarge low-level exercise thallium testing after thrombolytic treatment of acute myocardial infarction. Am J Cardiol 1990;66:1203-7.

1122. Hendel RC, Gore JM, Alpert JS, Leppo JA. Prognosis following interventional therapy for acute myocardial infarction: utility of dipyridamole thallium scintigraphy. Cardiology 1991;79:73-80.

1123. Miller TD, Gersh BJ, Christian TF, Bailey KR, Gibbons RJ. Limited prognostic value of thallium-201 exercise treadmill testing early after myocardial infarction in patients treated with thrombolysis. Am Heart J 1995;130:259-66.

1124. Mahmarian JJ, Mahmarian AC, Marks GF, Pratt CM, Verani MS. Role of adenosine thallium-201 tomography for defining longterm risk in patients after acute myocardial infarction. J Am Coll Cardiol 1995;25:1333-40.

1125. Cerqueira MD, Maynard C, Ritchie JL, Davis KB, Kennedy JW. Long-term survival in 618 patients from the Western Washington Streptokinase in Myocardial Infarction trials. J Am Coll Cardiol 1992;20:1452-9.

1126. Miller TD, Christian TF, Hopfenspirger MR, Hodge DO, Gersh BJ, Gibbons RJ. Infarct size after acute myocardial infarction measured by quantitative tomographic 99mTc sestamibi imaging predicts subsequent mortality. Circulation 1995;92:334-41.

1127. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol 2002;39:30-6.

1128. Brown KA, Heller GV, Landin RS, et al. Early dipyridamole (99m)Tc-sestamibi single photon emission computed tomographic imaging 2 to 4 days after acute myocardial infarction predicts in-hospital and postdischarge cardiac events: comparison with submaximal exercise imaging. Circulation 1999; 100:2060-6.

1129. Risk stratification and survival after myocardial infarction. N Engl J Med 1983;309:331-6.

1130. Zaret BL,Wackers TH, Terrin M, et al. Does left ventricular ejection fraction following thrombolytic therapy have the same prognostic impact described in the prethrombolytic era? Results of the TIMI II Trial [abstr]. J Am Coll Cardiol 1991;17:214A.

1131. Roig E, Magriñá J, Garcia A, et al. Prognostic value of exercise radionuclide angiography in low risk acute myocardial infarction survivors. Eur Heart J 1993;14:213-8.

1132. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44-51.

1133. Rashid H, Exner DV, Mirsky I, Cooper HA, Waclawiw MA, Domanski MJ. Comparison of echocardiography and radionuclide angiography as predictors of mortality in patients with left ventricular dysfunction: studies of left ventricular dysfunction. Am J Cardiol 1999;84:299-303.

1134. Rahimtoola SH. The hibernating myocardium. Am Heart J 1989;117:211-21.

1135. Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation 1982;66:1146-9.

1136. Rahimtoola SH. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation 1985;72:V123-35.

1137. Di Carli MF. Assessment of myocardial viability after myocardial infarction. J Nucl Cardiol 9:229-35.

1138. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002;39:1151-8.

1139. Afridi I, Grayburn PA, Panza JA, Oh JK, Zoghbi WA, Marwick TH. Myocardial viability during dobutamine echocardiography predicts survival in patients with coronary artery disease and severe left ventricular systolic dysfunction. J Am Coll Cardiol 1998;32:921-6.

1140. Rohatgi R, Epstein S, Henriquez J, et al. Utility of positron emission tomography in predicting cardiac events and survival in patients with coronary artery disease and severe left ventricular dysfunction. Am J Cardiol 2001;87:1096-9, A6.

1141. Bax JJ,Wijns W, Cornel JH, Visser FC, Boersma E, Fioretti PM. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled data. J Am Coll Cardiol 1997;30:1451-60.

1142. Beller GA. Noninvasive assessment of myocardial viability. N Engl J Med 2000;343:1488-90.

1143. Beek AM, Kühl HP, Bondarenko O, et al. Delayed contrastenhanced magnetic resonance imaging for the prediction of regional functional improvement after acute myocardial infarction. J Am Coll Cardiol 2003;42:895-901.

1144. Gerber BL, Garot J, Bluemke DA, Wu KC, Lima JA. Accuracy of contrast-enhanced magnetic resonance imaging in predicting improvement of regional myocardial function in patients after acute myocardial infarction. Circulation 2002;106:1083-9.

1145. Bates DW, Miller E, Bernstein SJ, Hauptman PJ, Leape LL. Coronary angiography and angioplasty after acute myocardial infarction. Ann Intern Med 1997;126:539-50.

1146. Scott IA, Harden H, Coory M. What are appropriate rates of invasive procedures following acute myocardial infarction: a systematic review. Med J Aust 2001;174:130-6.

1147. Llevadot J, Giugliano RP, Antman EM, et al, for the InTIME (Intravenous nPA for Treatment of Infarcting Myocardium Early) II Investigators. Availability of on-site catheterization and clinical outcomes in patients receiving fibrinolysis for ST-elevation myocardial infarction. Eur Heart J 2001;22:2104-15.

1148. Rogers WJ, Baim DS, Gore JM, et al. Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue- type plasminogen activator: results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A trial. Circulation 1990;81:1457-76.

1149. O’Neill WW. “Watchful waiting” after thrombolysis: it’s time for a re-evaluation. J Am Coll Cardiol 2003;42:17-9.

1149a. Antman EM, Van de Werf F. Pharmacoinvasive therapy: the future of treatment for ST-elevation myocardial infarction. Circulation 2004;109:2480-6.

1150. Gottlieb SO, Gottlieb SH, Achuff SC, Baumgardner R, Mellits ED, Weisfeldt ML, Gerstenblith G. Silent ischemia on Holter monitoring predicts mortality in high-risk post-infarction patients. JAMA 1988;259:1030-5.

1151. Tzivoni D, Gavish A, Zin D, et al. Prognostic significance of ischemic episodes in patients with previous myocardial infarction. Am J Cardiol 1988;62:661-4.

1152. Bonaduce D, Petretta M, Lanzillo T, et al. Prevalence and prognostic significance of silent myocardial ischaemia detected by exercise test and continuous ECG monitoring after acute myocardial infarction. Eur Heart J 1991;12:186-93.

1153. Langer A, Minkowitz J, Dorian P, et al, for the Tissue Plasminogen Activator: Toronto (TPAT) Study Group. Pathophysiology and prognostic significance of Holter-detected ST segment depression after myocardial infarction. J Am Coll Cardiol 1992;20:1313-7.

1154. Petretta M, Bonaduce D, Bianchi V, et al. Characterization and prognostic significance of silent myocardial ischemia on predischarge electrocardiographic monitoring in unselected patients with myocardial infarction. Am J Cardiol 1992;69:579-83.

1155. Jereczek M, Andresen D, Schröder J, et al. Prognostic value of ischemia during Holter monitoring and exercise testing after acute myocardial infarction. Am J Cardiol 1993;72:8-13.

1156. Currie P, Ashby D, Saltissi S. Prognostic significance of transient myocardial ischemia on ambulatory monitoring after acute myocardial infarction. Am J Cardiol 1993;71:773-7.

1157. Gill JB, Cairns JA, Roberts RS, et al. Prognostic importance of myocardial ischemia detected by ambulatory monitoring early after acute myocardial infarction. N Engl J Med 1996;334:65- 70.

1158. Deedwania PC. Asymptomatic ischemia during predischarge Holter monitoring predicts poor prognosis in the postinfarction period. Am J Cardiol 1993;71:859-61.

1159. Kuchar DL, Thorburn CW, Sammel NL. Prediction of serious arrhythmic events after myocardial infarction: signal-averaged electrocardiogram, Holter monitoring and radionuclide ventriculography. J Am Coll Cardiol 1987;9:531-8.

1160. Gomes JA, Winters SL, Martinson M, Machac J, Stewart D, Targonski A. The prognostic significance of quantitative signalaveraged variables relative to clinical variables, site of myocardial infarction, ejection fraction and ventricular premature beats: a prospective study. J Am Coll Cardiol 1989;13:377-84.

1161. el-Sherif N, Denes P, Katz R, et al, for the Cardiac Arrhythmia Suppression Trial/Signal-Averaged Electrocardiogram (CAST/ SAECG) Substudy Investigators. Definition of the best prediction criteria of the time domain signal-averaged electrocardiogram for serious arrhythmic events in the postinfarction period. J Am Coll Cardiol 1995;25:908-14.

1162. Vatterott PJ, Hammill SC, Bailey KR, Wiltgen CM, Gersh BJ. Late potentials on signal-averaged electrocardiograms and patency of the infarct-related artery in survivors of acute myocardial infarction. J Am Coll Cardiol 1991;17:330-7.

1163. McClements BM, Adgey AA. Value of signal-averaged electrocardiography, radionuclide ventriculography, Holter monitoring and clinical variables for prediction of arrhythmic events in survivors of acute myocardial infarction in the thrombolytic era. J Am Coll Cardiol 1993;21:1419-27.

1164. Hohnloser SH, Franck P, Klingenheben T, Zabel M, Just H. Open infarct artery, late potentials, and other prognostic factors in patients after acute myocardial infarction in the thrombolytic era: a prospective trial. Circulation 1994;90:1747-56.

1165. Farrell TG, Bashir Y, Cripps T, et al. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. J Am Coll Cardiol 1991;18:687-97.

1166. Bigger JT, Fleiss JL, Rolnitzky LM, Steinman RC. The ability of several short-term measures of RR variability to predict mortality after myocardial infarction. Circulation 1993;88:927-34.

1167. Kleiger RE, Miller JP, Bigger JT, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59:256-62.

1168. La Rovere MT, Bigger JT, Marcus FI, Mortara A, Schwartz PJ, for the ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 1998;351:478-84.

1169. Schwartz PJ, La Rovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death: experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation 1992;85:I77-91.

1170. Schwartz PJ, Vanoli E, Stramba-Badiale M, et al. Autonomic mechanisms and sudden death: new insights from analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction. Circulation 1988;78:969-79.

1171. La Rovere MT, Specchia G, Mortara A, Schwartz PJ. Baroreflex sensitivity, clinical correlates, and cardiovascular mortality among patients with a first myocardial infarction: a prospective study. Circulation 1988;78:816-24.

1172. Farrell TG, Paul V, Cripps TR, et al. Baroreflex sensitivity and electrophysiological correlates in patients after acute myocardial infarction. Circulation 1991;83:945-52.

1173. Gold MR, Bloomfield DM, Anderson KP, et al. A comparison of T-wave alternans, signal averaged electrocardiography and programmed ventricular stimulation for arrhythmia risk stratification. J Am Coll Cardiol 2000;36:2247-53.

1174. Ikeda T, Sakata T, Takami M, et al. Combined assessment of Twave alternans and late potentials used to predict arrhythmic events after myocardial infarction: a prospective study. J Am Coll Cardiol 2000;35:722-30.

1175. Gilman JK, Jalal S, Naccarelli GV. Predicting and preventing sudden death from cardiac causes. Circulation 1994;90:1083- 92.

1176. Dalal H, Evans PH, Campbell JL. Recent developments in secondary prevention and cardiac rehabilitation after acute myocardial infarction. BMJ 2004;328:693-7.

1177. Qureshi AI, Suri MF, Guterman LR, Hopkins LN. Ineffective secondary prevention in survivors of cardiovascular events in the US population: report from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2001; 161:1621-8.

1178. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003;42:201-8.

1179. Conti CR. Management of patients with acute myocardial infarction and end-stage renal disease. J Am Coll Cardiol 2003; 42:209-10.

1180. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002;137:555-62.

1181. LaBresh KA, Ellrodt AG, Gliklich R, Liljestrand J, Peto R. Get with the guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med 2004;164:203-9.

1182. Lee KW, Lip GY. Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. Arch Intern Med 2003;163:2368-92.

1183. Fletcher GF, Balady GJ, Amsterdam EA, et al. Exercise standards for testing and training: a statement for healthcare professionals from the American Heart Association. Circulation 2001;104:1694-740.

1184. Wenger NK, Froelicher ES, Smith LK, et al. AHCPR Supported Guidelines. Clinical Practice Guideline Number 17: Cardiac Rehabilitation. US Dept of Health and Human Services. Public Health Service. Agency for Health Care Policy and Research. National Heart, Lung and Blood Institute, October 1995. AHCPR publication No. 96-0672.

1185. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001;87:819-22.

1186. Mehta RH, Montoye CK, Faul J, et al, for the American College of Cardiology Guidelines Applied in Practice Steering Committee. Enhancing quality of care for acute myocardial infarction: shifting the focus of improvement from key indicators to process of care and tool use. J Am Coll Cardiol 2004;43:2166-73

1187. Bowles KH, Foust JB, Naylor MD. Hospital discharge referral decision making: a multidisciplinary perspective. Appl Nurs Res 2003;16:134-43.

1188. Plach S, Wierenga ME, Heidrich SM. Effect of a postdischarge education class on coronary artery disease knowledge and selfreported health-promoting behaviors. Heart Lung 1996;25:367- 72.

1189. O’Neill C, Normand C, Cupples M, McKnight A. Cost effectiveness of personal health education in primary care for people with angina in the greater Belfast area of Northern Ireland. J Epidemiol Community Health 1996;50:538-40.

1190. Larson CO, Nelson EC, Gustafson D, Batalden PB. The relationship between meeting patients’ information needs and their satisfaction with hospital care and general health status outcomes. Int J Qual Health Care 1996;8:447-56.

1191. Theis SL, Johnson JH. Strategies for teaching patients: a metaanalysis. Clin Nurse Spec 1995;9:100-5, 120.

1192. Hill J. A practical guide to patient education and information giving. Baillieres Clin Rheumatol 1997;11:109-27.

1193. Kingsbury K. Taking AIM: how to teach primary and secondary prevention effectively. Can J Cardiol 1998;14 Suppl A:22A- 26A.

1194. Winslow E, Bohannon N, Brunton SA, Mayhew HE. Lifestyle modification: weight control, exercise, and smoking cessation. Am J Med 1996;101:4A25S-31S; discussion.

1195. The multiple risk factor intervention trial (MRFIT): a national study of primary prevention of coronary heart disease. JAMA 1976;235:825-7.

1196. Moore SM. Effects of interventions to promote recovery in coronary artery bypass surgical patients. J Cardiovasc Nurs 1997;12:59-70.

1197. Oldridge NB, Guyatt GH, Fischer ME, Rimm AA. Cardiac rehabilitation after myocardial infarction: combined experience of randomized clinical trials. JAMA 1988;260:945-50.

1198. Wang WW. The educational needs of myocardial infarction patients. Prog Cardiovasc Nurs 1994;9:28-36.

1199. Chan V. Content areas for cardiac teaching: patients’ perceptions of the importance of teaching content after myocardial infarction. J Adv Nurs 1990;15:1139-45.

1200. Cogswell B, Eggert MS. People want doctors to give more preventive care: a qualitative study of health care consumers. Arch Fam Med 1993;2:611-9.

1201. Mittelmark MB, Leupker RV, Grimm R, Kottke TE, Blackburn H. The role of physicians in a community-wide program for prevention of cardiovascular disease: the Minnesota Heart Health Program. Public Health Rep 103:360-5.

1202. Rhodes KS, Bookstein LC, Aaronson LS, Mercer NM, Orringer CE. Intensive nutrition counseling enhances outcomes of National Cholesterol Education Program dietary therapy. J Am Diet Assoc 1996;96:1003-10; quiz 1011-2.

1203. Lindsay C, Jennrich JA, Biemolt M. Programmed instruction booklet for cardiac rehabilitation teaching. Heart Lung 1991;20:648-53.

1204. Lewis D. Computer-based approaches to patient education: a review of the literature. J Am Med Inform Assoc 1999;6:272-82.

1205. Ganguli G. Consumers devise drug cost-cutting measures: medical and legal issues to consider. Health Care Manag (Frederick) 2003;22:275-81.

1206. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med 1993;119:1187-97.

1207. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994;344:1383-9.

1208. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.

1209. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.

1210. Riegger G, Abletshauser C, Ludwig M, et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis 1999;144:263-70.

1211. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-62.

1212. Knatterud GL, Rosenberg Y, Campeau L, et al, for the Post CABG Investigators. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Circulation 2000;102:157-65.

1213. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo- controlled trial. Lancet 2002;360:7-22.

1214. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990;322:1700-7.

1215. Rubins HB, Robins SJ, Collins D, et al, for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-8.

1216. Arntz HR, Agrawal R, Wunderlich W, et al. Beneficial effects of pravastatin (+/-cholestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). Am J Cardiol 2000;86:1293-8.

1217. Schwartz GG, Olsson AG, Ezekowitz MD, et al, for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-8.

1218. Stenestrand U, Wallentin L for the Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001;285:430-6.

1219. Cannon CP, Braunwald E, McCabe CH, et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1562-4.

1220. Aronow HD, Novaro GM, Lauer MS, et al. In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis. Arch Intern Med 2003;163:2576-82.

1221. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288:1723-7.

1222. Nutrition and Your Health: Dietary Guidelines for Americans. Fourth Edition. US Department of Agriculture. US Department of Health and Human Services, Washington, DC, 1995.

1223. Winniford MD, Jansen DE, Reynolds GA, Apprill P, Black WH, Hillis LD. Cigarette smoking-induced coronary vasoconstriction in atherosclerotic coronary artery disease and prevention by calcium antagonists and nitroglycerin. Am J Cardiol 1987; 59:203-7.

1224. Deanfield J, Wright C, Krikler S, Ribeiro P, Fox K. Cigarette smoking and the treatment of angina with propranolol, atenolol, and nifedipine. N Engl J Med 1984;310:951-4.

1225. Barry J, Mead K, Nabel EG, et al. Effect of smoking on the activity of ischemic heart disease. JAMA 1989;261:398-402.

1226. Burling TA, Singleton EG, Bigelow GE, Baile WF, Gottlieb SH. Smoking following myocardial infarction: a critical review of the literature. Health Psychol 1984;3:83-96.

1227. Good Information For Smokers: You Can Quit Smoking. Consumer booklet. U.S. Public Health Service. http://www.surgeongeneral. gov/tobacco/lowlit.htm, September 2002. Accessed December 16, 2002.

1228. Treating Tobacco Use and Dependence. Quick Reference Guide for Clinicians. U.S. Public Health Service. http://www.surgeongeneral. gov/tobacco/tobaqrg.htm, October 2000. Accessed December 16, 2002.

1229. Houston-Miller N. Smoking cessation. In: Houston-Miller N, Taylor CB, eds. Lifestyle Management for Patients with Coronary Heart Disease. Champaigne, IL: Human Kinetics; 1995:85-104.

1230. Glover ED, Glover PN, Payne TJ. Treating nicotine dependence. Am J Med Sci 2003;326:183-6.

1231. Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the nicotine patch for smoking cessation: a meta-analysis. JAMA 1994;271:1940-7.

1232. Gourlay SG, McNeil JJ. Antismoking products. Med J Aust 1990;153:699-707.

1233. Kimmel SE, Berlin JA, Miles C, Jaskowiak J, Carson JL, Strom BL. Risk of acute first myocardial infarction and use of nicotine patches in a general population. J Am Coll Cardiol 2001; 37:1297-302.

1234. Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease. Nicotine replacement therapy for patients with coronary artery disease. Arch Intern bMed 1994;154:989-95.

1235. Sønderskov J, Olsen J, Sabroe S, Meillier L, Overvad K. Nicotine patches in smoking cessation: a randomized trial among over-the-counter customers in Denmark. Am J Epidemiol 1997;145:309-18.

1236. Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996;335:1792-8.

1237. Mahmarian JJ, Moyé LA, Nasser GA, et al. Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. J Am Coll Cardiol 1997;30:125-30.

1238. Covey LS, Glassman AH. A meta-analysis of double-blind placebo- controlled trials of clonidine for smoking cessation. Br J Addict 1991;86:991-8.

1239. Bernstein DA. Modification of smoking behavior: an evaluative review. Psychol Bull 1969;71:418-40.

1240. Davison GC, Rosen RC. Lobeline and reduction of cigarette smoking. Psychol Rep 1972;31:443-56.

1241. Ford S, Ederer F. Breaking the cigarette habit. JAMA 1965;194:139-42.

1242. Bouvy ML, Buurma H, Egberts AC. Determinants for successful smoking cessation with bupropion in daily practice. Pharm World Sci 2003;25:207-11.

1243. Swan GE, McAfee T, Curry SJ, et al K. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Arch Intern Med 2003;163:2337-44.

1244. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustainedrelease bupropion and placebo for smoking cessation. N Engl J Med 1997;337:1195-202.

1245. Gutstein DE, Fuster V. Pathophysiologic bases for adjunctive therapies in the treatment and secondary prevention of acute myocardial infarction. Clin Cardiol 1998;21:161-8.

1246. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1997;96:2751-3.

1247. Hurlen M, Smith P, Arnesen H. Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction. The WARIS-II (Warfarin-Aspirin Reinfarction Study) design. Scand Cardiovasc J 2000;34:168- 71.

1248. van Es RF, Jonker JJ,Verheugt FW, Deckers JW, Grobbee DE for the Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002; 360:109-13.

1249. Brouwer MA, van den Bergh PJ, Aengevaeren WR, et al. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. Circulation 2002;106:659-65.

1250. Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989;321:129-35.

1251. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988;296:313-6.

1252. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclo-oxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.

1253. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003;361:573-4.

1254. Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003;108:1191-5.

1255. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of longterm therapy with captopril. Circulation 1985;72:406-12.

1256. Pfeffer MA, Braunwald E, Moyé LA, Basta L, et al, for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-77.

1257. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.

1258. Køber L, Torp-Pedersen C, Carlsen JE, et al, for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-6.

1259. Johnstone D, Limacher M, Rousseau M, et al. Clinical characteristics of patients in studies of left ventricular dysfunction (SOLVD). Am J Cardiol 1992;70:894-900.

1260. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.

1261. Rutherford JD, Pfeffer MA, Moyé LA, et al, for the SAVE Investigators. Effects of captopril on ischemic events after myocardial infarction: results of the Survival and Ventricular Enlargement trial. Circulation 1994;90:1731-8.

1262. Fox KM for the EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.

1263. Granger CB, McMurray JJ, Yusuf S, et al, for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6.

1264. McMurray JJ, Ostergren J, Swedberg K, et al, for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71.

1265. Yusuf S, Pfeffer MA, Swedberg K, et al, for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777- 81.

1266. The Beta-Blocker Pooling Project Research Group. The Beta- Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J 1988;9:8- 16.

1267. Barron HV, Viskin S, Lundstrom RJ, Wong CC, Swain BE, Truman AF, Selby JV. Effect of beta-adrenergic blocking agents on mortality rate in patients not revascularized after myocardial infarction: data from a large HMO. Am Heart J 1997;134:608- 13.

1268. Gheorghiade M, Colucci WS, Swedberg K. Beta-blockers in chronic heart failure. Circulation 2003;107:1570-5.

1269. Chen J, Radford MJ,Wang Y, Marciniak TA, Krumholz HM. Are beta-blockers effective in elderly patients who undergo coronary revascularization after acute myocardial infarction? Arch Intern Med 2000;160:947-52.

1270. Krumholz HM, Radford MJ,Wang Y, Chen J, Heiat A, Marciniak TA. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA 1998;280:623-9.

1271. Hochman JS, Califf RM. Acute myocardial infarction. In: Antman EA, Colucci WS, Gotto AM, Josephson ME, Loscalzo J, Oparil S, Popma JJ, eds. Cardiovascular therapeutics: a companion to Braunwald’s heart disease. 2nd ed. Philadelphia, PA: WB Saunders Co Ltd; 2002:235-91.

1272. Marciniak TA, Ellerbeck EF, Radford MJ, et al. Improving the quality of care for Medicare patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. JAMA 1998;279:1351-7.

1273. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-97.

1274. Goldman L, Sia ST, Cook EF, Rutherford JD, Weinstein MC. Costs and effectiveness of routine therapy with long-term betaadrenergic antagonists after acute myocardial infarction. N Engl J Med 1988;319:152-7.

1275. Brand DA, Newcomer LN, Freiburger A, Tian H. Cardiologists’ practices compared with practice guidelines: use of beta-blockade after acute myocardial infarction. J Am Coll Cardiol 1995;26:1432-6.

1276. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. Hypertension 2003;41:1178-9.

1277. ALLHAT Officers and Coordinators for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981- 97.

1278. Salpeter S, Ormiston T, Salpeter E . Cardioselective beta-blockers for reversible airway disease. Cochrane Database of Systematic Reviews (4):CD002992, 2002.

1279. Hennekens CH, Albert CM, Godfried SL, Gaziano JM, Buring JE. Adjunctive drug therapy of acute myocardial infarction: evidence from clinical trials. N Engl J Med 1996;335:1660-7.

1280. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.

1281. Wang CH, Weisel RD, Liu PP, Fedak PW, Verma S. Glitazones and heart failure: critical appraisal for the clinician. Circulation 2003;107:1350-4.

1282. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003;108:2941-8.

1283. Stevenson JC, Crook D, Godsland IF, Collins P, Whitehead MI. Hormone replacement therapy and the cardiovascular system: nonlipid effects. Drugs 1994;47:35-41.

1284. Kafonek SD. Postmenopausal hormone replacement therapy and cardiovascular risk reduction: a review. Drugs 1994;47:16-24.

1285. Petitti DB. Coronary heart disease and estrogen replacement therapy: can compliance bias explain the results of observational studies? Ann Epidemiol 1994;4:115-8.

1286. Whitehead M. Progestins and androgens. Fertil Steril 1994; 62:161S-167S.

1287. Hulley S, Grady D, Bush T, et al, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.

1288. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999;100:713-6.

1289. Stanford JL,Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274:137-42.

1290. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.

1291. Gorsky RD, Koplan JP, Peterson HB, Thacker SB. Relative risks and benefits of long-term estrogen replacement therapy: a decision analysis. Obstet Gynecol 1994;83:161-6.

1292. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-9.

1293. Grady D, Herrington D, Bittner V, et al, for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.

1294. Becker LB, Han BH, Meyer PM, et al. Racial differences in the incidence of cardiac arrest and subsequent survival: the CPR Chicago Project. N Engl J Med 1993;329:600-6.

1295. van Daele ME, McNeill AJ, Fioretti PM, et al. Prognostic value of dipyridamole sestamibi single-photon emission computed tomography and dipyridamole stress echocardiography for new cardiac events after an uncomplicated myocardial infarction. J Am Soc Echocardiogr 1994;7:370-80.

1296. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001;344:1222-31.

1297. Rossouw JE, Anderson GL, Prentice RL, et al, for the Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321-33.

1298. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002;288:2432-40.

1299. Hodis HN, Mack WJ, Azen SP, et al, for the Women’s Estrogen- Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003;349:535-45.

1300. Barrett-Connor E, Grady D, Sashegyi A, et al, for the MORE Investigators (Multiple Outcomes of Raloxifene Evaluation). Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002;287:847-57.

1301. Cherry N, Gilmour K, Hannaford P, et al, for the ESPRIT team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 2002;360:2001-8.

1302. Cairns JA, Markham BA. Economics and efficacy in choosing oral anticoagulants or aspirin after myocardial infarction. JAMA 1995;273:965-7.

1303. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347:969-74.

1304. Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P, for the Combination Hemotherapy and Mortality Prevention (CHAMP) Study Group. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation 2002;105:557-63.

1305. O’Connor CM, Gattis WA, Hellkamp AS, et al. Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS). Am J Cardiol 2001;88:541-6.

1306. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997;350:389-96.

1307. Herlitz J, Holm J, Peterson M, et al, for the LoWASA Study Group. Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction: the LoWASA Study. Eur Heart J 2004;25:232-9.

1308. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;343:499-503.

1309. Orford JL, Fasseas P, Melby S, et al. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J 2004;147:463-7.

1310. Spencer FA, Becker RC. When guidelines collide... Am Heart J 2004;147:395-7.

1311. Vaitkus PT, Barnathan ES. Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis. J Am Coll Cardiol 1993; 22:1004-9.

1312. Keating EC, Gross SA, Schlamowitz RA, et al. Mural thrombi in myocardial infarctions: prospective evaluation by two-dimensional echocardiography. Am J Med 1983;74:989-95.

1313. Cregler LL. Antithrombotic therapy in left ventricular thrombosis and systemic embolism. Am Heart J 1992;123:1110-4.

1314. Reeder GS, Lengyel M, Tajik AJ, Seward JB, Smith HC, Danielson GK. Mural thrombus in left ventricular aneurysm: incidence, role of angiography, and relation between anticoagulation and embolization. Mayo Clin Proc 1981;56:77-81.

1315. Lip GY. Intracardiac thrombus formation in cardiac impairment: the role of anticoagulant therapy. Postgrad Med J 1996;72:731- 8.

1316. Sherman DG, Dyken ML, Fisher M, Harrison MJ, Hart RG. Antithrombotic therapy for cerebrovascular disorders. Chest 1989;95:140S-155S.

1317. Weintraub WS, Ba’albaki HA. Decision analysis concerning the application of echocardiography to the diagnosis and treatment of mural thrombi after anterior wall acute myocardial infarction. Am J Cardiol 1989;64:708-16.

1318. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998;31:749-53.

1319. Lip GY, Gibbs CR. Anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review. QJM 2002;95:451-9.

1320. US Department of Health and Human Services. Physical Activity Fundamental to Preventing Disease. Office of the Assistant Secretary for Planning and Evaluation. http://aspe.hhs.gov/health/reports/physicalactivity/, June 2002. Accessed December 16, 2002.

1321. Deleted in press.

1322. Fletcher GF, Balady G, Blair SN, et al. Statement on exercise: benefits and recommendations for physical activity programs for all Americans: a statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association. Circulation 1996;94:857-62.

1323. Pate RR, Pratt M, Blair SN, et al. Physical activity and public health: a recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 1995;273:402-7.

1324. Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003;107:3109-16.

1325. Pollock ML, Franklin BA, Balady GJ, et al. AHA science advisory: resistance exercise in individuals with and without cardiovascular disease: benefits, rationale, safety, and prescription: an advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association; Position paper endorsed by the American College of Sports Medicine. Circulation 2000;101:828-33.

1326. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993;328:1450-6.

1327. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B,Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993;328:1444-9.

1328. Gey KF, Puska P, Jordan P, Moser UK. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr 1991;53:326S-334S.

1329. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-6.

1330. Kushi LH, Folsom AR, Prineas RJ, Mink PJ,Wu Y, Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 1996;334:1156- 62.

1331. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999;354:447-55.

1332. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-35.

1333. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-5.

1334. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-9.

1335. Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology 1992;3:194-202.

1336. Flaherty JT, Pitt B, Gruber JW, et al. Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. Circulation 1994;89:1982-91.

1337. DeMaio SJ, King SB, Lembo NJ, et al. Vitamin E supplementation, plasma lipids and incidence of restenosis after percutaneous transluminal coronary angioplasty (PTCA). J Am Coll Nutr 1992;11:68-73.

1338. Leaf A, Jorgensen MB, Jacobs AK, et al. Do fish oils prevent restenosis after coronary angioplasty? Circulation 1994;90: 2248-57.

1338a. Kris-Etherton PM, Lichtenstein AH, Howard BV, Steinberg D, Witzman JL. Antioxidant vitamin supplements and cardiovascular disease. Circulation. In press.

1339. ENRICHD Investigators. Enhancing Recovery in Coronary Heart Disease (ENRICHD) study intervention: rationale and design. Psychosom Med 2001;63:747-55.

1340. Bush DE, Ziegelstein RC, Tayback M, et al. Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. Am J Cardiol 2001;88:337-41.

1341. Frasure-Smith N, Lespérance F, Gravel G, et al. Depression and health-care costs during the first year following myocardial infarction. J Psychosom Res 2000;48:471-8.

1342. Welin C, Lappas G, Wilhelmsen L. Independent importance of psychosocial factors for prognosis after myocardial infarction. J Intern Med 2000;247:629-39.

1343. Irvine J, Basinski A, Baker B, et al. Depression and risk of sudden cardiac death after acute myocardial infarction: testing for the confounding effects of fatigue. Psychosom Med 1999;61:729-37.

1344. Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 1996;93:1976-80.

1345. Ladwig KH, Lehmacher W, Roth R, Breithardt G, Budde T, Borggrefe M. Factors which provoke post-infarction depression: results from the post-infarction late potential study (PILP). J Psychosom Res 1992;36:723-9.

1346. Lane D, Carroll D, Ring C, Beevers DG, Lip GY. Mortality and quality of life 12 months after myocardial infarction: effects of depression and anxiety. Psychosom Med 2001;63:221-30.

1347. Mayou RA, Gill D, Thompson DR, Day A, Hicks N, Volmink J, Neil A. Depression and anxiety as predictors of outcome after myocardial infarction. Psychosom Med 2000;62:212-9.

1348. Carney RM, Blumenthal JA, Catellier D, et al. Depression as a risk factor for mortality after acute myocardial infarction. Am J Cardiol 2003;92:1277-81.

1349. Crilley JG, Farrer M. Impact of first myocardial infarction on self-perceived health status. QJM 2001;94:13-8.

1350. Swenson JR, O'Connor CM, Barton D, et al, for the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Group. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. Am J Cardiol 2003;92:1271-6.

1351. Friedman S. Cardiac disease, anxiety, and sexual functioning. Am J Cardiol 2000;86:46F-50F.

1352. Ziegelstein RC, Fauerbach JA, Stevens SS, Romanelli J, Richter DP, Bush DE. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. Arch Intern Med 2000;160:1818-23.

1353. Lane D, Carroll D, Ring C, Beevers DG, Lip GY. Predictors of attendance at cardiac rehabilitation after myocardial infarction. J Psychosom Res 2001;51:497-501.

1354. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288:701-9.

1355. Berkman LF, Blumenthal J, Burg M, et al, for Writing Committee for the ENRICHD Investigators. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 2003;289:3106-16.

1356. Alonzo AA. Acute myocardial infarction and posttraumatic stress disorder: the consequences of cumulative adversity. J Cardiovasc Nurs 1999;13:33-45.

1357. Berkman LF, Syme SL. Social networks, host resistance, and mortality: a nine-year follow-up study of Alameda County residents. Am J Epidemiol 1979;109:186-204.

1358. Case RB, Moss AJ, Case N, McDermott M, Eberly S. Living alone after myocardial infarction: impact on prognosis. JAMA 1992;267:515-9.

1359. Ruberman W, Weinblatt E, Goldberg JD, Chaudhary BS. Psychosocial influences on mortality after myocardial infarction. N Engl J Med 1984;311:552-9.

1360. Frasure-Smith N, Lespérance F, Gravel G, et al. Social support, depression, and mortality during the first year after myocardial infarction. Circulation 2000;101:1919-24.

1361. Deleted in press.

1362. Coppotelli HC, Orleans CT. Partner support and other determinants of smoking cessation maintenance among women. J Consult Clin Psychol 1985;53:455-60.

1363. Suls J, Green P, Rose G, Lounsbury P, Gordon E. Hiding worries from one’s spouse: associations between coping via protective buffering and distress in male post-myocardial infarction patients and their wives. J Behav Med 1997;20:333-49.

1364. Clarke DE, Walker JR, Cuddy TE. The role of perceived overprotectiveness in recovery 3 months after myocardial infarction. J Cardiopulm Rehabil 1996;16:372-7.

1365. Education, communication, and methods of intervention. In: Houston-Miller N, Taylor CB. Lifestyle Management for Patients with Coronary Heart Disease (Current Issues in Cardiac Rehabilitation, Monograph no. 2). Champaigne, IL: Human Kinetics; 1995:21-30.

1366. Crowe JM, Runions J, Ebbesen LS, Oldridge NB, Streiner DL. Anxiety and depression after acute myocardial infarction. Heart Lung 1996;25:98-107.

1367. Cossette S, Frasure-Smith N, Lespérance F. Clinical implications of a reduction in psychological distress on cardiac prognosis in patients participating in a psychosocial intervention program. Psychosom Med 2001;63:257-66.

1368. Jones DA, West RR. Psychological rehabilitation after myocardial infarction: multicentre randomised controlled trial. BMJ 1996;313:1517-21.

1369. Linden W. Psychological treatments in cardiac rehabilitation: review of rationales and outcomes. J Psychosom Res 2000; 48:443-54.

1370. Linden W, Stossel C, Maurice J. Psychosocial interventions for patients with coronary artery disease: a meta-analysis. Arch Intern Med 1996;156:745-52.

1371. Feigenbaum E, Carter E. Health Technology Assessment Report No. 6. US Department of Health and Human Services. Public Health Service. National Center for Health Services, Research, and Health Care Technology Assessment. Publication No. PHS 883427, 1988.

1372. Balady GJ, Ades PA, Comoss P, et al. Core components of cardiac rehabilitation/secondary prevention programs: a statement for healthcare professionals from the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation Writing Group. Circulation 2000;102:1069-73.

1373. Jolliffe JA, Rees K, Taylor RS, Thompson D, Oldridge N, Ebrahim S. Exercise-based rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2001 CD001800.

1374. DeBusk RF, Miller NH, Superko HR, et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med 1994;120:721-9.

1375. Barber K, Stommel M, Kroll J, Holmes-Rovner M, McIntosh B. Cardiac rehabilitation for community-based patients with myocardial infarction: factors predicting discharge recommendation and participation. J Clin Epidemiol 2001;54:1025-30.

1376. Spencer FA, Salami B, Yarzebski J, Lessard D, Gore JM, Goldberg RJ. Temporal trends and associated factors of inpatient cardiac rehabilitation in patients with acute myocardial infarction: a community-wide perspective. J Cardiopulm Rehabil 2001;21:377-84.

1377. Frasure-Smith N, Lespérance F, Talajic M. Depression and 18- month prognosis after myocardial infarction. Circulation 1995;91:999-1005.

1378. O’Connor GT, Buring JE,Yusuf S, Goldhaber SZ, Olmstead EM, Paffenbarger RS, Hennekens CH. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989;80:234-44.

1379. Lavie CJ, Milani RV. Effects of cardiac rehabilitation and exercise training programs in patients greater than or equal to 75 years of age. Am J Cardiol 1996;78:675-7.

1380. Ziegelstein RC. Depression in patients recovering from a myocardial infarction. JAMA 2001;286:1621-7.

1381. Rost K, Smith GR. Return to work after an initial myocardial infarction and subsequent emotional distress. Arch Intern Med 1992;152:381-5.

1382. Froelicher ES, Kee LL, Newton KM, Lindskog B, Livingston M. Return to work, sexual activity, and other activities after acute myocardial infarction. Heart Lung 1994;23:423-35.

1383. Lewin R. Return to work after MI, the roles of depression, health beliefs and rehabilitation. Int J Cardiol 1999;72:49-51.

1384. Brodie B, Grines CL, Spain M, et al. A prospective, randomized trial evaluating early discharge (day 3) without non-invasive risk stratification in low risk patients with acute myocardial infarction: PAMI-2. J Am Coll Cardiol 1995;25:5A.

1385. Petrie KJ, Cameron LD, Ellis CJ, Buick D, Weinman J. Changing illness perceptions after myocardial infarction: an early intervention randomized controlled trial. Psychosom Med 2002;64:580-6.

1386. Ostir GV, Goodwin JS, Markides KS, Ottenbacher KJ, Balfour J, Guralnik JM. Differential effects of premorbid physical and emotional health on recovery from acute events. J Am Geriatr Soc 2002;50:713-8.

1387. Sansone GR, Alba A, Frengley JD. Analysis of FIM instrument scores for patients admitted to an inpatient cardiac rehabilitation program. Arch Phys Med Rehabil 2002;83:506-12.

1388. Froom P, Cohen C, Rashcupkin J, et al. Referral to occupational medicine clinics and resumption of employment after myocardial infarction. J Occup Environ Med 1999;41:943-7.

1389. Boudrez H, De Backer G. Recent findings on return to work after an acute myocardial infarction or coronary artery bypass grafting. Acta Cardiol 2000;55:341-9.

1390. Mittag O, Kolenda KD, Nordman KJ, Bernien J, Maurischat C. Return to work after myocardial infarction/coronary artery bypass grafting: patients’ and physicians’ initial viewpoints and outcome 12 months later. Soc Sci Med 2001;52:1441-50.

1391. Kavanagh T, Matosevic V, Thacker L, Belliard R, Shephard RJ. On-site evaluation of bus drivers with coronary heart disease. J Cardiopulm Rehabil 1998;18:209-15.

1392. Covinsky KE, Chren MM, Harper DL, Way LE, Rosenthal GE. Differences in patient-reported processes and outcomes between men and women with myocardial infarction. J Gen Intern Med 2000;15:169-74.

1393. Haskell WL. Rehabilitation of the coronary patient. In: Wenger NK, Hellerstein HK, eds. Design and implementation of cardiac conditioning program. New York, NY: Churchill Livingstone, 1978:147.

1394. Usher MC, Dennis CA, Schwartz RG, Ahn DK, DeBusk RF. Physician influences on timing of return to work after myocardial infarction. Circulation 1986;74:II-490.

1395. US Department of Transportation. Status of Medical Review in Driver Licensing: Policies, Programs and Standards, 1992.

1396. Code of Federal Regulation 14CFR 121. Pg 427, Section 25.841. Published by the office of Federal Register, January 1, 2002.

1397. Deleted in press.

1398. Code of Federal Regulation 14 CFR 121. Appendix A:555-7. Published by the office of the Federal Register, January 1, 2002.

 


Copyright © 2004 by the American College of Cardiology and American Heart Association, Inc.

Back to Top | | Copyright © 2008 American College of Cardiology
Heart House | 2400 N Street, NW | Washington, DC 20037